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Some current therapeutic agents used in treatment of liver cancer have pronounced 
side effects, thus a research program has been developed to screen for new, safe and 
effective agents from Traditional Chinese Medicine (TCM) for the treatment of 
human hepatocellular carcinoma. In this project, TCMs with historical clinical 
application on hepatoma treatment were reviewed. Sophora flavescens (Leguminosae), 
which was found to have significant anti-proliferative effect on human hepatocellular 
carcinoma cell lines HepG2 and Hep3B cells, was chosen for intensive study. The 
bioassay-guided fractionation of ethanol extract of the roots of Sophora flavescens led 
to the isolation of six bioactive compounds including Maackiain, Leachianone A, 
Sophoraflavanone G, Kushenol X, Sophoraflavanone J and Sophoraflavanone K (a 
new lavanduyly flavanone). Sophoraflavanone G, with the highest yield and 
anti-proliferative activity, was chosen for further mechanistic studies. From the result 
of MTT assay, Sophoraflavanone G showed growth inhibitory effect on HepG2 cells, 
Hep3B cells as well as multidrug resistant human hepatocellular carcinoma R-HepG2 
cells. The results of DNA fragmentation, cell cycle analysis and phosphatidylserine 
externalization assays suggested that the anti-tumor effect of Sophoraflavanone G on 
HepG2 and RHepG2 cells was mediated by induction of apoptosis. Western blotting 
analysis showed that Sophoraflavanone G-induced apoptosis may involve the 
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activation of caspase-8, cleavage of Bid protein, release of cytochrome c, activation of 
caspase-9 and caspase-3 as well as the release of apoptosis-inducing factor (AIF). By 
cDNA microarray analysis, a number of candidate genes were found to be 
differentially expressed in Sophoraflavanone G-treated HepG2 cells. Down-regulation 
of GLUT 3 was validated by traditional reverse transcription polymerase chain 
reaction (RT-PCR). It implied the involvement of glucose transport in 
Sophoraflavanone G-induced signaling pathway. In parallel, differential protein 
expression profile of HepG2 and RHepG2 cells induced by Sophoraflavanone G was 
investigated by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). It 
was found that Sophoraflavaone G induced the up-regulation of aldo-keto reductase 
family member CI (AKRCl) and peroxiredoxin 1 (Prdxl) and down-regulation of 
DJ-1 protein on HepG2 cells. On RHepG2 cells, the expression of heat shock protein 
5 (glucose-regulated protein) (GRP78) and peroxiredoxin 1 (Prdxl) were increased; 
while ENOl protein and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) were 
down-regulated after Sophoraflavanone G treatment. It implied that one of the 
possible antitumor mechanisms of Sophoraflavanone G on RHepG2 cells may be 
mediated through deactivation of glycolytic enzymes and deprivation of energy 
production. The data shown only represents part of the picture. The underlying 











爲高麗槐素(Maackiain)，Leachianone A，槐屬二氫黃国 G (Sophoraflavanone G)， 
苦醇X (Kushenol X )和槐屬二氫黃酮 J (Sophoraflavanone J)，另外一個爲新的 













酵素連鎖反應（RT-PCR)的實驗，更進一步證實葡萄糖轉運體蛋白3 (GLUT 3) 
的表達模式於HepG2被下調。這推論出槐屬二氫黃酮G誘發的信號傳導途徑 
牽涉葡萄糖的運輸。另外透過二維電泳系統（two-dimensional polyacrylamide gel 
electrophoresis)，識別由槐屬二氫黃国G引發的蛋白差別表達模式。經過基質輔 
助 雷 射 脫 附 游 離 - 飛 行 時 間 質 譜 儀 （Matrix-assisted laser 
desorption/ionization-time of flight mass spectrometry)白勺分析，已經確認了那些有 
差別表達的蛋白的身份。在加有24^iM槐屬二氫黃酮G的人類肝癌細胞HepG2 
中，酸酮還原酶家族成員 C1 (aldo-keto reductase family member CI) (AKRICI) 
和過氧化物酶（peroxiredoxin l)(Prdxl)蛋白的表達增加，而DJ-1蛋白的表達減 
少。對於人類抗藥性肝癌細胞RHepG2，槐屬二氫黃国G增加了葡萄糖調控蛋 
白 78 (glucose-regulated protein 78) (GRP78)和過氧化物酶（peroxiredoxin 1) 
( P r d x l ) 的表達，同時減少了烯醇化酶（ E N 0 1 ) 和甘油醛磷酸脫氫酶 
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1.1 Hepatocellular Carcinoma (HCC) 
1.1.1 Incidence of Hepatocellular Carcinoma 
Liver cancer ranks as the sixth most common type of cancer worldwide and the 
prevalence is highest in Southeast Asia and sub-Saharan Africa. However, the 
incidence of liver cancer has been increasing in Western Europe, US and Japan over 
the past twenty years. According to the information provided by American Cancer 
Society, in 2005, there are more than 667,000 new cases of liver cancer diagnosed 
throughout the world. Among the diagnosed cases, about 83% of liver cancers are 
hepatocellular carcinoma (HCC). 
HCC, with 598,000 deaths per year worldwide, is the third most common cause 
of cancer-related death (Parkin et al., 2005; Hawkins and Dawson, 2006). The major 
risk factors of HCC are chronic infection with hepatitis B virus (HBV) and hepatitis C 
virus (HCV). Toxins like alcohol and aflatoxin, hereditary metabolic liver diseases 
like hereditary hemochromatosis, type II diabetes and obesity are the other etiologies 
of HCC (Blum, 2005; Thorgeirsson et al, 2006). Individual polymorphisms of 
drug-metabolizing enzymes such as cytochrome p450 oxidases may also contribute to 
the genetic factors which increase the susceptibility of HCC development. Regardless 
of the factors, malignant transformation of hepatocytes, i.e. hepatocarcinogenesis, 
may occur through the pathway of increasing liver cell turnover induced by chronic 
2 
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liver injury, regeneration and cirrhosis (Blum, 2005). 
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1.1.2 Therapies for Hepatocellular Carcinoma 
The choice for treatment of HCC depends on the size, location and number of 
tumors as well as the severity of the underlying liver disease. Only 20% of patients 
are suitable for the curative treatment, for example surgical resection or liver 
transplantation. Others are subjected to the palliative therapy like chemoembolisation 
(Perry et al., 2005). 
In fact, surgery is the best choice for patients with early tumors and 
well-preserved hepatic function. Since long-term survival after resection depends on 
tumor size, presence of vascular invasion and status of underlying liver function, 50% 
to 70% of 5-year survival rate can be obtained in patients with single tumors, good 
liver functional reserve and absence of clinically relevant portal hypertension. 
However the 5-year survival rate drops to 25% in patients with negative predicators 
like portal hypertension and raised serum bilirubin. Even after successful HCC 
resection, tumor recurrence still approaches 75% at 5 years which may due to 
hepatocyte damage, regeneration in cirrhotic livers, microvascular invasion or 
additional tumor nodules. The tumor recurrence includes both local recurrence and de 
novo tumors in the remaining liver (Blum, 2005; Llovet, 2005; Perry et al., 2005). 
Liver transplantation is a good choice for patients concerning the risk of HCC 
recurrence since it has the advantages of removing tumors as well as the remaining 
4 
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diseased liver which results in decreasing the risk of HCC recurrence. However, 
transplantation should be restricted to patients with single tumors of less than 5cm in 
diameter or three tumors of less than 3cm and at the same time, without 
macrovascular or lymphatic invasion. Based on these criteria, the selected patients 
have survival rate of 75% at 4 years with only 8% tumor recurrence. Although liver 
transplantation seems to be an ideal therapy for HCC, it is difficult to relieve the 
burden of HCC to the world due to shortage of donor organs. In average, in some 
Western countries, the waiting time of liver transplantation is longer than 12 months 
and because of tumor progression, the drop-out rate of patients reaches 20% to 50%. 
Thus, some hospitals or centers still use surgical resection as the first option for the 
ideal candidates (Blum, 2005; Llovet, 2005; Perry etal, 2005). 
Percutaneous ethanol injection (PEI) is one of the most widely used therapy for 
HCC which aims at destroying tumor cells and leaving the surrounding liver 
undamaged. The treatment involves the injection of pure ethanol into the tumor. 
Ethanol diffuses evenly into the tumor cells in which surrounding dense cirrhotic 
tissue or tumor capsule septations act to restrict the alcohol within the lesion, and 
causes coagulative necrosis by a number of physiological mechanisms (Clark and 
Soulen, 2002). It can achieve tumor response rate of 90% to 100% in HCCs smaller 
than 2cm in diameter and it is usually used for the treatment of patients with single 
5 
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HCC lesion smaller than 5cm in diameter or up to three lesions smaller than 3cm in 
diameter. Although it is a safe and relatively low cost treatment, several complications 
like localized pain, haemorrhage and transient alcohol intoxication may occur (Blum, 
2005; Llovet, 2005; Perry et aL, 2005). 
Radiofrequency ablation (RFA) is an alternative to PEL It is effective in 
achieving tumor necrosis in small lesion with diameter smaller than 5cm but has a 
higher overall survival rate at 3 years than PEL In this therapy, an electrode emits 
radio waves into the tumors. The conversion of waves to friction energy causes 
coagulation necrosis of surrounding tissue which gives a uniform area of ablation. 
The dense surrounding tissue in cirrhotic patients can concentrate the heat and give a 
larger ablated area while the nearby vessels act as heat-sinks to lessen the affected 
area. Despite these encouraging effects, this therapy causes bowel perforation, sepsis 
and intraperitoneal haemorrhage (Blum, 2005; Llovet, 2005; Perry et aL, 2005). 
Last but not least, transcatheter arterial chemoembolisation (TACE) is one of the 
therapies aiming to necrose or control the tumor without affecting the healthy liver 
cells and it commonly uses for the treatment of patients with non-resectable HCC and 
preserved liver function. It is effective in curing tumors with size up to 10cm in 
diameter. Chemotherapeutic agents like doxorubicin or cisplatin mixed with lipiodol 
are introduced into hepatic arterial blood supply of the lesion and followed by 
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embolisation of the feeding artery by gelfoam cubes. The patients undergoing TACE 
will experience fever, nausea and vomiting, raised transaminases and hepatic 
decompensation which may be irreversible in some patients (Blum, 2005; Llovet, 
2005; Perry al, 2005). 
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1.2 Multidrug Resistance of Tumor Cells 
Multidrug resistance (MDR) of tumor cells is the major reason for the high 
failure rate of cancer chemotherapy. MDR is the protection mechanism of tumor cells, 
which previously exposed to a single drug, against an array of anticancer drugs with 
different chemical structures and molecular mechanisms of action (Lin and Yamazaki, 
2003). 
Tumor cells have different strategies to cause MDR. The hypothesis include 
disruption of apoptotic signaling pathways by altering the levels of apoptotic genes 
and proteins, amplification of genes related to the signaling pathway of drugs, 
enhancement of DNA repair and overexpression of efflux transporters (Gottesman et 
al., 2002; Lin and Yamazaki, 2003). Reduction of intracellular drug concentration by 
increasing the efflux of drugs is one of the most significant forms of resistance against 
currently used anticancer agents. P-glycoprotein was the first identified efflux 
transporter to enhance MDR in cancer cells (Lin and Yamazaki, 2003). Subsequently, 
recent studies revealed four more efflux transporters, multidrug resistance-associated 
protein 1 (MRPl) (Cole et al., 1994), MRP2, MRP3 (Dantzig et al., 2003) and breast 
cancer resistance protein (BCRP) (Maliepaard et al., 1999) which were contributed to 
MDR. 
P-glycoprotein, a phosphorylated and glycosylated 170kDa protein of 1280 
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amino acids, is the most widely observed efflux transporter in clinical 
transport-associated MDR. P-glycoprotein, which encoded by MDRl gene, transports 
large hydrophobic, uncharged or slightly positively charged compounds like 
doxorubicin against concentration gradient at the expense of metabolic energy 
(Luqmani, 2005). As a result, tumor cells with overexpression of p-glycoprotein have 
a low intracellular therapeutic concentration of active anticancer agents and thus, 
multidrug resistant ability is developed. 
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1.3 Therapeutic Potential of Traditional Chinese Medicine 
on Human Hepatoma 
Because of the development of MDR in tumor cells as well as the ineffectiveness 
of traditional therapies, it is essential to discover an alternative way to reduce the 
burden that cancer brings to the world. Natural products research is a good mean in 
the discovery of innovative anticancer agents. A review pointed out that 
approximately 60% of anticancer agents which are commercially available or in the 
late stages of clinical trials were developed from natural products (Cragg et al., 1997). 
For example, taxol used for the treatment of ovarian cancer and breast cancer was 
purified from Taxus brevifolia (Kingston, 2001). 
In our laboratory, a research project was launched to screen for safe and effective 
agents from Traditional Chinese Medicine (TCM) for the treatment of cancer, 
particularly human hepatocellular carcinoma which is one of the interests in our 
laboratory. In this project, TCMs with historical clinical application on hepatoma 
treatment were reviewed. Shortlisted TCMs (Table 1.1) were screened for the 
anti-proliferative activity on human hepatocellular carcinoma cells HepG2 and Hep3B. 
Among the 35 shortlisted TCMs, Oldenlandia diffusa, Scutellaria barbata, Paeonia 
lactiflora and Sophora flavescens showed significant anti-tumor effect on HepG2 and 
10 
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Table 1.1 The 35 shortlisted TCMs with historical clinical application on 
hepatoma treatment. 
Chinese name Latin name Chinese name Latin name 
南、沙參 Adenophora 焦谷芽 Oryza sativa 
當歸 Angelica sinensis 牡丹皮 Faeonia suffruticosa 
白紫草 Amehia guttata 白苟 Paeonia lactiflora 
艾葉 Artemisia argyi J"三七 Panax notoginseng 
乳香 Boswellia carterii 車前子 Plantago asiatica 
柴胡 Bupleurum chinense 夏枯草 Prunella vulgaris 
青皮 Citrus tangerina 太子參 P&eudostellaria 
黨參 Codonopsis pilosula 石見穿 Salvia chinensis 
牡蠣 Crassostrea gigas 五味子 Schisandra chinensis 
焦山楂 Crataegus 半KM Scutellaria barbata 
丁香 Eugenia 垂盆草 Sedum sarmentosum 
北沙、參 Glehnia Uttoralis 神曲 Medicata Fermentata 
甘草 Glycyrrhiza uralensis 白英 Solarium lyratum 
烏藥 Lindera aggregaia 根片 Solarium melongena 
紅紫草 Lithospermum 龍葵 Solarium nigrum 
金錢草 Lysimachia 苦參 Sophora flavescens 
白花蛇舌草 Oldenlandia diffusa 蒲公英 Tamxa_ 
焦麥芽 Triticum aestivum 
According to the Chinese literatures, TCMs with historical clinical application on 
hepatoma treatment were selected and screened for the anti-proliferative effect on 
human hepatocellular carcinoma cells in vitro. Sophora flavescens was chosen for 
fiuther mechanistic studies. 
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1.4 Sophora flavescens Ait. 
Sophora flavescens Ait. is a perennial shrub spread widely and commonly 
cultivated in northeast Asia. The shrub can reach approximately five feets with leaves 
of various shapes, greenish-yellow flowers and brown seed pods (Fig. 1.1 A). The root 
of Sophora flavescens Ait. (Fig. LIB), which was known as "kushen"(苦參）i.e. 
Sophorae Radix, is listed in the Chinese Pharmacopoeia and is a well-known Chinese 
herbal medicine used as diuretic and for the treatment of gastrointestinal disorder, 
diarrhea, skin ulcers and inflammation (Tang and Eisenbrand, 1992; Kimura, 1996; 
Zhu, 1998). The root ranges from 4 to 12 inches in length and an inch in diameter. 
They are prepared for herbal use by bundling and cutting them cross-wise into slices 
which are then dried under sun (Women fitness). 
According to Chinese medical literature, traditionally, the root of Sophora 
flavescens was used as a supplement to treat cancer by stimulating immune 
mechanism (Chang, 1992). Besides, it was also applied for the treatment of 
arrhythmia, especially in cases of coronary disease with premature beats (Chang and 
But, 1986). As mentioned in Modem Study and Application of Materia Medica, 
Sophorae Radix was used for the treatment of female reproductive system infections 
as well as allergic reactions (Dong and Yu, 1990). 
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i U l H 
(Adapted from: http://www.hkolsternl/home-nl/+fotobestajiden/+sophoraflavescens‘htm) 
B 
Fig. 1.1 Photos of Sophora flavescens. A) Fruiting body of Sophora flavescens, 
B) Dried root of Sophora flavescens. 
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1.5 Biological Activities of Sophorae Radix 
The applications of Kushen mentioned in the above section were developed 
mainly during the period 1974-1979. In order to elucidate the bioactive compounds 
leading to the effects of Sophorae Radix, different groups of researchers tried to 
examine the structures and activities of its chemical constituents. Until now, alkaloids 
and flavonoids are reported to be the major chemical constituents of Sophora 
flavescens (Tang and Eisenbrand，1992). Matrine and oxymatrine are the main 
alkaloids in Sophorae Radix while lavandulyl flavanones, which are rarely distributed 
in the plant kingdom, are mainly found in Sophora species (Kim et al., 2004). 
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1.5.1 Antitumor Activities 
Kurarinone, a lavanduyl flavanone isolated from Sophora flavescens, was also 
reported to have cytotoxic activity against MCF-7/6 breast cancer cells in a 
dose-dependent manner with IC50 value, concentration that causes 50% inhibition of 
cell proliferation, of 22.2|xM (Naeyer et aL, 2004). It was also reported to have the 
ability to inhibit the growth of human myeloid leukemia HL-60 cells, human 
hepatocarcinoma HepG2 cells, human lung carcinoma A549 cells, human ovarian 
cancer SK-OV-3 cells, human skin melanoma SK-MEL-2 cells and human colorectal 
carcinoma HCT-15 cells with IC50 values of 18.5, 36.2, 9.0, 9.4, 6.4 and 8.6|LIM 
respectively (Ryu et aL, 1997; Kang et aL, 2000; Ko et aL, 2000). 
2‘-methoxykurarinone and leachianone A, flavonoids with a lavandulyl 
side-chain isolated from Sophora flavescens, were also reported to have cytotoxic 
effect on human myeloid leukemia HL-60 cells with IC50 values of 13.7 and 11.3|uM 
respectively and human hepatocarcinoma HepG2 cells with IC50 values of 21.1 and 
13.3^M respectively (Kang et aL, 2000; Ko et al., 2000). 




1.5.2 Antibacterial, Antimalarial and Antiviral Activities 
Chen et al. (2005) reported that kurarinone, a flavonoid with a lavanduly side 
chain isolated from Sophora flavescens, has antibacterial activities against 
Streptococcus niutans, methicillin-resistant Staphylococcus aureus and 
vancomycin-resistant enterococci. 
Kuroyanagi et al. (1999) also demonstrated that prenylflavanone derivatives with 
lavandulyl or isopentenyl moieties isolated from Sophora flavescens have potent 
antibacterial activities against gram-positive bacteria Staphylococcus aureus, Bacillus 
subtilis. Among these compounds, Kushenol R, isokurarinone and kushenol A showed 
significant antibacterial activities against skin residential floras, S. epidermidis and 
Propionibacterium acnes. 
This suggested that flavonoids isolated from Spophora flavescens have the 
potential to apply for the treatment of bacteria-caused diseases or conditions. 
Besides antibacterial activities, Kim et al. (2004) showed that three lavandulyl 
flavanones, (2S)-2'-methoxykurarinone, sophoraflavanone G and leachianone A, 
isolated from Sophora flavescens, have in vitro antimalarial activities against 
Plasmodium falciparum. Analysis of structure-activity relationship showed that the 
position of methoxyl groups in flavanone skeleton plays an important role in 
antimalarial activities. This suggested that new antimalarial agents can be developed 
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by modifying the phenolic hydroxyl groups in lavandulyl flavanone skeleton. 
Sophoridine, an alkaloid isolated from Sophorae Radix, has been reported to 
have antiviral activities against coxsackievirus B3 (CVB3) which cause fatal viral 
myocarditis. It was suggested that sophoridine may be able to prevent inflammatory 
responses and enhance host resistance against virus infection by increasing the 
expression of IFN-a and IL-10, and at the same time, decrease myocardial apoptosis 
and dysfunction by suppressing TNF- a expression (Zhang et al., 2006). 
Kurorinone, matrine extracted from Sophora flavescens Ait, has been reported to 
have the ability to inhibit HBV replication by promoting leukocytosis and extract of 
Sophora Radix can also inhibit hepatitis B surface antigen (HBsAg) secretion in vitro 
(Liu et al., 1991; Chen and Fu, 1997; Chen et al., 1999; Liu et al, 2003). It was 
reported that oxymatrine isolated from Sophora flavescens inhibit HBV by triggering 
immune reponse in vivo (Chen et al., 2002; Dong et al” 2002). This may account for 
the effect of Sophora Radix in the treatment of chronic hepatitis. 
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1.6 Objectives and Significance of Study 
Currently administered therapeutic anticancer agents in clinical treatment have 
pronounced side effects and sometimes are not effective in treating multidrug resistant 
human hepatocellular carcinoma cells. Thus, this project aimed at isolating bioactive 
compounds from Sophora flavescens which contribute to the anti-proliferative effect 
on human hepatocellular carcinoma cells as well as multidrug resistant human 
hepatocellular carcinoma cells. Understanding the action mechanisms of the bioactive 
compounds can also provide us with a better understanding of drug targeting and 
therapeutic potential of the other natural compounds with similar structure. 
1.6.1 Bioassay-guided Isolation of Active Compounds from 
Sophora flavescens 
Because of the pharmaceutical value of Sophora flavescens, we tried to isolate 
the active compounds responsible for the anti-proliferative effect of Sophora 
flavescens on HepG2 and Hep3B cells. In order to achieve that, bioassay-guided 
isolation was adopted in which human hepatocellular carcinoma cells HepG2 and 
Hep3B were used for screening process. 
19 
INTRODUCTION 
1.6.2 Action Mechanisms of the Bioactive Compounds 
Isolated from Sophora flavescens 
After isolation, the most abundant bioactive compound with significant 
anti-proliferative activity against HepG2 and Hep3B cells was selected for intensive 
mechanistic study. The underlying action mechanisms of this compound on human 
hepatocellular carcinoma HepG2 and multidrug resistance human hepatocellular 
carcinoma RHepG2 cell were investigated. RHepG2 cells were used to represent the 
multidrug resistant tumor cell model with overexpression of P-glycoprotein. The 
action mechanism was traced out by examining the changes in levels of apoptotic 
proteins and comparing the differential mRNA expression profile as well as protein 
expression profile of the control and bioactive compound-treated cells. 
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CHAPTER TWO 
MATERIALS AND METHODS 
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2.1 Cell Culture 
2.1.1 Cell Lines 
A) HepG2 
HepG2 is one of the most common human hepatocellular carcinoma cell model 
used in liver cancer research. It was purchased from American Type Culture 
Collection (ATCC) with the cell line code ATCC® number HB-8065. The cells were 
derived from a 15-year-old Caucasian man and propagated in Roswell Park Memorial 
Institute Tissue Culture Medium 1640 (RPMI 1640) supplemented with 10% (v/v) 
fetal bovine serum (Invitrogen) and 1% (v/v) penicillin-streptomycin (Invitrogen). 
They were allowed to grow in 37°C, 5% carbon dioxide (CO2) humidified incubator. 
B) HepSB 
Hep3B is also an human hepatocellular carcinoma cell line purchased from 
ATCC, ATCC® number HB-8064. It was established from an 8-year-old Black boy. 
The cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% (v/v) fetal bovine serum (GibcoBRL) and 1% (v/v) 
penicillin-streptomycin (GibcoBRL) and grew in 37°C, 5% CO2 humidified incubator. 
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C) Resistance HepG2 (RHepG2) 
It is a multidrug resistant human hepatocellular carcinoma cell line derived from 
HepG2 cell line. R-HepG2 cell line was developed by our research group (Chan et al., 
2000). In the development of R-HepG2 cell line, HepG2 cells resistant to doxorubicin 
were selected by stepwise increasing the doxorubicin concentration in culture medium. 
Selection was started from 0.1 Cells resistant to 100 |iM doxorubicin was 
maintained and cultured as R-HepG2 cell line. Multidrug resistance property of 
R-HepG2 cells was confirmed by treating HepG2 and R-HepG2 cells with 
chemotherapeutic drugs including doxorubicin, vincristine and methotrexate and 
MTT assay was preformed at 48 hours after drug treatment. Overexpression of 
p-glycoprotein and MDRl gene in RHepG2 cells were confirmed by Western and 
Northern blot analysis (Chan et al., 2000). RHepG2 cells were cultured and 
maintained with RPMI1460 culture medium (Invitrogen) with the presence of 10% 
(v/v) fetal bovine serum (Invitrogen), 1% (v/v) penicillin-streptomycin (Invitrogen) 
and 1.2 |iM doxorubicin (Sigma) in a 37�C humidified incubator supplied with 5% 
CO2. 
D) WRL-68 
It is a human normal hepatic cell line purchased from ATCC, ATCC® number 
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CL-48. This cell line characterized by its non-tumorigenicity and it is derived from 
human fetal liver which carries the activity of some specific enzymes (Gutierrez-Ruiz 
et al., 1994). The cells were maintained in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% (v/v) fetal bovine serum (GibcoBRL) and 1% (v/v) 
penicillin-streptomycin (GibcoBRL) and grew in 37�C, 5% CO2 humidified incubator. 
2.1.2 Cell Culture Media 
RPMI 1640 medium (Roswell Park Memorial Institute Tissue Culture Medium 
1640) was used for culturing HepG2 and RHepG2 cells while DMEM medium 
(Dulbecco's Modified Eagle's Medium) was used for culturing Hep3B and WRL-68 
cells. Preparation steps for RPMI 1640 and DMEM medium were similar. A pack of 
the medium powder was dissolved in 1 L of distilled water followed by addition of 2 
g of sodium bicarbonate (Sigma). The pH was adjusted to 7.2 before sterilization by 
filtration with 0.22 fxm bottle-top filter (Millipore). Sterilized medium was kept at 4°C 
until use. For culturing the cells, the sterilized medium was supplemented with 10% 
(v/v) fetal bovine serum (Invitrogen) and 1% (v/v) penicillin-streptomycin 
(Invitrogen). 
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2.2 Isolation of Bioactive Compounds from Sophora 
flavescens 
Dried-roots of Sophora flavescens were purchased from Guangzhou. A voucher 
specimen was identified (voucher number 2004-2531) and deposited in the Institute of 
Chinese Medicine, The Chinese University of Hong Kong. The specimen were 
morphologically authenticated by Dr. Chak-Yin Lee (李澤賢博士)，South China 
Botanical Garden, The Chinese Academy of Sciences (中国科学院华南植物硏究所). 
All experiments were performed using this batch of specimen. 1 kg of air-dried root 
of Sophora flavescens was refluxed with 8 liter of 95% ethanol for 2 hours. Ethanol 
extract of 2 kg of Sophorae Radix was prepared. After filtration of the ethanol extract, 
the filtrate was evaporated under reduced pressure to give syrup. The syrup was 
partitioned between 1 liter of water (H2O) and 400 ml of ethyl acetate (EtOAc). After 
that, the EtOAc layer was collected and the H2O layer was extracted with 300 ml 
fresh EtOAc twice. The ethyl acetate extracts were combined and washed with 200 ml 
of 10% hydrochloric acid and H2O and finally adjusted to pH 7. The pH-adjusted 
ethyl acetate fraction was evaporated and ground into powder which weighted 50.4 g. 
The powder was subjected to silica gel column chromatography and eluted 
successively with discontinuous gradient solvent of hexane and EtOAc at the ratio of 
1:1, 1:2 and 1:4 respectively. The compositions of eluents were analyzed by Thin 
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Layer Chromatography (TLC) and those eluents with similar compositions were 
grouped together. Finally, eleven fractions were obtained and named as KuS 101-
KuSll l . 
KuS 104, KuS 106, KuS 107 and KuS 111 fractions were selected for further 
purification using silica gel column chromatography. Fraction KuS 104 was further 
isolated by silica gel column eluting with hexane : EtOAc (4:1, 3:1 and 2:1). Fraction 
KuS 106 was further purified by silica gel column using hexane : EtOAc (2:1). 
Fraction KuS 107 was separated on a silica gel column using hexane : EtOAc (1:1) to 
give a fraction which, based on TLC, contained trace of impurities. This fraction was 
further purified by silica gel column chromatography with dichloromethane (CH2CI2): 
methanol (MeOH) (93 : 7). Fraction KuS 111 was separated by HPLC with Allich RP 
C-8 column and the solvent system used was acetonitrile : water (1 :1). The powders 
of the purified bioactive compounds were stored at room temperature. Before use, the 
powders were dissolved in absolute ethanol to make the final concentration to 
lOmg/ml and sterilized by filtration. The bioactive compounds dissolved in absolute 
ethanol were stored at -20°C. 
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2.3 MTT Assay 
MTT assay was used to study the cytotoxicity of the bioactive compounds 
isolated from Sophorae Radix in vitro. Ix cells per well in 100 |LI1 culture medium 
were seeded in a flat bottom 96-well plate. The plates were then incubated in 37°C, 
5% CO2 humidified incubator for 24 hours. After that, the medium was removed and 
the cells were incubated in 100 |LI1 of medium with increasing concentration of drugs 
for 48 hours. The cells incubated with medium containing 1% of ethanol were served 
as solvent control. After 48hour-incubation, medium was discarded and 30 jul of MTT 
solution (5 mg/ml in PBS) (Sigma-Aldrich) was added. The cells with MTT solution 
were incubated at 37�C for 3 hours. The MTT solution was then removed and 100 |LI1 
of DMSO was added to dissolve the insoluble crystals. The absorbance at 540 nm of 
each well was detected by ELISA plate reader (Bio-Rad) and then plotted against drug 
concentration to obtain the cell survival curve. The absorbance of solvent control cells 
was determined as 100% cell survival. The concentration of drug which inhibited cell 
growth by 50%, i.e. IC50, was determined from the cell survival curve. 
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2.4 Cell Cycle Analysis 
The cell cycle profiles of the Sophoraflavanone G-treated cells were obtained by 
analyzing the cellular DNA content via the use of flow cytometric method. 3 x 10^ per 
well of HepG2 or RHepG2 cells were seeded in a 6-well plate and allowed to grow 
for 24 hours in 37�C，5% CO2 humidified incubator. After that, the cells were exposed 
to appropriate concentration of Sophoraflavanone G for 24 hours and 48 hours and 
then the samples were collected and washed in phosphate buffered saline (PBS) 
(136 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM Na2HP04 and adjusted to 
pH7.4). The cells incubated with ethanol, in which the concentration was adjusted 
according to the highest ethanol concentration present in the drug-treated sample, 
were served as control. Then, the cells were fixed overnight in ice-cold 70% ethanol 
at -20°C. In the next day, the cell suspension was centrifuged at 800 x g for 3 minutes 
and washed twice with 1ml PBS. Finally the cells were resuspended in 0.5 ml PBS 
solution containing Ribonuclease A (RNase A) (Sigma) with final concentration of 1 
mg/ml and propidium iodide (PI) (Sigma) with final concentration of 50 |Lig/ml. The 
cell suspensions were incubated at 37°C for 30 minutes at dark. After incubation, the 
red fluorescence of PI was detected using FACSort flow cytometry (Becton Dickinson) 
with 10,000 events recorded for each sample. 
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2.5 Detection of Phosphatidylserine Externalization with 
Annexin V-FITC and PI 
Phosphatidyserine (PS) externalization is also one of the characteristics of 
apoptotic cells. TAGS™ Annexin V-FITC kit (Trevigen, Inc.) was used to further 
confirm the involvement of apoptosis in Sophoraflavanone G-treated cells. 3x10^ per 
well of HepG2 or RHepG2 cells were seeded in a 6-well plate and allowed to grow 
for 24 hours in 37°C, 5% CO2 humidified incubator. After that, the cells were 
incubated with different concentrations of Sophoraflavanone G for 24 hours and 48 
hours. The cells incubated with ethanol, in which the concentration was adjusted 
according to the highest ethanol concentration present in the drug-treated sample, 
were served as control. The treated-cells were then harvested and washed twice with 
PBS. Only 5 x 10^ cells per sample were used for the assay and they were incubated 
with 100|xl Annexin V incubation reagent (10 |il of lOX binding buffer, 10 jiil of PI, 3 
|xl of Annexin V-FITC conjugate and 77 |xl of distilled water) for 15 minutes at room 
temperature in dark. After incubation, 400 |xl of IX binding buffer was added to stop 
the binding reaction and the cells were immediately analysed with FACSort flow 
cytometry (Becton Dickinson). 
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2.6 DNA Fragmentation Assay 
DNA fragmentation is one of the hallmark biochemical changes in apoptotic 
cells and this assay was performed to evaluate whether the action mechanism of 
Sophoraflavanone G involves induction of apoptosis. 1 x 10^ of HepG2 or RHepG2 
cells were seeded in 100 mm dish. After 24 hours, different concentrations of 
Sophoraflavanone G was added and incubated for 24 hours and 48 hours in 37°C, 5% 
CO2 humidified incubator. The cells incubated with ethanol, in which the 
concentration was adjusted according to the highest ethanol concentration present in 
the drug-treated sample, were served as control. After that, cells were detached from 
culture dishes by trypsinization and cell pellets were collected by centrifugation at 
4�C, 800 X g for 3 minutes. Cell pellets were washed with PBS twice and then lysed 
with 200 III lysis buffer (3% NP-40, 20 mM EDTA, 50 mM Tris-Cl pH 7.5) for 10 
minutes at 37°C. After incubation, the samples were centrifuged at 6,000 x g for 5 
minutes and the supernatants with apoptotic DNA fragments were collected. 50 jiil of 
5% SDS was added to the supernatant followed by incubation with 10 |xl RNAse A (4 
|xg/|il) (Sigma) at 56�C for 1.5 hour. Then, the samples were incubated with 20 
proteinase K (1.5 |Lig/|il) (Sigma) at 56°C for another 1.5 hour. Cellular DNA was 
finally obtained by precipitating with 30 of 3M sodium acetate (NaOAc) (Sigma) 
and 750 \i\ of absolute ethanol. DNA pellets were collected by centrifugation at 
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13,600 X g for 30 minutes and then washed with 70% ethanol followed by air dry. The 
air-dried DNA pellets were resuspended with 20 |LI1 T I O E Q . I buffer (0.1 mM EDTA, 10 
mM Tris-Cl pH7.5). Before gel analysis, the samples were incubated at 37°C until the 
DNA pellets were completely dissolved. Finally, DNA was subjected for gel 
electrophoresis in Ix Tris-Acetate-EDTA (TAE) buffer, which was diluted from 5Ox 
TAE buffer (2 M Tris base, 5.74% glacial acetic acid, 50 mM EDTA, pH8.0), with 
1.5% agarose gel and the bands were visualized by ultraviolet illumination. 
One-hundred base pairs DNA marker (Amersham Biosciences) was served as size 
reference. 
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2.7 Western Blot Analysis 
2.7.1 Extraction of Total Cellular Protein 
2 X 10^ of HepG2 or RHepG2 cells were seeded in 100mm dish and allowed to 
grow for 24 hours in 37°C, 5% CO2 humidified incubator. After that, the cells were 
incubated with different concentrations of Sophoraflavanone G. The cells incubated 
with ethanol, in which the concentration was adjusted according to the highest ethanol 
concentration present in the drug-treated sample, were served as control. After 
different drug treatment periods, the cells were harvested and washed twice with PBS. 
Adjusted by the size of cell pellets, 30-200 |li1 of lysis buffer (2% SDS, 10% glycerol, 
62.5 mM Tris-HCl, pH 6.8) was added and the samples were allowed to stand on ice 
for 2 hours. The cells were then boiled for 10 minutes followed by centrifugation at 
13,600 X g for 10 minutes at 4�C. Supernatants containing total cellular proteins were 
collected and stored at -20°C until use. 
2.7.2 Extraction of Cytosolic Protein 
2 X 10^ of HepG2 or RHepG2 cells were seeded in 100 mm dish and were 
incubated with different concentrations of Sophoraflavanone G in 37°C, 5% CO2 
humidified incubator. The cells incubated with ethanol, in which the concentration 
was adjusted according to the highest ethanol concentration present in the 
32 
MATERIALS AND METHODS 
drug-treated sample, were served as control. After 48 hours, the cells were collected 
and washed with PBS for two times. 1 x 10^ cells of each sample were lysed with 
30 III of lysis buffer (75 mM NaCl, 1 mM NaH2P04, 8 mM Na2HP04, 250 mM 
sucrose, 21 }xg/ml aprotinin, 5 |xg/ml leupeptin, 1 mM PMSF and 25 jiig digitonin) and 
vortexed vigorously for 30 seconds. The cells debris was separated from the 
supernatant by centrifugation at 10,000 x g for 60 seconds at 4°C. The supernatant 
with cytosolic proteins was collected and mixed with equal volume of 2x SDS loading 
dye (10% glycerol, 0.4% SDS, 0.05% bromophenol blue, 20 mM EDTA, 0.5 M 
Tris-HCl, 5% 2-mercaptoethanol). The mixture was boiled for 10 minutes and 
centrifuged again at 13,600 x g for 7 minutes at 4�C. The supernatant was collected 
and stored at -80°C until use. 
2.7.3 Determination of Protein Concentration 
Bicinchoninic acid (BCA) protein assay was used to determine the amount of 
proteins in the supernatant. In this assay, bovine serum albumin (BSA) (Bio-Rad) was 
used to create the protein standard curve in which 10)LI1 of different concentrations of 
BSA (0, 0.2, 0.4, 0.6, 0.8 and 1 mg/ml) were added to 96-well plate. For the samples, 
1 }il of supernatant was mixed with 9 of distilled water which was then added to 
96-well plate. All the BSA standards and samples were done in triplicate. 200 [d of 
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BCA reaction mixture (BCA solution (Sigma) mixed with 50 mM CUSO4.5H2O 
solution in the ration of 49:1) was then added to each well and incubated at 37�C for 
30 minutes. The absorbance at 540 nm was detected by ELISA plate reader. The BSA 
standard curve was created by plotting the absorbance at 540 nm against BSA 
concentration (Fig 2.1). 
y = 0.0362X + 0.0005 
日 R2 = 0.9991 ^ ^ ^ 
口 0.3 - ^ ^ ^ ^ ^ 
r ^ ^ ^ 
0.1 - ^ ^ ^ ‘ 
0 ^ ^ 1 1 1 1 1 
0 2 4 6 8 10 
Amount of protein (fig) 
Fig 2.1 Bovine Serum Albumin (BSA) standard curve used for protein 
concentration determination. 
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2.1 A Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
According to the user's manual provided by manufacturer, the apparatus of 
vertical electrophoresis system (Bio-Rad) was set up. After that, based on the 
molecular weight of target protein, different percentages of separating gel was set. 
The compositions were shown in Table 2.1. On top of the separating gel, a 4.5% 
stacking gel was set according to the compositions shown in Table 2.1. 
Table 2.1 The compositions of different percentage of SDS gel. 
Separating gel Stacking gel 
8% 12.5% 15% 4.5% 
Distilled water 1.9 ml 1.108 ml 0.975 ml 1.2 ml 
30% Acrylamide , , � 1.07 ml 1.67 ml 2 ml 0.3 ml 
(Bio-Rad) 
4 X lower gel buffer 1 ml 1 ml 1 ml / 
4 X upper gel buffer / / / 0.5 ml 
TEMED (Bio-Rad) 4.65 |LI1 4.65 |LI1 4.65 i^l 2.65 jid 
10% APS (Bio-Rad) 20 |LI1 20 fil 20 )x\ 15 |LI1 
Remarks: a) 4x lower gel buffer included 1.5 MTris, OAYo SDS. The pH was adjusted to 8.8. 
b) 4x upper lower gel buffer included 500 mM Tris, 0.4% SDS. The pH was adjusted 
to 6.8. 
c) 10% (w/v) ammonium persulfate (APS) was prepared by dissolving APS (Bio-rad) 
in distilled water. 
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For the separation of total cellular proteins, in the first place, protein 
concentrations of the samples were determined according to the BSA standard curve. 
Equal amount of protein samples (30 to 50 |Lig) were used for SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). Equal volume of 2x SDS loading dye was mixed with 
the protein samples and the mixtures were boiled for 10 minutes before loading to the 
wells of polyacrylamide gel. 
For the separation of cytosolic proteins, no concentration determination was 
needed. The supernatant collected was ready for SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) after boiling at 100�C for 5 minutes. 
Rainbow™ colored protein molecular weight marker (Amersham Biosciences), 
which served as size reference, was also loaded. The gel in Ix SDS running 
buffer ,which was diluted from lOX SDS running buffer (250 mM Tris base, 500 mM 
glycine, 1% SDS), was electrophoresed under constant voltage of 120 V for about 2 
hours. 
2.7.5 Electroblotting of Protein 
Semi-Dry Electrophoretic Transfer Cell (semi-dry blotter, Bio-Rad) was used to 
transfer the protein from polyacrylamide gel to 0.45 [im Polyvinylidene difluoride 
(PVDF) membrane (Immobilon, Millipore). The apparatus was set up according to the 
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user's manual. At the first place, three blotter papers were soaked in electroblotting 
buffer (E-blot buffer) (66.7 ml lOx Tris glycine, 100 ml methanol, 500 ml distilled 
water) and put on the platinum anode. After that, the dry PVDF membrane was 
soaked in absolute methanol for re-hydration. The hydrated PVDF followed by 
acrylamide gel were put on top of the three blotter papers in which the upper stacking 
gel of the acrylamide gel was cut. Another three blotter papers were soaked in E-blot 
buffer and put on top of the gel. The separated proteins were transferred from the gel 
to the PVDF membrane at constant current at 150 mA (for 2 gels) for 45 to 70 
minutes which was determined according to the sizes of the target proteins. After 
electroblotting, the PVDF membrane with proteins was probed with the antibodies 
specific to the target proteins while the gel was stained with commassie blue staining 
solution (0.05% Commassie brilliant blue R-250 dissolved in acetic acid, methanol 
and distilled water in the ratio of 1:3:10) and destaining solution (acetic acid, 
methanol and distilled water in the ratio of 4:1:5) to ensure complete protein transfer. 
2.7.6 Probing of Proteins with Antibodies 
The PVDF membrane transferred with proteins was blocked with 10% non-fat 
milk in Ix Tris-buffered saline-tween-20 (TBS-T) with 0.1% of tween-20 (Sigma), 
which was diluted from lOx TBS (100 mM Tris, 1.5 M NaCl), at room temperature 
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for 1 hour. The membrane was then washed with TBS-T for 15 minutes for three 
times and probed with primary antibodies (Table 2.2) in 10% non-fat milk at 4�C 
overnight. In the next day, the membrane was washed with TBS-T for 15 minutes 
three times and probed with secondary antibodies (Table 2.2), which were conjugated 
with horseradish peroxidase, at room temperature for 1 hour. Then, the membrane was 
washed again with TBS-T for 15 minutes three times. After thorough washing, the 
target proteins were detected by enhanced chemiluminescence (ECL) assay 
(Amersham Biosciences). 
Table 2.2 List of primary and secondary antibodies used. 
Antibodies Molecular Ratio Source Company 
weight (kDa) 
Anti-Beta-actin ^ 1:5000 Mouse Sigma 
Anti-Bid 22&15 Goat Santa cruz 
Anit- Pro-Caspase-3 35 1:1000 Mouse Santa Cruz 
Anit-caspase-8 50/55 &36M0 1:1000 Mouse Pharmingen 
Anti-Caspase-9 46 & 35 1:1000 Mouse Stressgen 
Anti-Cytochrome C H 1:500 Rabbit Santa Cruz 
Anti-PARP 116 & 85 1:1000 Rabbit Santa Cruz 
Anti-AIF 57 Rabbit Santa Cruz 
Anti-Mouse-HRP - 1:1000 Goat Zymed 
conjugate 
Anti-Rabbit-HRP - 1:1000 Goat Santa Cruz 
conjugate 
Anti-Goat-HRP - 1:1000 Donkey Santa Cruz 
conjugate 
The primary and secondary antibodies used in this project were listed. The ratio 
presented in the table represented the amount of antibodies used for probing the 
corresponding protein. 
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2.7.7 Enhanced Chemiluminescence (ECL) Assay 
The target proteins recognized by the antibodies were detected by ECL assay 
(Amersham Biosciences). In this assay, ECL detection reagent 1 and reagent 2 were 
mixed with 1:1 ratio. The membrane was then immersed in the mixture for 30 seconds 
and wrapped. The membrane was put into a hypersensitive film cassette (Amersham 
Biosciences) and exposed to Fuji Medical x-ray film (Super Rx, Fuji Photo Products 
Co. Ltd.) in dark with various time periods. After that, the film was developed by film 
processor (M35 X-OMAT, Kodak) and band intensities were analyzed by Image J 
software. 
2.8 Detection of Mitochondrial Membrane Potential by JC-1 
Fluorescent Dye 
The mitochondrial membrane potential (中m) was detected by flow cytometry 
with the use of cationic fluorescent probe JC-1 
(5,5\6,6'-tetrachloro-l,r,3,3'-tetraethyl-benzimidazolylcarbocyanine iodide) 
(Molecular Probes). 3 x 10^  per well of HepG2 or RHepG2 cells were seeded in a 
6-well plate. After 24 hours, various concentrations of Sophoraflavanone G were 
added and the cells were allowed to grow in 37°C, 5% CO2 humidified incubator. The 
cells incubated with ethanol, in which the concentration was adjusted according to the 
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highest ethanol concentration present in the drug-treated sample, were served as 
control. After drug treatment for 24 hours and 48 hours, cells were collected and 
washed with PBS. Finally, the cell pellets were resuspended in 500 |j,1 PBS containing 
10 |xM of JC-1 followed by incubation at 37°C for 15 minutes in dark. The stained 
cells were analysed by FACSort flow cytometry (Becton Dickinson) immediately. 
2.9 cDNA Microarray Analysis 
2.9.1 Isolation of Total RNA 
3 X 10^  of HepG2 cells were seeded in 6-well plate and allowed to grow for 24 
hours in 37°C, 5% CO2 humidified incubator. The cells were then incubated with 
2 4 | L I M of Sophoraflavanone G for 24 hours. 1ml TRIzol® Reagent (Invitrogen, Life 
Technologies) was used for extraction of total RNA. The cells were lysed by TRIzol 
Reagent at room temperature for 5 minutes. 200 |LI1 of chloroform was added to the 
lysate. The mixture was then vortexed vigorously for 15 seconds and centrifuged at 
13,600 X g for 15 minutes at 4°C. After centrifugation, the upper aqueous layer was 
collected. 500 |xl of isopropanol was added to the aqueous layer and incubated for 15 
minutes at -20°C for RNA precipitation. The mixture was then subjected to 
centrifugation at 13,600 x g for 10 minutes at 4�C. The RNA pellet was collected by 
discarding the supernatant and washed with 1ml 75% ethanol. Finally, the sample was 
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centrifuged at 6,000 x g for 5 minutes at 4°C and allowed to dry at room temperature 
for 10 minutes. RNA pellet was dissolved with 20 |LI1 of DEPC-treated sterile distilled 
water. Dissolved RNA was stored at -80°C. The purity of RNA was accessed by 
measuring the absorbance at 260 nm and 280 nm. The purified RNA with high quality 
should have the ratio of absorbance at 260/280 nm exceeding 1.75. 
2.9.2 Microarray Hybridization and Analysis 
The qualified RNA was sent to Affymetrix to perform microarray hybridization 
and analysis. The GeneChip expression array selected was GeneChip Human Genome 
U133A 2.0 Array. The procedures used by Affymetrix were described in Affymetrix 
GeneChip® Expressioin Analysis Technical Manual which can be accessed in their 
company homepage. To summarize the procedures according to the technical guide, 
doubled-stranded cDNA was synthesized from the total RNA of our samples. Then, an 
in vitro transcription reaction was done to produce biotin-labeled cRNA from the 
cDNA. The cRNA was fragmented before hybridization. The fragmented target and 
probe array controls were mixed to form a hybridization cocktail which was 
hybridized to the probe array during a 16-hour incubation. Following hybridization, 
the array was automatically washed and stained. Finally, the probe array was scanned 
and saved as data image file which was then analyzed for probe intensities and 
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reported in tabular and graphical formats. Fig. 2.2 showed the flow chart of the 
procedure described. 
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One-Cycle Target Labeling 
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Fig. 2.2 GeneChip labeling assay for Expression array. The flow chart showed the 
procedures used by Affymetrix to conduct microarray hybridization experiment. 
(Extracted from Expression Analysis Technical Manual, with Specific Protocols for 
use with the Hybridization, Wash and Stain Kit which can be accessed at 
http://www. affymetrix. com/ support/technical/manuals. afifx) 
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2.9.3 Validation of Candidate Genes 
2.9.3.1 Determination of RNA Concentration 
Total RNA was extracted from Sophoraflavanone G-treated sample as described 
in section 2.9.1. After that, the RNA concentration was determined 
spectrophotometrically by measuring the absorbance at 260 nm. The absorbance at 
260 nm was used to calculate the RNA concentration by the following formula: 
[RNA] (|ig/ml) = 40/(1/ O.D.260). 
2.9.3.2 First-Strand cDNA Synthesis 
First- strand cDNA was synthesized by using Thermoscript™ RT-PCR system 
for ist-strand cDNA synthesis kit (Invitrogen, Life Technologies). As suggested by the 
manufacturer, 2 |xg of RNA was mixed with 1 \i\ oligo dT, 2 |LI1 lOmM dNTP and 
DEPC-treated water to give final reaction volume of 12 |LI1. The mixture was 
incubated at 65°C for 5 minutes to denature the RNA and primer. After incubation, 
4 111 5x cDNA synthesis buffer, 1 0 0.1 M DTT, 1 |li1 RNaseOUT™(40 units/|Lil), 1 
ThermoScriptTM Reverse Transcriptase (15 units/|il) and 1 \i\ DEPC-treated water 
were added to the RNA-primer mixture. First-strand cDNA was synthesized at 55°C 
for 1 hour and the reaction was terminated by incubating at 85°C for 5 minutes. 
Finally, 1 )LI1 of RNase H was added to the reaction mixture which was then incubated 
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at 37°C for 20 minutes. The product, first-strand cDNA, synthesized was stored at 
-20°C until use. 
2.9.3.3 Reverse-Transcription Polymerase Chain Reaction 
(RT-PCR) of Candidate Genes 
Amplification of the candidate genes from the first-strand cDNA was performed 
to validate their differential expression in Sophoraflavanone G-treated HepG2 cells. 
Primers used for amplification of the target genes were designed according to the 
sequence in NCBI database (accession number for glucose transporter 3 is NM006931; 
while for beta actin is NMOOllOl). The sequences of the primers were shown in table 
2.2. The PCR reaction mixture was set according to table 2.3 and it was subjected for 
PGR reaction (Table 2.4) using PCR machine (Applied Biosystems). The PCR 
products were analyzed by 1% agarose gel with ethidium bromide and visualized by 
ultraviolet. 
Table 2.3 PCR primers for the amplification of candidate genes. 
Genes Direction Primer Sequence Product size 
Beta actin Forward 5, CCG GGA CCT GAC TGA CTA CCT 3’ 5 84 bp 
Reverse 5 ’ CCT AG A AGC ATT TGC GGT GGA 3 ’ 
Glucose Forward 5' TCC CAA GAC ATC CAG GAG AT 3' 657 bp 
transporter 3 Reverse 5 ’ ACG GGT CTC AGG GAC TTT GA 3 ’ 
(GLUT3) 
The PCR primers of the candidate gene were designed according to the respective 
gene sequences in NCBI database. Beta actin was used as the house-keeping gene to 
normalize the amount of cDNA template in different samples. 
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Table 2.4 Compositions of PCR reaction mixture. 
Reagents Volume (fil) 
— lOx PCR buffer 2.5 
25 mM MgCb 2 
2 mM dNTP mix ^ 
10 mM Forward primer 0.75 
10 mM Reverse Primer 0.75 
Phusion™ Taq DNA polymerase 1 
(0.5 unit/jil) (Finnzymes) 
cDNA template 4 
Nuclease-free water 11.5 
— Total 25 
PCR reaction mixture was set according the table presented for the amplification of 
the candidate genes with the use of corresponding primers. 
Table 2.5 PCR cycle for the amplification of candidate genes. 
Purpose Temperature Time Number of cycle 
Initial DNA 98'C 30 seconds 1 
denaturation 
DNA denaturation 98 T 10 seconds 
Primer annealing 60T 30 seconds 38 
Extension 72°C 20 seconds 
Final extension 72 10 min 1 
Storage 4 °C Infinity -
With the use of first-strand cDNA as template, the candidate genes were amplified 
using the PCR cycle mentioned in this table. The PCR products were analyzed by 1% 
agarose gel with ethidium bromide. 
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2.10 Two-Dimensional (2-D) Polyacrylamide Gel 
Electrophoretic Analysis 
2.10.1 Extraction of Total Cellular Protein for 2-D Gel 
Electrophoresis 
2 X 106 of HepG2 or RHepG2 cells were seeded in 100 mm dish. After 24 |liM 
Sophoraflavanone G treatment for 48 hours, the cells were collected and lysed by 200 
III of lysis buffer (8 M urea, 4% (w/v) CHAPS, 2% (v/v) pharmalyte 3-10). The cells 
were vortex vigorously for 30 seconds followed by sonication for 10 minutes. The cell 
lysate was then centrifuged at 13,600 x g for 20 minutes to remove the cell debris. 
The supernatant containing the total cellular protein was collected and stored at -80°C 
until use. 
2.10.2 Determination of Protein Concentration 
Before 2-D gel electrophoretic analysis, protein concentration of each sample 
was determined by Braford assay. Bovine serum albumin (BSA) (Sigma) was used to 
create the protein standard curve in which 1 \i\ of different concentrations of BSA (0, 
0.2, 0.4，0.6, 0.8 and 1 mg/ml) were added to 96-well plate. 1 of sample was also 
added to the plate. All the BSA standards and samples were done in triplicate. 200 |li1 
of Ix Braford reagent (Bio-Rad) was then added to each well and incubated at room 
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temperature for 5 minutes. The absorbance at 595 nm was detected by ELISA plate 
reader within 15 minutes. The BSA standard curve was created by plotting the 
absorbance at 595 nm against BSA concentration (Fig 2.3). 
y = 0.1345X - 0.0093 
0.3 , 
R = 0.9968 
0.25 - ^ 
国 ^ ^ ^ 
宗 0 15 ^ ^ 
。 0 . 0 5 - ^ ^ 
0 ‘ ^ • • 
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-0 .05 L 
Amount of protein (ug) 
Fig. 2.3 Bovine Serum Albumin (BSA) standard curve used for protein 
concentration determination. 
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2.10.3 First-Dimension Isoelectric Focusing (lEF) 
Non-linear pH 3-10 Immobiline DryStrip (Amersham Biosciences) with 13 cm 
in length was used for the first dimension protein separation. 200 |ig of protein in 
rehydration solution (8 M urea, 2% (w/v) CHAPS, 0.5% (v/v) IPG buffer, 18.15 mM 
DTT and 0.002% (v/v) bromophenol blue) was added evenly to the strip holder. After 
that, the Immobiline DryStrip was put in the strip holder (Amersham Biosciences) 
with gel side down. At each end the gel was contacted with the strip holder electrodes. 
1ml DryStrip Cover Fluid (Amershem Biosciences) was applied to overlay the strip in 
order to minimize evaporation and urea crystallization. Then, the cover was placed 
back on the strip holder and the holder was placed on the Ettan IPGphor™ Isoelectric 
Focusing Unit (Amersham Bioscience). The isoelectric focusing (lEF) was conducted 
through a series of voltage steps: 30 V for 10 hours (gradient), 200 V for 1 hour 
(step-and-hold), 500 V for 1 hour (step-and-hold), 8,000 V for 30 minutes (gradient), 
8,000 V for 6.5 hours (step-and-hold). The total voltage-hour was around 50,000 Vh. 
After lEF, the IPG strips were stored at -80°C until use. 
2.10.4 Second-Dimension SDS-PAGE 
The strip taken out from -80°C was thaw at room temperature for a few minutes 
followed by equilibration in 10 ml DTT-containing SDS equilibration buffer (50 mM 
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Tris-HCl, pH8.8, 6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS, 0.002% (v/v) 
bromophenol blue, 100 mg DTT) at room temperature for 15 minutes. Then the strip 
was subjected for second equilibration in 10ml iodoacetamide-containing SDS 
equilibration buffer (50 mM Tris-HCl, pH8.8, 6 M urea, 30% (v/v) glycerol, 2% (w/v) 
SDS, 0.002% (v/v) bromophenol blue, 250 mg iodoacetamide) at room temperature 
for 15 minutes. After equilibration, the strip was ready for second-dimension 
SDS-PAGE with 12.5% polyacrylamide gel (Table 2.1). The strip was placed on the 
top of the polyacrylamide gel and the filter paper soaked with rainbow-colored protein 
molecular marker (Amersham Biosciences) was placed at the acidic end of the IPG 
strip. The strip and the filter paper were sealed in place by 1.5 ml melted agarose. 
Then, the cassette was placed into SE 600 Ruby Electrophoresis Unit (Amersham 
Biosciences) and run at 150 V for 6 hours until the bromophenol blue dye front 
reached the bottom of the gel. 
2.10.5 Visualization of 2-D Gel by Sliver Staining 
After SDS-PAGE, the polyacrylamide gel was visualized by PlusOne™ Silver 
Staining Kit (Amersham Biosciences). According to the protocol suggested by the 
manufacturer, the gel was first fixed in fixing solution (40% (v/v) absolute ethanol, 
10% (v/v) acetic acid, glacial) at room temperature for 30 minutes. After that, the gel 
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was sensitized in sensitizing solution (30% (v/v) absolute ethanol, 0.2% (w/v) sodium 
thiosulphate, 800 mM sodium acetate) at room temperature for 30 minutes. The 
sensitized gel was washed with distilled water for 5 minutes three times. Then, silver 
reaction was performed by incubating the gel in silver nitrate solution (0.25% (w/v) 
silver nitrate solution, 0.0148% (v/v) formaldehyde) for 20 minutes. After silver 
staining, the gel was washed with distilled water for 1 minutes two times followed by 
developing in developing solution (300 mM sodium carbonate, 0.0074% (v/v) 
formaldehyde) for about 5 minutes until the protein spots were appeared. The 
developing reaction was stopped by stopping solution (40 mM EDTA-Na) • H2O) for 
10 minutes. Finally, the gel was washed with distilled water for 5 minutes three times 
and stored in distilled water at 4°C. 
2.10.6 Identification of Differentially Expressed Proteins 
with Matrix Assisted Laser Desorption-Ionization 
Time-of-Flight Mass Spectrometry (MALDI-TOF-MS) 
The stained gel was scanned and analyzed by computer software ImageMaster 
2D version 2.0 (Amersham Biosciences). Differentially expressed proteins were 
excised and subjected for trypsin digestion. The excised spots were first subjected for 
detaining by 20 }il of the mixture of 30 mM potassium ferricyanide and lOOmM 
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sodium thiosulphate (1:1). Once the dark stain was removed, the spots were washed 
by 30 |il of distilled water. After that, the excised spots were equilibrated in 30 |LI1 of 
200 mM ammonium bicarbonate for 10 minutes twice. After equilibration, the gel was 
dehydrated with 100 |il acetonitrile for five minutes three times. The dehydrated gel 
was dried in speed vaccum for 5 minutes until it appeared dust-like. The dried gel was 
then rehydrated in 10 )LI1 of 50 mM ammonium bicarbonate with 400 ng trypsin 
enzyme (Promega) and incubated on ice for 30 minutes. After incubation, 20 |il of 50 
mM ammonium bicarbonate was added to the trypsin mixture followed by digestion 
at 30°C overnight. The digested proteins were extracted by 20 )LI1 of 50 mM 
ammonium bicarbonate and sonicated for 10 minutes. Then, 20 |LI1 of the mixture of 
acetonitrile and 5% trifluoroacetic acid (TFA) (1:1) was added and the mixture was 
sonicated for 10 minutes. After that, the supernatant was removed to a new eppendrof 
tube. The digested protein in the gel was further extracted twice by 20 |j.1 of the 
mixture of acetonitrile and 5% TFA (1:1) and sonication for 10 minutes. And finally, 
10 |il of acetonitrile was added to the gel and sonicated for 10 minutes. The 
supernatants were then combined and dried with speed vaccum. 
The vaccum-dried samples were resuspended in 10 |li1 of 0.1% TFA followed by 
desalting in ZipTipC 18 (Millipore) which is a 10 pipette tip packed with 
halfmicroliter of silica CI8. The ZipTip was first wetted with 10 jiil of 50% 
52 
MATERIALS AND METHODS 
acetonitrile followed by equilibration with 10 |xl of 0.1% TFA. The digested proteins 
were then bound to the silica by aspirating and dispensing for 10 cycles. The 
remaining solution was dispensed as waste. The ZipTip bound with digested protein 
was washed with 10 |xl of 0.1% TFA. Finally, the proteins were eluted with 2 |xl of 
50% acetonitrile/0.1% TFA by aspirating and dispensing for 5 cycles. The eluted 
proteins were subjected for identification by matrix assisted laser 
desorption-ionization time-of-flight mass spectrometry (MALDI-TOF-MS). 
MALDI-TOF-MS analysis was conducted by Mr Dennis Ip who is the technician 
in Department of Biochemistry, The Chinese University of Hong Kong. The peptide 
mass fingerprints of the target proteins obtained from MALDI-TOF-MS analysis were 
subjected for NCBI database searching. 
2.11 Statistical Analysis 
Statistical difference of survival between the solvent control samples and 
drug-treated samples was analyzed with Student's Mest. Statistical significance was 
set at p-value <0.05. 
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3.1 Bioassay-guided Isolation of Bioactive Compounds from 
Sophora flavescens 
2 kg of the dried root of Sophora flavescens was extracted using the method 
described in Material and Method section. The extract was partitioned and separated 
by silica gel column chromatography using the method described in Material and 
Method section. The eluents were collected by flask with 50 ml/flask and they were 
numbered with the same sequence as they were collected. The compositions of 
eluents were analyzed by Thin Layer Chromatography (TLC) and those eluents with 
similar compositions were grouped together. Finally, eleven fractions were obtained 
and named as KuS 101-KuSlll (TableS.l). 
In this project, we aim at purifying bioactive compounds with significant 
anti-proliferative activity on human hepatocellular carcinoma cells. Thus, 
bioassay-guided isolation method was adopted in which the anti-proliferative effects 
of the fractions were screened on HepG2 and Hep3B cell lines by the use of MTT 
assay. MTT represents 3-[4,5-dimenthylthiazol-2-yl]-2,5-diphenyl tetrazolium 
bromide which is the major component in this assay. MTT solubilized in 1 x PBS is 
yellowish in color. The tetrazolium ring of MTT can be cleaved by mitochondrial 
dehydrogenases of viable cells which results in water insoluble purple MTT formazan 
crystal. By dissolving the insoluble crystals in DMSO, the resulting purple solution 
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can be quantitated by ELISA plate reader. The increase in absorbance represents an 
increase in the amount of MTT formazan formed and thus, an increase in viable cells 
number. 
In this assay, HepG2 and Hep3B cells were seeded on 96-well plates (1 x 
cells per well). After 24 hours, the cells were incubated with different fractions of 
different concentration for 48 hours. The percentage of cells survival after the 
treatment of drugs at different concentration was calculated by comparing with the 
solvent-treated control cells. 
From Fig. 3.1 and Fig. 3.2, KuS 101 did not showed significant anti-proliferative 
effect on both cell lines while KuS 102 showed a significant anti-proliferative effect 
on HepG2, but not on Hep3B. The remaining fractions showed significant 
anti-proliferative effect on both HepG2 and Hep3B cells (Table 3.4 and Fig 3.1). IC50, 
concentration that caused 50% inhibition of cell proliferation, of each fraction on 
HepG2 and Hep3B cells were calculated (Table 3.4) based on the graphs presented on 
Fig. 3.1 and Fig. 3.2. 
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Table 3.1 The amount of each fraction collected. 
Fractions Eluent Number Amount (g) 
KuS 101 1-8 7.565 
KuS 102 9-13 1.836 
KuS 103 14-18 1.620 
KuS 104 19-27 2.801 
KuS 105 28-39 3.431 
KuS 106 40-58 2.658 
KuS 107 59-72 1.925 
KuS 108 73-81 0.875 
KuS 109 82-100 1.575 
KuS 110 101-106 0.601 
KuS 111 107-110 3.330 
The eluents from the silica gel column were collected by flask with 50 ml/flask and 
the eluent numbers represented the sequence they collected. According to TLC 
analysis, eluents with similar compositions were grouped together and subjected to 
vacuum dry. The amount of each fraction represented the weight after vacuum dry, i.e. 
the yield of each fraction. Results shown are the representative of two independent 
experiments. 
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Fig. 3.1 Anti-proliferative effect of KuS 101 to KuS 111 on HepG2 cells. HepG2 
cells were seeded in 96-well plate (1 x lO^ cells per well). After 24 hours, the cells 
were incubated with different fractions of different concentrations for 48 hours at 
37'C, 5% CO2. The percentage of cell survival, which was calculated with respective 
to the control, was determined by MTT assay. Data was expressed as mean 土 standard 
deviation of six replicates. 
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Table 3.2 P-value of each points on HepG2 growth response curve (Fig.3.1). 
Point 1 Point 2 Point 3 Point 4 Point 5 Point 6 
(O/ug/ml) (6.25fig/ml) (12.5陀/ml) (2 5呢/ml) (50jug/ml) (lOOjug/ml) 
KuSlOl - <0.8 <0.05 <0.01 <0.01 <0.8 
KuS102 - <0.01 <0.01 <0.01 <0.01 <0.01 
KuS103 - <0.01 <0.01 <0.01 <0.01 <0.01 
KuSm - <0.01 <0.01 <0.01 <0.01 <0.01 
KuS105 - <0.8 <0.01 <0.01 <0.01 <0.01 
KuS106 - <0.8 <0.01 <0.01 <0.01 <0.01 
KuSlO? - ^ <0.01 <0.01 <0.01 <0.01 
KuSlOS - ^ <0.01 <0.01 <0.01 <0.01 
KuS109 - <0.8 ^ <0.01 <0.01 <0.01 
KuSllO - <0.05 ^ <0.01 <0.01 <0.01 
KuSlll - ^ <0.01 <0.01 <0.01 <0.01 
Statistical analyses were made by means of Student's r-test between the drug-treated 
and control sample (0 fxg/ml). P-values smaller than 0.05 were considered to be 
statistically significant. 
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Fig. 3.2 Anti-proliferative effect of KuS 101 to KuS 111 on Hep3B cells. Hep3B 
cells were seeded in 96-well plate (1 x cells per well). After 24 hours, the cells 
were incubated with different fractions of different concentration for 48 hours at 37 °C, 
5% CO2. The percentage of cell survival, which was calculated with respective to the 
control, was determined by MTT assay. Data shown was expressed as 土 standard 
deviation of six replicates. 
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Table 3.3 P-value of each points on Hep3B growth response curve (Fig.3.2) 
Point 1 Point 2 Point 3 Point 4 Point 5 Point 6 
(Ojug/ml) (6.25 fig/ml) (12.5 陀/ml) (25 fig/ml) (50 jug/ml) (100 fig/ml) 
- <0.5 — <0.05 <0.05 — <0.05 <0.5 _ 
KuS102 - ^ ^ ^ ^ <0.5 
KuSlOS - ^ ^ <0.01 <0.01 <0.01 
KuS104 - <0.05 — <0.01 —<0.01 <0.01 <0.01 
KuSI05 - ^ <0.01 <0.01 <0.01 <0.01 
KuSJ06 - < 0 ^ <0.01 <0.01 <0.01 <0.01 
KuS107 - ^ <0.01 <0.01 <0.01 <0.01 
KuSlOS - <0.8 <0.01 <0.01 <0.01 <0.01 
KuS109 - ^ <0.01 <0.01 <0.01 <0.01 
KuSllO - ^ <0.01 <0.01 <0.01 <0.01 
KuSlll - ^ <0.01 <0.01 <0.01 <0.01 
Statistical analyses were made by means of Student's Mest between the drug-treated 
and control sample (0 |ig/ml). P-values smaller than 0.05 were considered to be 
statistically significant. 
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Table 3.4 The IC50 of each fraction on HepG2 and Hep3B cells. 
IC50 (^ig/ml) 
Fractions HepG2 Hep3B 
KuS 101 - -
KuS 102 2.984 --
KuS 103 26.715 45.920 
KuS 104 15.612 13.190 
KuS 105 11.381 11.665 
KuS 106 11.336 13.187 
KuS 107 18.679 14.670 
KuS 108 21.721 19.153 
KuS 109 24.713 16.890 
KuS 110 24.873 13.779 
KuS 111 14.183 11.343 
The I C 5 0 , concentration that causes 50% inhibition of cell proliferation, was 
calculated based on the graphs presented on Fig. 3.1 and Fig. 3.2. Results shown are 
the representative of three independent experiments. 
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The fractions with sufficient amount as well as significant anti-proliferative 
effect on HepG2 and Hep3B were selected for further purification by silica gel 
column chromatography. The selected fractions included KuS 104, KuS 106, KuS 107 
and KuS 111. 
Fraction KuS 104 eluted with hexane:EtOAc (1:1) was further isolated by 
silica gel column eluting with hexaneiEtOAc (4:1, 3:1 and 2:1) to give compound 
104-1 (70 mg) and 104-3 (160 mg). 
Fraction KuS 106 eluted with hexane : EtOAc (1:1) was further purified by silica 
gel column using hexane : EtOAc (2:1) to give compound 106-1 (380 mg). 
Fraction KuS 107 eluted with hexane : EtOAc (1:2) was separated on a silica gel 
column using hexane : EtOAc (1:1) to give a fraction which, based on TLC, contained 
trace of impurities. This fraction was further purified by silica gel column 
chromatography eluting with CH2CI2: MeOH (93 : 7) to yield compound 107-1 
(180 mg). 
Fraction KuS 111 was separated by HPLC with Allich RP C-8 column and the 
solvent system used was acetonitrile : water (1 :1) to give compound III6-F3 (about 
40 mg) and III7-F2 (about 20 mg). 
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3.2 Structure Identification of the Bioactive Compounds 
Isolated from Sophora flavescens 
Six compounds were successfully isolated from this bioassay-guided purification 
method. All of them were characterized by spectrospical analysis with ultra-violet 
(UV), mass spectrometry (MS), nuclear magnetic resonance (NMR) and by direct 
comparison of spectroscopic data of each compound with those corresponding 
compounds reported in literatures. The analysis was done with the help of Mr. P.M. 
Hon, Institute of Chinese Medicine, The Chinese University of Hong Kong. 
Compound 104-1 is a white crystal with melting point range from 99 to 100; UV 
nm : 311, 285 ； EI MS m/z (rel. int) : 284 (100)，267,197, 162,134,104; 
NMR spectrum and ^^ C NMR spetrum were shown in Table 3.3 and Table 3.4 
respectively. It was identified as maackiain by comparing its m.p., MS, NMR and 
13c NMR spectra with literature values (Shibata and Nishikawa, 1963) (Unpublished 
data done by Mr. P.M. Hon) 
Compound 104-3 is a white crystal with melting point range from 156 to 159; 
UV 二 nm : 295; EI MS m/z (rel. int) : 438 (20), 315 (100), 219(15), 165 (80), 69 
(30); NMR spectrum was shown in Table 3.3. This compound was identified as 
leachianone A by comparing its m.p., MS and ^H NMR spectra with published values 
(linuma et al., 1990) (Unpublished data done by Mr. P.M. Hon) 
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Compound 106-1 is a white crystal with melting point range from 176 to 178; 
UV nm : 295; EI MS m/z (rel. int) : 424(20), 406 (18), 301 ( 60), 283 (100), 219 
(20), 165 (60), 69 (50); NMR spectrum was shown on Table 3.3. By comparing 
our data with the published values, it was identified as sophoraflavanone G (Shirataki 
et al, 1988). (Unpublished data done by Mr. P.M. Hon) 
Compound 107-1 is in powder form with light yellow color; UV ？iT" nm : 295; 
EI MS m/z (rel. int) : 440 (10), 422(10), 317 (25), 299 (30), 165 (100)，124(70), 
109( 80)，67 (90); NMR spectrum and '^C NMR spetrum were shown on Table 3.3 
and Table 3.4 respectively. By comparing our data with the published values, it was 
identified as Kushenol X (Kurayanagi et al, 1999). (Unpublished data done by Mr. 
P.M. Hon) 
Compound III6-F3 is in amorphous powder form with light yelloew color; UV 
nm : 291; EI MS m/z (rel. int) : 438 [M]+ (20), 420 (28), 351 ( 55), 179(60), 
110 (40) 69 (100); 1h NMR spectrum and "C NMR spetrum were shown on Table 3.3 
and Table 3.4 respectively. These data were identical to that reported in literature 
(Matsuo et aL, 2003). However, this compound was not named by the author. Thus, 
we named it as Sophoraflavanone J. (Unpublished data done by Mr. P.M. Hon) 
Compound III7-F2 was isolated as yellow amorphous powder. High resolution 
FAB mass spectrum showed [M+H]+ at m/z 471.2390, corresponding to a molecular 
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formula of C 2 7 H 3 4 O 7 . In its 'H NMR spectrum (Table 3.3) , typical ABX three 
one-proton with doubles signals at 5 5.52 (IH, dd, J 二 12.9, 3.0 Hz; H-2) ,2.87 (IH, 
dd, J = 12.9, 16.0 Hz; H-3a) and 2.71 (IH, dd, J = 3.0,16.0 Hz; H-3b) showed 
compound III7-F2 to be a flavanone. In the aromatic region of the spectrum showed 
the presence of four protons. One of them as singlet at 5 6.00 was assigned to the 
proton of A ring (H-6). Whereas the remaining three, one as doublet at 5 7.14 (IH, d. J 
=7 .3 Hz), one as doublet at 6.25 (IH, dd, J = 7.3, 2.2 Hz) and one as doublet at 6.22 
(IH, d, J = 2.2 Hz), were assigned to H-6，，H-5' and H-3', respectively. This indicated 
that compound III7-F2 has two oxygenation groups at C-2' and C-4' in B ring moiety. 
Except the skeleton of flavanone, its and " c NMR spectra (Table 3.3 and 
Table 3.4) also showed four tertiary methyls, three methylenes, one methine, two 
quaternary carbons linking oxygen atom and two methoxy groups. This revealed the 
present of Cio alkyl side chain in compound III7-F2, which possesses a ring structure 
due to the absent of double bond and the 11 degrees of unsaturation. While in the 
C-alkyl side chain moiety, there are two quaternary carbons linking oxygen atom (at 6 
76.17,s and 81.04,s). One of them linked with the only aliphatic methoxy group in 
compound III7-F2, another should be connected with oxygen atom of the hydroxyl 
group at C-7 of flavanone nucleus formed a 2,2-dimethyl -3,4-dihydropyran ring . 
Careful examination of the ^H and ^^ C NMR spectra including NMR 
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COSY, 13c NMR and DEPT, HMQC and HMBC data had led to unambiguous 
assignments of all signals. The linkage position of the C- alkyl moiety, C-6 or C-8, 
was unequivocally established to be at C-8 of the A ring by HMBC spectrum, i.e. the 
methylene protons at 5 2.72 and 2.05 (each IH, m; H- l " ) showed correlation with 
C-7 (at 5 162.72,s), C-8 (5 104.12,s) and C-9 (5 164.49,s). In the HMBC spectrum, 
the aliphatic methoxy protons (6 3.06, 3H,s) were correlated with a carbon assigned at 
C-5" (5 76.17,s) and the aromatic methoxy protons (5 3.70,3H,s) were correlated with 
C-5 (5 162.31,s). So the two methoxy groups were located at C-5" and C-5, 
respectively. Consequently, compound III7-F2 was established as 2,,4，-dihydroxy-
5-methoxy- [2,2-dimethyl-3-(3-methyl-3-methoxyl-butyl)-3,4-dihydropyrano]-[5,6: 
8,7] - flavanone, a new lavandulyl flavanone, and named as sophoraflavanone K. 
(Unpublished data done by Mr P.M. Hon). 
The established chemical structure of each compounds are summarized in Fig. 
3.3. 
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Table 3.5 The ^H NMR spectral data for Compound 104-1，104-3，106-1,107-1， 
III6-F3 and III7-F2 (J, Hz). (Unpublished data done by Mr. P.M. Hon) 
H Compound Compound Compound Compound Compound Compound 
104-1 104-3 106-1 107-1 III6-F3 III7-F2 
4.40’dd.(4.2,l 5.75，dd(13.5,2 5.75,dd(13.5,2 5.59.d，(11.7) 5.59.dd,(12.9, 5.52.dd,(12.9, 
0.2) .7) .7) 3.0) 3.0) 
3.74,dd(10.2，l 
^ 
3,67，ddd 3.18.dd，(13.5, 3.17,dd，(13.5, 4.92,d,(11.7) 2.88,dd.(12.9, 2.87,dd,(12.9, 
(4.2,6.9,15.5) 16.8.) 16.8.) 15.6) 16.0) 
2.84,dd(16.8,2 2.89dd(16.8,2. 2.71’dd,(15.6, 2.71,dd(16.7,3 
-1) 1} ^ .0) 
4 5.63,d,(6.9) 
5 7.45,d(8.4) 




3' 6.65,s 6.52,s 6.54,s 6.33,(2.2) 6.22(2.2) 
6.99,s 6.63,d,(8.1) 6.54,d(7.8) 6.56,d,(9.0) 6.34，dd(9.0,2. 6.25，dd(7.3,2. 
V 2) 
6' 7.55,d,(8.1) 7.49d(7.8) 7.45,d(9.0) 7.23’dd(9.0) 7.14,dd(7.3) 
,, 2.65,m 2.66,m 2.65,m 2.69,m 2.72,m 
2.18,m 2.18，m 2.17,m 2.16,m 2.05,m 
2" 2.83,m 2.78,m 2.65,m l,71,m 1.33,m 
,, 2.18,m 2.18,m 2.17’m 2.25,m 1.32，m 
1.81,m 1.81,m 1.84,m 1.84,m 1.05’m 
4" 5.14,m 5.13,m 5.14,m 5.17,m 1.33,2H,m 
6" 1.81,s 1.82,s 1.78,s 1.68,s 1.05,s 
7” 1.75,s 1.76,s 1.75，s 1.57,s 1.04,s 
9 •‘ 1.66,s 1.66,s 1.68，s 1.22,s 1.08,s 
4.69,d(2.3) 4.71,d(2.3) 4.66,d,(2.1) 1.41,s 1.33,s 
10" 
4.77,d(2.3) 4.77,d(2.3) 4.73,d,(2.1) 




Remarks: s represents singlet; d represents doublet; dd represents double doublet; m represents multilet. 
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Table 3.6 The NMR spectral data for Compound 104-1，107-1, III6-F3 and 
III7-F2. (Unpublished data done by Mr. P.M. Hon) 
Position Compound Compound Compound Compound 
104-1 107-1 III6-F3 III7-F2 
2 67.41 79.8 76.27,d 76.71,d 
3 41.53 73.0 45.80,t 45.72,t 
4 80.01 199.0 193.88,s 193.95,s 
5 133.08 ^ 162.25,s 162.31,s 
6 110.67 96.7 95.02,d 95.09,d 
7 160.04 163.2 162.78,7 162,72,s 
8 104.05 104.6,s 104.12,s 
9 157.99 164.48,s 164.49,s 
10 112.87 109.0 106.41,s 109.60,s 
1' 119.78 116.1 118.79,s 118.57,s 
2， 105.93 157.21,s 157.44,s 
3' 一143.06 — 103.6 103.98,d 104.06,d 
4’ 一149.41 一 160.3 160.10,s 160.25,s 
5 ' 94.21 108.0 108.18,d 108.27,d 
6’ 一155.52 130.9 128.74,d — 129.03,d 
1” ^ 23.40，t 23.50,t 
2” ^ 42.69,d 42.80,d 
3” 一 28.0 30.72,t 25.78,t 
4" 124.09,d 26.50,t 
5” 132.3 134.62,s 一 76.17s 
6" ^ 26.45,q 27.70,q 
7，, 18.43,q 23.85,q 
8" 80.99,s 81.04,s 
9" 22.10,q 21.46,q 
10” n ^ 28.36,q 28.41,q 
Ar-OCHs 56.57,q 56.67,q 一 
R-OCHs 49.58,q 
-OCH2O- 102.47 I I Z I I I I Z I I ^ Z I I Z I I I 
Remarks: s represents singlet; d represents doublet; t represents triplet; q represents quatre. 
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Y " 
10" ^ ' 4 " 
XT 
A . Maackiain (compound 104-1) B . Leachianone A (compound 104-3) 
M.W.284 Rl = 0CH3 R2 = H; M.W.438 
C . Sophoraflavanone G (compound 106-1) 
Rl = OH R2 = H; M.W.424 
D . Kushenol X (compound 107-1) 
R l = O H R 2 = o h ； M . W . 4 4 0 
丫 f 
R2 O OCH3 o 
E . Sophoraflavanone J (compound III6-F3) F. Sophoraflavanone K (compound III7-F2) 
RI = OH R2 = 0CH3; M.W.438 M.W.470 
Fig. 3.3 Chemical structures of the bioactive compounds isolated from Sophora 
flavescens. Based on the spectroscopic data obtained from UV, MS and NMR 
spectrum, the chemical structure of the compounds were established. Compound 
104-1, 104-3, 106-1, and 107-1 were identified as macckain, leachianone A, 
sophoraflavanone G and Kushenol X respectively. Compound III6-F3, named as 
sophoraflavanone J, was previously isolated and characterized but not named. 
Compunds III7-F2 was a new lavandulyl flavanone isolated from Sophora flavescens 
and named as sophoraflavanone K. M.W. represented molecular weight (Unpublished 
data done by Mr. P.M. Hon) 
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3.3 In Vitro Anti-tumor Effect of the Bioactive Compounds 
Isolated from Sophora flavescens 
Six bioactive compounds were isolated from Sophora flavescens by the use of 
bioassay-guided isolation method. In order to confirm their anti-proliferative effect on 
human hepatocellular carcinoma cells in vitro, the purified bioactive compounds were 
incubated with HepG2 and Hep3B cells and the percentage of cells survival after the 
treatment of these compounds was detected by MTT assay. 
HepG2 cells and Hep3B cells were seeded on 96-well plates (1 x 10^ cells per 
well). After 24 hours, the cells were incubated with different concentrations of 
bioactive compounds for 48 hours and MTT assay was performed as described in 
Materials and Methods section. The percentage of cells survival after the treatment of 
drugs at different concentration was calculated by comparing with the solvent-treated 
control cells and the I C 5 0 values of the bioactive compounds on HepG2 and Hep3B 
cells were calculated (Table 3.7) based on the graphs presented in Fig. 3.4. 
Maackiain showed the lowest anti-proliferative effect on both HepG2 and Hep3B 
cells while the remaining five compounds, Leachianone A, Sophoraflavanone G, 
Kushenol X, Sophoraflavanone J and Sophoraflavanone K showed a significant 
anti-proliferative effect on both human hepatocellular carcinoma cells HepG2 and 
Hep3B, with I C 5 0 ranging from 20 |iM to 30 \lM. 
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Fig. 3.4 Anti-proliferative effect of Maackiain, Leachianone A, Sophoraflavanone 
G^  Kushenol X, Sophoraflavanone J and Sophoraflavanone K on HepG2 and 
Hep3B cells. HepG2 cells and Hep3B cells were seeded on 96-well plates (1 x 
cells per well). After 24 hours, the cells were incubated with different concentrations 
of bioactive compounds for 48 hours at 37�C，5% CO� . The percentage of cell 
survival, which calculated with respective to the control, was determined by MTT 
assay. The percentage of cell survival was found to be decreased with increasing 
concentration of Maackiain (A), Leachianone A (B), Sophoraflavanone G (C), 
Kushenol X (D), Sophoraflavanone J (E) and Sophoraflavanone K (F) in these two 
cell lines. Data shown were the mean 土 standard deviation of six replicates. 
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Table 3.7 The IC50 values of Maackiain, Leachianone A, Sophoraflavanone G, 
Kushenol X，Sophoraflavanone J and Sophoraflavanone K on HepG2 and 
Hep3B cells. 
IC50 OiM) 
Compound HepG2 Hep3B 
Maackiain 101.16 114.12 
Leachianone A 23.36 12.92 
Sophoraflavanone G 19.41 25.02 
Kushenol X 33.80 51.16 
Sophoraflavanone J 26.12 21.37 
Sophoraflavanone K 20.50 16.13 
The I C 5 0 , concentration that causes 50% inhibition of cell proliferation, was 
calculated based on the graphs presented on Fig. 3.4. Results shown are the 
representative of three independent experiments. 
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HEPATOCELLULAR CARCINOMA CELLS 
4.1 In Vitro Anti-tumor Effect of Sophoraflavanone G 
Among the five purified bioactive components mentioned in the previous chapter, 
Sophoraflavanone G was chosen for further studies. Sophoravanone G was first 
reported in 1988 (Shirataki et al., 1988). It was reported to have the ability to inhibit 
the growth of human myeloid leukemia HL-60 cells, human hepatocarcinoma HepG2 
cells, human lung carcinoma A549 cells, human ovarian cancer SK-OV-3 cells, 
human skin melanoma SK-MEL-2 cells and human colorectal carcinoma HCT-15 
cells with I C 5 0 values of 12.5，13.3, 6.4，7.9，3.9 and 5.7 |iM, respectively (Ryu et a!., 
1997; Ko et al., 2000). However, there is not much research investigating its action 
mechanism on human hepatocellular carcinoma. 
Initially, by the use of MTT assay, the anti-proliferative effect of 
Sophoraflavanone G on human hepatocellular carcinoma cells lines HepG2, Hep3B 
and multidrug resistant human hepatocellular carcinoma cells lines R-HepG2 was 
studied. In this assay, the cells were incubated with different concentrations of 
Sophoraflavanone G for 48 hours. The percentage of cell survival after the treatment 
of drugs at different concentrations was calculated by comparing with the 
solvent-treated control cells. 
The anti-proliferative effects of Sophoraflavanone G on these three cell types 
were found to be dose-dependent (Fig. 4.1), i.e. the percentage of cell survival was 
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decreased with increasing concentration of Sophoraflavanone G. The I C 5 0 values of 
Sophoraflavanone G on HepG2, Hep3B and RHepG2 for 48 hours treatment were 
1 9 . 4 1 | I M , 2 5 . 0 2 | L I M and 2 7 | I M , respectively. 
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Fig. 4.1 Anti-proliferative effect of Sophoraflavanone G on HepG2, Hep3B and 
RHepG2 cells. A) HepG2 cells, B) Hep3B cells and C) RHepG2 cells were seeded on 
96-well plates (1 x lO^ cells per well). After 24 hours, the cells were incubated with 
different concentrations of Sophoraflavanone G for 48 hours at 37°C, 5% CO2. The 
percentage of cell survival, which calculated with respective to the control, was 
determined by MTT assay. Data shown were the mean +_standard deviation of six 
replicates. 
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4.2 Cell Cycle Analysis of Human Hepatocellular Carcinoma 
Cells and Multidrug Human Hepatocellular Carcinoma 
Cells 
DNA replication and cell divisions are tightly coordinated in normal cells which 
results in normal growth of cell population. The cell division cycle is divided into four 
sequential phases. Diploid cells start at G1-phase in which the enzymes required 
during cell division are prepared. After that the cells enter S-phase during which the 
DNA content is replicated. Until the DNA content is doubled, the cells reach 
G2-phase. Eventually, the cells enter M phase for the occurrence of actual cell 
division. After mitosis, the cells are ready to start another division cycle. However, in 
tumor cells, regulation of cell cycle is lost. The imbalance of cell proliferation and cell 
death causes the expansion of tumor cell population. Because of this, most of the 
drugs used in cancer therapy involve the induction of cell cycle arrest or apoptosis 
(Collins et al., 1997; Garrett, 2001). 
As suggested by MTT assay, Sophoraflavanone G is able to exert 
anti-proliferative effect on HepG2 and RHepG2 carcinoma cells. In order to study the 
action mechanism of this compound on tumor cells, it is crucial to investigate its 
effect on cell cycle by monitoring the change of DNA contents after drug treatment. 
The cell cycle profiles of tumor cells and drug-treated tumor cells were examined 
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by propidium iodide (PI) staining and analysed by flow cytometry. PI binds to DNA 
by intercalating between the bases into double-stranded nucleic acids without any 
sequence preference. Its fluorescence is enhanced 20- to 30-fold once the dye binds to 
DNA. The fluorescence emitted, which represents the DNA content in the cells, can 
be detected by flow cytometry. 
The fluorescence emitted from the stained drug-treated cells was detected by 
flow cytometry and a sub G1 peak was observed in the Sophoraflavanone G-treated 
samples (Fig. 4.2 and Fig. 4.3). The sub G1 peak represents the apoptotic or necrotic 
cells. Since cell permeabilization or alcohol fixation does not fully preserve the 
fragmented DNA within the apoptotic cells, this fraction of DNA leaks out of the 
apoptotic cells during subsequence washing and staining steps. Therefore, cells 
undergoing apoptosis have reduced DNA content and are detected as the population 
with low DNA stainability, i.e. sub G1 peak, in the cell cycle profile (Darzynkiewicz 
et al., 1997). 
The data showed that subGi population in Sophoraflavanone G-treated HepG2 
and RHepG2 cells was increased in a dose and time-dependent manner (Fig. 4.2, Fig. 
4.3，Table 4.1 and Table 4.2). 
Interestingly, it was observed that, on HepG2 cells, there was an increased in 
percentage of G2/M phase after low concentration of Sophoraflavanone G treatment. 
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This suggested that Sophoraflavanone G may be able to induce cell cycle arrest at 
G2/M phase before undergoing apoptosis. However, this observation was not shown 
on RHepG2 cells. 
83 
MECHANISTIC STUDY OF SOPHORAFLA VANONE G IN THE IND UCTION OF APOPTOSIS IN 
HEPATOCELLULAR CARCINOMA CELLS 
24hrs treatment 48hrs treatment 
A. Control (0.2% ETOH) E. Control (0.2% ETOH) 
L- � 1 -
C 1C2! 0 1022 
B. 23,58 jxM of Sophoraflavanone G F. 23,58 /iM of Sophoraflavanone G 
Ia 1 La . 
C 35.38 uM of Sophoraflavanone G G 35.38 /iMof Sophoraflavanone G 
I 
c •” ‘ 
D. 47,17 uM of Sophoraflavanone G H. 47.17 /iM of Sophoraflavanone G 
Fig. 4.2 Cell cycle profile of HepG2 cells after the treatment of 
Sophoraflavanone G for 24 hours and 48 hours. HepG2 cells were seeded in 6-well 
plate (3 X 10^ cells per well) and incubated with 0.2% ethanol (solvent control) and 
different concentrations of Sophoraflavanone G for 24 hours (A-D) and 48 hours 
(E-H). The cells were collected and stained with propidium iodide. The stained 
samples were analyzed by flow cytometry from which the cell cycle profile could be 
obtained. Results shown are the representative of three independent experiments. 
84 
MECHANISTIC STUDY OF SOPHORAFLA VANONE G IN THE IND UCTION OF APOPTOSIS IN 
HEPATOCELLULAR CARCINOMA CELLS 
Table 4.1 The percentage distribution of sub Gi, Gi，S and G2/M phase of HepG2 
cells after the treatment of Sophoraflavanone G for 24 hours and 48 hours. 
Sub Gi Gi/Go S G2/M 
I Control 1.43% 55.56% 10.10% 24.74% 
1 — 
b 23.58 1.77% 44.75% 4.21% 46.26% 
2 
35.38 juM 6.16% 42.76% 14.76% 34.88% 
s 
% 
^ 47.17 juM 43.27% 32.77% 10.10% 12.29% 
1 Control 1.37% 60.88% 9.53% 22.95% 
1 
2 
is 23J8 uM 3.60% 44.62% 4.69% 44.99% 
go 
u 
"S 35.38 //M 52.88% 27.86% 6.96% 11.48% 
s 
0 
1 47.17 /iM 55.3% 32.3% 7.36% 4.93% 
Based on the cell cycle profile obtained from flow cytometry analysis, the statistical 
percentage of each phase in the cell cycle was calculated and demonstrated in this 
table. Results shown are the representative of three independent experiments. 
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24hrs treatment 48hrs treatment 
A. Control (0.25% ETOH) E. Control (0,25% ETOH) 
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丄 iiw 
FL2 丄 0 10'? 
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D. 58.96 /iM of Sophoraflavanone G H. 58,96 j^M of Sophoraflavanone G 
'Li. ； L 
Fig. 4.3 Cell cycle profile of RHepG2 cells after the treatment of 
Sophoraflavanone G for 24 hours and 48 hours. RHepG2 cells were seeded on 
6-well plate (3 x 10^ cells per well) and incubated with 0.25% ethanol (solvent control) 
and different concentrations of Sophoraflavanone G for 24 hours (A-D) and 48 hours 
(E-H). The cells were collected and stained with propidium iodide. The stained 
samples were analyzed by flow cytometry from which the cell cycle profile could be 
obtained. Results shown are the representative of three independent experiments. 
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Table 4.2 The percentage distribution of sub Gi, Gi, S and G2/M phase of 
RHepG2 cells after the treatment of Sophoraflavanone G for 24 hours and 48 
hours. 
Sub Gi Gi/Go S G2/M 
I Control 1.55% 66.79% 13.38% 18.06% 
S 
私 
S 35.38 juM 2.67% 66.96% 13.32% 16.69% 
bD 
g 
't 47.17 juM 2.38% 65.22% 13.49% 17.89% 
s 
% 
3 58.96 juM 3.72% 56.04% 8.23% 29.79% 
1 Control 1.87% 66.38% 11.76% 19.29% 
a 
2 
Js juM 16.43% 54.60% 14.53% 12.56% 
S 
二 47.17 //M 24.85% 48.98% 13.52% 10.68% 
I 
i 58.96 uM 29.30% 47.70% 11.71% 9.82% 
L J 
Based on the cell cycle profile obtained from flow cytometry analysis, the statistical 
percentage of each phase in the cell cycle was demonstrated in this table. Results 
shown are the representative of three independent experiments. 
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4.3 Induction of Apoptosis in Hepatocellular Carcinoma 
Cells by Sophoraflavanone G 
Apoptosis is part of programmed cell death that removes the unwanted cells in 
an organism via the regulated manner. This regulated process is responsible for 
maintaining tissue homeostasis by mediating the equilibrium between cell 
proliferation and death. Morphological characteristics of apoptosis include membrane 
blebbing, cell shrinkage, chromatin condensation and nucleosomal fragmentation 
(Ricci and Zong, 2006). While the biochemical changes which characterize apoptosis 
include loss of mitochondrial membrane potential， externalization of 
phosphatidylserine (PS) and DNA laddering. Apoptosis has been considered to be the 
major mechanism of chemotherapy-induced cell death and it is essential to develop 
therapeutic agents which are able to induce apoptosis in fast growing tumor cells. 
Cell cycle analysis showed that Sophoraflavanone G is able to induce cell 
death in both tumor cells and multi-drug resistant tumor cells. Therefore, two assays, 
DNA fragmentation assay and Annexin V- PI co-staining assay, were done to 
determine whether Sophoraflavanone G can induce apoptosis in tumor cells. 
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4.3.1 Induction of Phosphatidylserine Externalization in 
Hepatocellular Carcinoma Cells by Sophoraflavanone G 
Phosphatidylserine (PS) is a negatively charged phospholipid which is 
predominantly present in membrane leaflets facing the cytosol. In the cells 
undergoing apoptosis, the phospholipids asymmetry of plasma membrane was broken 
up which results in PS externalization. Annexin V binds preferentially to phospholipd, 
like PS, in a Ca^^-dependent way. Thus, it is a sensitive marker for the detection of PS 
externalization (Vermes et al., 1995). 
However, translocation of PS to external cell surface occurs in both apoptotic 
and necrotic cells. In order to differentiate the cell population which undergoes 
apoptosis or necrosis, the treated cells were subjected to Annexin V-FITC and PI 
co-staining. PI is normally a membrane-impermeable dye. However, necrotic cells 
lose membrane integrity which results in influx of propidium and intracellular 
staining. So both Annexin V-FITC and PI can stain necrotic cells or late stage 
apoptotic cells while the early apoptotic cells with intact cell membrane can be 
stained by Annexin V-FITC only. In short, this assay is able to discriminate intact cells 
(FITCVPI), early apoptotic cells (FITC^/PF) and late apoptotic/necrotic cells 
(FITC+/PI+) (Fig. 4.4). 
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Fig. 4.4 Detection of phosphatidylserine externalization by flow cytometry. The 
cells stained with Annexin V- FITC and propidium iodide were analyzed by flow 
cytometry. Under normal conditions, the cells showed negative signals of both FITC 
and PI fluoresces. When apoptosis was triggered within the cells by stimulus, the 
early apoptotic cells with intact cell membrane showed positive signal of FITC as 
Annexin V-FITC successfully stained the externalized phosphatidylserine (PS). The 
cells without intact cell membrane, like late apoptotic cells or necrotic cells, were 
successfully stained with both PI and Annexin-V and showed positive signal of FITC 
and PI. 
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The data (Fig. 4.5 and Fig. 4.6) showed that the percentage of cell population in 
lower right quadrant (FITCVPF) in Sophoraflavanone G-treated HepG2 and RHepG2 
cells was increased in a dose-dependent manner. This indicated that Sophoraflavanone 
G is able to induce apoptosis in HepG2 and RHepG2 cells. When comparing the data 
of 24 hours and 48 hours treatment, there was an increase of cell population in upper 
right quadrant (FITC+/PI+). This indicated that HepG2 and RHepG2 cells entered late 
apoptotic stage after 48 hours treatment of Sophoraflavanone G. 
Surprisingly, it was observed that concentration of Sophoraflavanone G which 
induced PS externalization was higher than the I C 5 0 of the corresponding cell lines. 
This indicates that apoptosis was occurred only after the treatment with higher 
concentration of Sophoraflavnaone G or prolonged incubation. 
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Fig. 4.5 Induction of phosphatidylserine externalization in HepG2 cells by 
Sophoraflavanone G HepG2 cells were seeded on 6-well plate (3 x 10^ cells per 
well).After 24 hours, the cells were incubated with 0.25% ethanol (A, D), which 
served as control, and different concentrations of Sophoraflavanone G for 24 hours (B, 
C) and 48 hours (E, F) at 37°C, 5% CO2. The drug-treated cells were collected and 
stained with Annexin V-FITC and PI, followed by flow cytometry analysis. Results 
shown are the representative of three independent experiments. 
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Fig. 4.6 Induction of phosphatidylserine externalization in RHepG2 cells by 
Sophoraflavanone G. RHepG2 cells were seeded on 6-well plate (3 x 10^ cells per 
well).After 24 hours, the cells were incubated with 0.25% ethanol (A, D), which 
served as control, and different concentrations of Sophoraflavanone G for 24 hours (B, 
C) and 48 hours (E, F) at 37°C, 5% CO2. The drug-treated cells were collected and 
stained with Annexin V-FITC and PI, followed by flow cytometry analysis. The 
percentages of cell in lower right quadrant and upper right quadrant were increased in 
dose- and time-dependent manner. Results shown are the representative of three 
independent experiments. 
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4.3.2 Induction of DNA Fragmentation in Hepatocellular 
Carcinoma Cells by Sophoraflavanone G 
One of the biochemical hallmarks of apoptosis is the cleavage of chromosomal 
DNA into nucleosomal units by various endogenous nucleases like caspase-activated 
deoxyribonuclease (CAD) (Enari et al., 1998). 
DNA fragmentation can be visualized as laddering pattern by gel electrophoresis. 
Therefore, in this study, DNA was extracted from the nuclei of Sophoraflavanone 
G-treated cells and analyzed by electrophoresis on 1% agarose gel. 
As shown in the gel photos (Fig. 4.7 and Fig. 4.8), DNA fragmentation was 
initially induced in HepG2 and RHepG2 cells after 58.96|xM of Sophoraflavanone G 
treatment for 24 hours or 35.38|iM of Sophoraflavanone G treatment for 48 hours. 
This assay further confirmed that Sophoraflavanone G induced apoptosis on both 
HepG2 and RHepG2 cells in a dose- and time-dependent manner. 
It was also observed that concentration of Sophoraflavanone G which induced 
DNA fragmentaion was higher than the I C 5 0 of the corresponding cell lines. This 
indicates that apoptosis was occurred only after the treatment with higher 
concentration of Sophoraflavnaone G or prolonged incubation. 
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Fig. 4.7 Induction of DNA fragmentation in HepG2 cells after the treatment of 
Sophoraflavanone G for 24 hours and 48 hours. 
Ix 106 ofHepG2 cells were seeded 
in 100mm culture dish and incubated with different concentrations of 
Sophoraflavanone G for 24 and 48 hours at 37°C, 5% CO2. DNA extracted from the 
samples was analyzed by electrophoresis on 1% agarose gel. DNA fragmentation was 
observed in Sophoraflavanone G-treated HepG2 cells. Lane 1: Treated with 0.3% 
absolute ethanol for 24hours (Control). Lane 2: Treated with 35.38 |xM of 
Sophoraflavanone G for 24 hours. Lane 3: Treated with 47.17 |LIM of 
Sophoraflavanone G for 24 hours. Lane 4: Treated with 58.96 |iM of 
Sophoraflavanone G for 24 hours. Lane 5: Treated with 0.3% absolute ethanol for 48 
hours (Control). Lane 6: Treated with 35.38 |xM of Sophoraflavanone G for 48 hours. 
Lane 7: Treated with 47.17 |iM of Sophoraflavanone G for 48 hours. Lane 8: Treated 
with 58.96 |LIM of Sophoraflavanone G for 48 hours. Lane 9: 100 base pairs DNA 
marker. 
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Fig. 4.8 Induction of DNA fragmentation in RHepG2 cells after the treatment of 
Sophoraflavanone G for 24 hours and 48 hours. Ix 10^ of RHepG2 cells were 
seeded in 100mm culture dish and incubated with different concentrations of 
Sophoraflavanone G for 24 and 48 hours at 37�C, 5% CO2. DNA extracted from the 
samples was analyzed by electrophoresis on 1% agarose gel. DNA fragmentation was 
observed in Sophoraflavanone G-treated RHepG2 cells. Lane 1: Treated with 0.3% 
absolute ethanol for 24hours (Control). Lane 2: Treated with 35.38 |iM of 
Sophoraflavanone G for 24 hours. Lane 3: Treated with 47.17 \iM of 
Sophoraflavanone G for 24 hours. Lane 4: Treated with 58.96 |iM of 
Sophoraflavanone G for 24 hours. Lane 5: Treated with 0.3% absolute ethanol for 48 
hours (Control). Lane 6: Treated with 35.38 ]xM of Sophoraflavanone G for 48 hours. 
Lane 7: Treated with 47.17 |xM of Sophoraflavanone G for 48 hours. Lane 8: Treated 
with 58.96 |LIM of Sophoraflavanone G for 48 hours. Lane 9: 100 base pairs DNA 
marker. 
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4.3.3 Induction of Caspase-3 activation in Hepatocellular 
Carcinoma Cells by Sophoraflavanone G 
Most of the morphological changes occurred in apoptotic cells are caused by a 
set of cysteine proteases. These death proteases are homologous to each other and 
belong to a large protein family known as the caspases. Since caspases are essential 
for the occurrence of the apoptotic phenotype of cell death, they are regarded as the 
central executioners of the apoptotic pathway (Hengartner, 2000). 
Caspases are formed constitutively and normally present as inactive proenzyme. 
For the induction of full enzymatic activity, the pro-caspases require cleavage at 
specific internal aspirate residues which causes the separation of large and small 
subunits. The simplest way to activate a pro-caspase is to expose it to another, 
previously activated caspase molecule. This "caspase cascade" strategy of caspase 
activation is used extensively by cells which are undergoing apoptosis. For instance, 
activation of the upstream caspases, such as caspase-8 and caspase-9, by 
pro-apoptotic signals lead to proteolytic activation of the downstream effector 
caspases, caspase-3, caspase-6 and caspase-7. These effector caspases are the 
executors which cleave a set of vital proteins and initiate the apoptotic degradation 
phase including DNA fragmentation (Saraste and Pulkki, 2000). 
Caspase-3 is one of the effector caspases initiating apoptotic degradation. Thus, 
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it is essential to monitor the protein level of pro-caspase-3 in Sophoraflavanone 
G-treated HepG2 and RHepG2 cells, which provides another evidence to confirm that 
Sophoraflavanone G is able to induce apoptosis in vitro, by Western blot analysis. 
Fig. 4.9 showed that the level of pro-caspase-3 was decreased in a 
dose-dependent manner in both HepG2 and RHepG2 cells. This suggested that the 
inactive pro-caspase-3 was cleaved into active caspase 3 after Sophoraflavanone G 
treatment. 
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Fig. 4.9 Cleavage of inactive pro-caspase-3 into active caspase-3 in HepG2 and 
RHepG2 cells after the treatment of Sophoraflavanone G for 24 and 48 hours. 
2 X 10^ of HepG2 (A) or RHepG2 (B) cells were seeded on 100mm dish and 
incubated with different concentrations of Sophoraflavanone G for 24 and 48hours at 
37°C，5% CO2. Proteins were extracted from the samples and separated by 12.5% 
SDS-PAGE. After that, Western blot analysis was performed. Relative band intensities 
were calculated with respect to beta-actin. Results shown are the representative of 
three independent experiments. 
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Activated caspase-3 is able to cleave a number of proteins such as 
poly-(ADP-ribose) polymerase (PARP). PARP is a zinc-finger, chromatin-associated 
protein which is important for DNA repair, transcription and chromosomal stability. 
During apoptotic cell death, transient stimulation of PARP leads to poly(ADP-ribose) 
accumulation in early apoptotic cells. However, intact 116 kDa PARP was cleaved 
into 85 kDa and 24 kDa fragments by caspase-3 during the later stages of apoptosis 
which aims at preventing excessive ATP depletion and permitting completion of the 
apoptotic pathway (Rodriguez-Hernandez et al., 2006). Since PARP is one of the 
proteins cleaved by activated caspase-3, monitoring the level of intact 116 kDa PARP 
and 85 kDa PARP in Sophoraflavanone G-treated cells by Western blot analysis could 
further confirm whether the decrease of the level of pro-caspase-3 was due to the 
cleavage of inactive form to active form. 
It was found that the level of intact 116 kDa PARP was slightly decreased and 85 
kDa fragment was increased in a dose-dependent manner on both cell lines (Fig. 4.10). 
This result suggested that, after Sophoraflavanone G treatment, the pro-caspase-3 was 
cleaved into active form which in turn, cleaved the intact 116 kDa PARP into 85 kDa 
and 24 kDa fragments. 
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Fig. 4.10 Cleavage of 116 kDa PART into 85 kDa PARP in HepG2 and RHepG2 
cells after the treatment of Sophoraflavanone G for 24 and 48 hours. 2 x 10^  of 
HepG2 (A) or RHepG2 (B) cells were seeded on 100mm dish and incubated with 
different concentrations of Sophoraflavanone G for 24 and 48hours at 37�C, 5% CO2. 
Proteins were extracted from the samples and separated by 10% SDS gel. After that, 
Western blot analysis was performed. Relative band intensities were calculated with 
respect to beta-actin. Results shown are the representative of three independent 
experiments. 
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4.4 Underlying Mechanisms of Sophoraflavanone G-induced 
Apoptosis in Human Hepatocellular Carcinoma Cells 
Previous data showed that Sophoraflavanone G induced apoptosis in human 
hepatocellular carcinoma cells HepG2 and multi drug resistance human hepatocellular 
carcinoma cells RHepG2. Sophoraflavanone G-induced apoptosis involved the 
activation of an effector caspase, caspase-3, which is one of the members in the 
caspase cascade. Generally, the caspase cascade can be activated by two distinct 
routes. One route is initiated from the cell surface by apoptotic stimuli. The signals 
from the stimuli are transmitted by death receptors and an upstream caspase, 
caspase-8. This route is named as death receptor pathway or extrinsic pathway. The 
other route is initiated from intracellular apoptotic stimuli. In this pathway, a number 
of Bcl-2 family members, cytochrome c and caspase-9 are involved. Since 
mitochondria are the sites where the stimuli initiated, this pathway is named as 
mitochondria pathway or intrinsic pathway (Cho and Choi, 2002; Hengartner, 2000). 
In this section, the underlying mechanisms of Sophorafalvanon G-induced 
apoptosis in HepG2 and RHepG2 cells were investigated by examining the levels of 
several hallmark proteins in the death receptor pathway and mitochondria pathway. 
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4.4.1 Involvement of Death Receptor Pathway in 
Sophoraflavanone G-induced Apoptosis in Human 
Hepatocellular Carcinoma Cells 
The death receptor pathway is triggered by members of the death-recetpor 
superfamily such as tumor nercosis factor receptor I. Binding of ligands to the 
corresponding death receptors induces receptor clustering and formation of a 
death-inducing signaling complex. This complex recruits multiple pro-caspase-8 
molecules through the adaptor molecule, Fas-associated death domain protein 
(FADD). Upon recruitment, the pro-caspase-8 molecules are cleaved and activated 
through induced proximity (Hengartner, 2000). Since capase-8 is the most apical 
caspase in the death receptor pathway, the levels of pro-caspase-8 and active 
caspase-8 proteins were investigated in Sophoraflavanone G-treated HepG2 and 
RHepG2 cells. 
It was found that the level of pro-caspase-8 was slightly decreased and activated 
caspase-8 was increased in a dose-dependent manner in both cell lines (Fig. 4.11). 
This suggested that Sophoraflavanone G-induced apoptosis involved the death 
receptor pathway via the activation of caspase-8, an upstream caspase of the caspase 
cascade. Since the Western blots for caspase-8 were not very satisfactory, further 
investigation should be done to confirm the observation. 
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Fig. 4.11 Activation of Caspase-8 in HepG2 and RHepG2 cells after the treatment 
of Sophoraflavanone G for 24 and 48 hours. 2x 10^  of HepG2 (A) or RHepG2 (B) 
cells were seeded on 100mm dish and incubated with different concentrations of 
Sophoraflavanone G for 24 and 48hours at 37°C，5% CO2. Proteins were extracted 
from the samples and separated by 12.5% SDS gel. After that, Western blot analysis 
was performed. Relative band intensities were calculated with respect to beta-actin. 
Results shown are the representative of three independent experiments. 
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4.4.2 Involvement of Bid protein in Sophoraflavanone 
G-induced Apoptosis in Human Hepatocellular Carcinoma 
Cells 
Bid protein is a pro-apoptotic Bcl-2 family member with BH3 domain only. It is 
reported that caspase-8 directly cleaves Bid following its own activation as caspase-8 
prefers the Asp59 site of Bid. Cleavage of p22 Bid at internal Asp sites results in a 
major pi5 and minor pi3 and p l l fragments, pi5 Bid is able to translocate to 
mitochondria as an integral membrane protein, where it promotes cytochrome c 
release. Thus，it is believed that Bid is the protein which provides the cross-talk and 
integration between the death receptor and mitochondrial pathway (Gross et al., 1999; 
Hengartner, 2000; Esposti, 2002; Grinberg et al., 2002). 
Since the data showed that Sophoraflavanone G-induced apoptosis involved the 
activation of caspase-8, it was speculated that Bid protein was also involved and 
provided a bridge between death receptor and mitochondrial pathway. In this section, 
the levels of p22 Bid and pi5 Bid were investigated in Sophoraflavanone G-treated 
HepG2 and RHepG2 cells by Western blot analysis. 
It was found that the level of p22 Bid was slightly decreased and pi5 Bid was 
increased in a dose-dependent manner in both cell lines (Fig. 4.12). This suggested 
that Sophoraflavanone G-induced apoptosis involved the death receptor pathway via 
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the activation of caspase-8 and leads to cleavage of p22 Bid into pi5 Bid. Since the 
Western blot for pi5 Bid protein was not very satisfactory, further investigation 
should be done to confirm the observation. 
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Fig. 4.12 Cleavage of p22 Bid into pl5 Bid in HepG2 and RHepG2 cells after the 
treatment of Sophoraflavanone G for 48 hours. 2 x 
106 of HepG2 (A) or RHepG2 
(B) cells were seeded on 100mm dish and incubated with different concentration of 
Sophoraflavanone G for 48hours at 37�C，5% CO2. Proteins were extracted from the 
samples and separated by 15% SDS gel. After that, Western blot analysis was 
performed. Relative band intensities were calculated with respect to beta-actin. 
Results shown are the representative of three independent experiments. 
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4.4.3 Involvement of Mitochondrial Pathway in 
Sophoraflavanone G-induced Apoptosis in Human 
Hepatocellular Carcinoma Cells 
The mitochondrial pathway is used extensively in response to internal insults 
such as DNA damage. These diverse response pathways converge on mitochondria 
through the activation pro-apoptotic member of Bcl-2 family. The pro-apoptotic and 
anti-apoptotic Bcl-2 family members meet at the surface of mitochondria and compete 
to regulate the release of cytochrome c. In the cytosol, cytochrome c associates with 
apoptotic protease-activating factor 1 (Apaf-1) which recruits pro-caspase-9, 
promoting its self-activation. Activated caspas-9 cleaves the down-stream effector 
caspase-3 which rapidly cleaves intracellular substrates and executes apoptosis 
(Hengartner, 2000; Ricci and Zong, 2006). 
The data presented above showed that p22 Bid was cleaved into pi5 Bid by 
activated caspase-8. It is speculated that pi5 Bid translocates to mitochondria and 
promotes cytochrome c release. Thus, the level of cytochrome c in Sophoraflavanone 
G-treated HepG2 and RHepG2 cells was evaluated. Since caspase-9 is the most 
upstream caspase in this pathway, the levels of pro-caspase-9 and active caspase-9 
were also examined in the Sophoraflavanone G-treated cells. 
For detecting the protein levels of cytochrome c, the drug-treated cells were 
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lysed to collect the cytosolic proteins while for detecting the levels of pro-caspase9 
and caspase-9, total cellular proteins were collected from drug-treated cells. 
It was found that the level of cytochrome c in the cytosol was increased in a 
dose-dependent manner in both cell lines (Fig. 4.13). This suggested that 
Sophoraflavanone G-induced apoptosis involves the death receptor pathway via the 
activation of caspase-8 and leads to cleavage of p22 Bid into pi 5 Bid. pi 5 Bid acts as 
the cross talk between death receptor and mitochondrial pathway by promoting the 
release of cytochrome c. Since the Western blot for cytochrome c was not very 
satisfactory, further investigation should be done to confirm the observation. 
The level of pro-caspase9 was slightly decreased and activated caspase-9 was 
increased in a dose-dependent manner in both cell lines (Fig. 4.14). This suggested 
that Sophoraflavanone G-induced apoptosis involves the mitochondrial pathway via 
the release of cytochrome c which in turn activates caspase-9, an upstream caspase of 
the caspase cascade. 
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Fig. 4.13 Release of cytochrome c into cytosol in HepG2 and RHepG2 cells after 
the treatment of Sophoraflavanone G for 48 hours. 2 x 10^  of HepG2 (A) or 
RHepG2 (B) cells were seeded on 100 mm dish and incubated with different 
concentrations of Sophoraflavanone G for 48hours at 37°C, 5% CO2. Cytosolic 
proteins were extracted from the samples and separated by 15% SDS gel. After that, 
Western blot analysis was performed. Relative band intensities were calculated with 
respect to beta-actin. Results shown are the representative of three independent 
experiments. 
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Fig. 4.14 Cleavage of pro-caspase-9 into active caspase-9 in HepG2 and RHepG2 
cells after the treatment of Sophoraflavanone G for 24 and 48 hours. 2 x 10^  of 
HepG2 (A) or RHepG2 (B) cells were seeded on 100 mm dish and incubated with 
different concentrations of Sophoraflavanone G for 48 hours at 37°C, 5% CO2. 
Proteins were extracted from the samples and separated by 12.5% SDS gel. After that, 
Western blot analysis was performed. Relative band intensities were calculated with 
respect to beta-actin. Results shown are the representative of three independent 
experiments. 
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4.4.4 Induction of Mitochondrial Membrane Depolarization 
in Human Hepatocellular Carcinoma Cells by 
Sophoraflavanone G 
There is a controversial view on the role of mitochondrial membrane potential 
(A^m) in cytochrome c release. Cytochrome c release has been suggested to occur via 
permeability transition (PT) associated mitochondrial swelling and thus rupture of the 
outer mitochondrial membrane (Scarlett and Murphy, 1997; Petit et al, 1998; 
Krajewski et al.，1999). PT is described as a sudden increase in permeability of the 
mitochondrial membrane to solutes with a molecular mass less than 1.5 kDa, as a 
consequence of the charge difference between the mitochondrial matrix and the 
cytosol, i.e. A^m (Ly et al., 2003). Thus, in some systems, dissipation of A^^^ has 
been associated with cytochrome c release from the mitochondria (Mignotte and 
Vayssiere, 1998). 
Western blotting analysis showed that cytochrome c was released in 
Sophoraflavanone G-treated HepG2 and RHepG2 cells. Since it has been reported that 
A中m is associated with cytochrome c release, the effect of Sophoraflavanone G on 
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iodide) is the common and specific cationic fluorescent probe for the detection of 
changes in A中m. JC-1 forms either J-aggregates or monomers with the emissions of 
the dye forms detectable by flow cytometry at 585 nm or 530 nm respectively. The 
high of normal cells loaded with JC-1 allows for the formation of red-fluorescent 
J-aggregates. Loss of results in dissipation of J-aggregates into monomers which 
causes the shift of fluorescent from red to green (Ly et al., 2003). 
The data were shown in Fig. 4.15 and Fig. 4.16. The x-axis represents the green 
fluorescent of monomeric JC-1 while y-axis represents the red fluorescent of dimeric 
JC-1. The values presented in each contour plot represent the percentage of cell in the 
right quadrant with higher green to red fluorescent ratio. High green to red fluorescent 
ratio represents the loss of A少m in the cells. 
After the treatment of Sophoraflavanone G on HepG2 and RHepG2 cells for 24 
and 48 hours, the percentages of cells with high green to red fluorescent ratio were 
increased with increasing concentration of Sophoraflavanone G. This result indicated 
that Sophoraflavanone G induced mitochondrial membrane depolarization in HepG2 
and RHepG2 cells. 
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Fig. 4.15 Induction of mitochondrial membrane potential depolarization in 
H e p G 2 cells by Sophoraflavanone G. HepG2 cells were seeded in 6-well plate (3 x 
105 cells per well). After 24 hours, the cells were incubated with 0.15% ethanol (A, G)， 
which served as control, and different concentrations of Sophoraflavanone G for 24 
hours (A-F) and 48 hours (G-L) at 37°C, 5% CO2. The drug-treated cells were 
collected and stained with JC-1, followed by flow cytometry analysis. Results shown 
are the representative of three independent experiments. 
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Fig. 4.16 Induction of mitochondrial membrane potential depolarization in 
R H e p G 2 cells by Sophoraflavanone G RHepG2 cells were seeded in 6-well plate (3 
X 10^ cells per well). After 24 hours, the cells were incubated with 0.15% ethanol (A, 
G), which served as control, and different concentrations of Sophoraflavanone G for 
24 hours (A-F) and 48 hours (G-L) at 37°C, 5% CO2. The drug-treated cells were 
collected and stained with JC-1, followed by flow cytometry analysis. Results shown 
are the representative of three independent experiments. 
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4.4.5 Involvement of Caspase-independent Pathway in 
Sophoraflavanone G-induced Apoptosis in Human 
Hepatocellular Carcinoma Cells 
Apoptosis-inducing factor (AIF) is a 57 kDa flavoprotein with two mitochondrial 
localization sequences and two nuclear localization signal sequences. Normally, AIF 
stores in the intermembrane space of mitochondria, and upon induction of apoptosis 
by staurosporine, AIF's translocation to the cytosol occurs concurrently with the 
dissipation of A中m in which it engages in a self-amplification loop. Cytosolic AIF is 
then translocated and resided in the nucleus. In the nucleus, AIF is capable of 
inducing DNA condensation and fragmentation of isolated nuclei in a 
caspase-independent manner. AIF can induce not only the nuclear hallmark of 
apoptosis but also other characteristics of apoptotic cell death, such as externalization 
of phosphatidylserine in the plasma membrane (Susin et al., 1999; Hunot and Flavell, 
2001; Cho and Choi, 2002). 
The data showed that Sophoraflavanone G is able to induce mitochondrial 
membrane potential depolarization. It is speculated that AIF is also be able to release 
into cytosol and trigger caspase-independent apoptosis in the nucleus. Thus, in this 
section, the level of cytosolic AIF in Sophoraflavanone G-treated HepG2 and 
RHepG2 cells was examined. 
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It was found that the level of AIF in the cytosol was increased in a 
dose-dependent manner in both cell lines (Fig. 4.17). This suggested that 
Sophoraflavanone G-induced apoptosis involves the caspase-independent pathway via 
the release of AIF from mitochondria to nucleus. 
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Fig. 4.17 Release of AIF into cytosol in HepG2 and RHepG2 cells after the 
treatment of Sophoraflavanone G for 48 hours. 2 x 10^  ofHepG2 (A) or RHepG2 
(B) cells were seeded in 100mm dish and incubated with different concentration of 
Sophoraflavanone G for 48 hours at 37°C, 5% CO2. Cytosolic proteins were extracted 
from the samples and separated by 12.5% SDS-PAGE. After that, Western blot 
analysis was performed. Relative band intensities were calculated with respect to 
beta-actin. Results shown are the representative of three independent experiments. 
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5.1 Identification of Differentially Expressed Genes in 
Sophoraflavanone G-treated Human Hepatocellular 
Carcinoma Cells by cDNA Microarray Analyasis 
Data presented above showed that Sophoraflavanone G is able to induce 
apoptosis in human hepatocellular carcinoma HepG2 and RHepG2 cells via death 
receptor pathway, mitochondrial pathway and caspase-independent pathway. However, 
apoptosis is the consequence triggered by other upstream cellular changes or stimulus, 
it is speculated that Sophoraflavanone G may induce other signaling pathway. 
cDNA microarray analysis is a large scale quantitative assay which enable the 
researchers to survey thousands of genes in parallel. By grouping the response genes 
into functional pathways, the response pattern illustrates the mechanism of disease, 
action mechanism of new compounds or predicts disease progression as well as 
functions of previously unannotated genes (Stoughton, 2005). Thus, in order to 
examine the Sophoraflavanone G-induced intracellular changes, cDNA microarray 
analysis was performed to screen for the changes of gene expression levels by 
comparing the mRNA expression profile of the control and Sophoraflavanone 
G-treated samples. 
To perform this assay, mRNA was extracted from the control HepG2 cells and 
Sophoraflavanone G-treated HepG2 cells. The extracted mRNA with high quality was 
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sent to Affmetrix to perform expression analysis using GeneChip expression array. 
The chip selected was GeneChip Human Genome U133A 2.0 Array which is a single 
array representing 14,500 well-characterized human genes. 
The probes intensity of each dot in the array was reported in signal log2 ratio by 
comparing the control sample with the Sophoraflavanone G-treated sample. To 
facilitate the analysis, the threshold log ratio was set as either above 2 or below -2, i.e. 
the log ratio either larger than 2 or smaller than -2 indicated that the difference in 
expression level between the control and Sophorflavanone G-treated sample was 
either up-regulated or down-regulated at least four-fold. While any spot showed the 
log ratio between 2 and -2 was regarded as similar expression level of this gene in the 
two samples. 
The data showed that there were 397 known genes up-regulated with the log 
ratio above 2 (Table 5.1) and 240 known genes down-regulated with the log ratio 
below -2 (Table 5.2). 
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Table 5.1 The up-regulated candidate genes under Sophoraflavanone G induction 
in HepG2 cells. 
Acession no | Abbreviation | Gene Name I Loe2 Ratio 
Apoptosis 
U32974 BIRC4 baculoviral lAP repeat-containing 4 ^ 
U97075 "CFLAR “ CASP8 and FADD-like apoptosis regulator 2.1 
NM—015675 GADD45B growth arrest and DNA-damage-inducible, beta 3A 
AI275690 l ^ L l “ myeloid cell leukemia sequence 1 (BCL2-related) 2.4 
NM_002392 MDM2 Mdm2, transformed 3T3 cell double minute 2, p53 binding protein ^ 
NM_002393 MDM4 Mdm4, transformed 3T3 cell double minute 4’ p53 binding protein ^ 
NM—002583 PAWR “ PRKC, apoptosis, WTl, regulator 2.6 
NM_007350 PHLDAl pleckstrin homology-like domain, family A, member 1 2 
AF001294 PHLDA2 pleckstrin homology-like domain, family A, member 2 3.7 
AF257318 ~SH3GLB1 “ SH3-domain GRB2-like endophilin B1 2 
NM_004760 STK17A serine/threonine kinase 17a (apoptosis-inducing) 2.2 
BC001281 TNFRSFIOB tumor necrosis factor receptor superfamily, member 10b 2.5 
Cell Adhesion 
NM_021101 CLDNl claudin 1 2 
AL044018 W LIM domain containing preferred translocation partner in lipoma 3.6 
NM_005936 MLLT4 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, ^ 
AI962377 " ^ F I B P l 一 PTPRF interacting protein, binding protein 1 (liprin beta 1) 
AF110314 PVRLl poliovinis receptor-related 1 (herpesvirus entry mediator C; nectin) 
AI812030 THBSl thrombospondin 1 2.9 
Cell Cycle Regulation 
NM_003567 BCAR3 breast cancer anti-estrogen resistance 3 ^ 
NM_030751 SNFILK SNFl-like kinase III SNFl-like kinase 2.5 
AJ277546 WEEl WEEl homolog (S. pombe) 2.6 
Cell Differentiation 
AA747426 IFRDl interferon-related developmental regulator 1 2.8 
NM_0023Q9 U F leukemia inhibitory factor (cholinergic differentiation factor) 2.8 
Cell Proliferation 
NM_001554 CYR61 cysteine-rich, angiogenic inducer, 61 
NM_003887 DDEF2 development and differentiation enhancing factor 2 2.1 
M60278 DTR diphtheria toxin receptor (heparin-binding epidermal growth factor-like 3.3 
NM—001432 ~EREG “ epiregulin 2.9 
BC005359 glia maturation factor, beta 2A 
BF340228 IGFBP3 insulin-like growth factor binding protein 3 ^ 
NM_00Q641 I l I I interleukin 11 5.2 
NM 002607 PDGFA platelet-derived growth factor alpha polypeptide 2 
BC005961 "PTHLH parathyroid hormone-like hormone III parathyroid hormone-like hormone 5.4 
NM_005414 " ^ I L SKI-like 2 
NM_016639 TNFRSF12A tumor necrosis factor receptor superfamily, member 12A 2 
Cytoskeleton Organization 
NM—001100 I ACTA 1 alpha 1, skeletal muscle 2.2 — 
BC000265 ARHGEF2 rho/rac guanine nucleotide exchange factor (GEF) 2 32 
M23254 CAPN2 ~ ^ p a i n 2, (m/II) large subunit 2.6 
AUl 55105 CTTN cortactin 2.8 
AL096710 DST — dystonin 4 J 
AV712733 FLNB "filamin B, beta (actin binding protein 278) 一 2.7 ~ 
AL523076 MAPIB microtubule-associated protein IB ^ 
NM—022765 NICAL NEDD9 interacting protein with calponin homology and LIM domains 
BC001017 PDLIM3 T d Z and LIM domain 3 — 2.2 ~ 
Z54367 PLECl plectin 1, intermediate filament binding protein 500kDa 4.5 
AA131826 SPTBNl spectrin, beta, non-erythrocytic 1 33 
AI214061 TPM4 tropomyosin 4 2.9 
AF091395 TRIO triple functional domain (PTPRF interacting) 5.9 — 
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DNA Repair 
NM_001924 GADD45A growth arrest and DNA-damage-inducible，alpha 2.6 
NM_014720 s u e STE20-1 ike kinase (yeast) 2.2 
Electron Transport 
NM_000499 C Y P l A l cytochrome P450, family 1, subfamily A, polypeptide 1 6.4 
NM_021187 CYP4F11 " ^ c h r o m e P450, family 4, subfamily F, polypeptide 11 2.4 
U42349 TUSC3 tumor suppressor candidate 3 4.8 — 
Heavy Metal Binding 
AL031602 M T 1 A / / / M T 1 E metallothionein 1A (functional)///metallothionein IE (functional) 2.7 
BF217861 M T I E metallothionein 1E (functional) “ 2.2 
BF246115 " I ^ I F ' metallothionein 1F (functional) 4.1 
NM_005950 M T I G “ metallothionein IG 3.4 
NM_005951 M T I H “ metallothionein IH 2.8 
R06655 " I ^ I K “ metallothionein IK 9.1 
NM—002450 " I ^ I X “ metallothionein IX 3.2 
NM_005953 MT2A metallothionein 2A 2.3 
Immune Response 
M57731 CXCL2 I chemokine (C-X-C motif) ligand 2 I 3.6 — 
NM_000574 ~DAF decay accelerating factor for complement (CD55, Cromer blood group 3.5 
AF043337 IL8 interleukin 8 ^ 
BC001606 NCF2 neutrophil cytosolic factor 2 (65kDa, chronic granulomatous disease, 6 
Kinase 
NM_014911 AAKl AP2 associated kinase 1 2.3 — 
NM_007314 ABL2 v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, ^ 
AI251890 CDC-like kinase 1 2.1 
NM_004073 ~PLK3 — polo-like kinase 3 (Drosophila) 3.9 
NM_025195 I TRIBl | tribbles homolog 1 (Drosophila) 2.2 — 
Metabolic Regulation — 
NM_001172 ARG2 arginase, type II 3.3 
NM_001673 ASNS asparagine synthetase 3.4 
NM_020164 ASPH aspartate beta-hydroxylase 4 
AI769685 CARS cysteinyl-tRNA synthetase ' U 
NM_001785 C P A cytidine deaminase 3.4 
NM_005213 — cystatin A (stefin A) ^ 
AL354872 CTH cystathionase (cystathionine gamma-lyase) ^ 
AA530892 DUSPl dual specificity phosphatase 1 ^ J 
U16996 DUSP5 dual specificity phosphatase 5 ^ 
D30658 GARS glycyl-tRNA synthetase 2 
NM_001498 GCLC glutamate-cysteine ligase, catalytic subunit 3 
NM_002061 GCLM glutamate-cysteine ligase, modifier subunit 3 
NM_002056 GFPTl glutamine-fructose-6-phosphate transaminase 1 ^ 
BC000498 GOTl glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase ^ 
NM_002149 HPCALl hippocalcin-like 1 3.3 
BC000879 KYNU kynureninase (L-kynurenine hydrolase) ^ 
AFL 17949 T o X L 2 ~ lysyl oxidase-like 2 2.4 
NM_006636 MTHFD2 methylene tetrahydrofolate dehydrogenase (NAD+ dependent), 2A 
NM_002627 PFKP phosphofructokinase, platelet ^ 
K03226 PLAU plasminogen activator, urokinase III plasminogen activator, urokinase 
AF070670 PPMIA protein phosphatase 1A (formerly 2C), magnesium-dependent’ alpha 3 
AW772123 PPP2R5C protein phosphatase 2, regulatory subunit B (B56), gamma isoform ^ 
AW006290 RIOK3 RIO kinase 3 (yeast) 2.6 
BC000669 SMOX spermine oxidase ^ 
N30649 SQSTMl sequestosome 1 2.6 
NM_003254 TIMPl tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, ^ 
n m 021158 TRIB3 tribbles homolog 3 (Drosophila) 3A 
NM 003330 TXNRDl thioredoxin reductase 1 2.4 
NM_003364 UPPl uridine phosphorylase 1 ^ 
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Phosphatase 
NM_000945 PPP3R1 I protein phosphatase 3 (formerly 2B), regulatory subunit B, 19kDa. alpha I 2 
NM—005401 PTPN14 protein tyrosine phosphatase, non-receptor type 14 21 
NM_007039 PTPN21 protein tyrosine phosphatase, non-receptor type 21 4.5 
NM一002842 PTPRH protein tyrosine phosphatase, receptor type, H 2 
Protein Ubiquitination 
NM_005744 ARIHl I ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein, 1 I 2.5 
BC004952 I NSPCl | likely ortholog of mouse nervous system polycomb 1 | 2 — 
Proteolysis 
NM_002422 MMP3 matrix metalloproteinase 3 (stromelysin 1, progelatinase) 
NM—006200 PCSK5 proprotein convertase subtilisin/kexin type 5 2.6 
NM_002773 "PRSS8 “ protease, serine, 8 (prostasin) 2.4 
AK001406 SENP6 SUMOl/sentrin specific protease 6 2.1 
Signal Transduction 
BC000529 GDF15 — growth differentiation factor 15 3 
NM—014776 GIT2 G protein-coupled receptor kinase interactor 2 3.9 
NM_006572 GNA13 guanine nucleotide binding protein (G protein), alpha 13 3 
AL049933 GNAIl guanine nucleotide binding protein (G protein), alpha inhibiting activity 2 
U66065 GRBIO growth factor receptor-bound protein 10 ^ 
BC005253 KLEIP “ kelch-like ECT2 interacting protein 5.8 
NM_005475 LNK lymphocyte adaptor protein 
NM_002925 RGSIO ~ regulator of G-protein signalling 10 
AF074979 RGS20 regulator of G-protein signalling 20 ^ 
NM_012250 RRAS2 related RAS viral (r-ras) oncogene homolog 2 2A 
BC000329 ~SFN stratifin 2.4 
NM-016387 S 0 C S 6 suppressor of cytokine signaling 6 
AF227517 SPRY4 sprouty homolog 4 (Drosophila) ^ 
NM_025106 SSB1 SPRY domain-containing SOCS box protein SSB-1 2.8 
NM_003473 ~STAM — signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 2.2 
AI571996 STAM2 signal transducing adaptor molecule (SH3 domain and ITAM motif) 2 2.3 
AF243424 ~STRN3 “ striatin, calmodulin binding protein 3 2 
L02911 A C V R l activin A receptor, type I ^ 
NM—021913 " a X L AXL receptor tyrosine kinase 3.1 
NM_001736 C5R1 complement component 5 receptor 1 (C5a ligand) 
NM—005228 EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) 
NM_004431 " e P H A 2 “ EphA2 2.2 
BE965369 F2RL1 coagulation factor II (thrombin) receptor-like 1 3.7 
AL554008 GPR56 G protein-coupled receptor 56 ^ 
NM_000418 IL4R interleukin 4 receptor 2.5 
NM_002288 LAIR2 leukocyte-associated Ig-like receptor 2 ^ 
U08839 PLAUR plasminogen activator, urokinase receptor ^ 
NM_005424 TIE tyrosine kinase with immunoglobulin and epidermal growth factor 3.7 
Structural Protein 
BC002649 HISTIHIC histone 1，Hlc 11 
AW665892 MFAP5 microfibrillar associated protein 5 “ 5.4 
U53823 ~OCLN “ occludin 2.2 
NM_020127 TUFTl tuftelin 1 2 
To be continued in the next page 
124 
MECHANISTIC STUDY OF SOPHORAFLA VANONE G ON HUMAN HEPA TOCELL ULAR 
CARCINOMA CELLS BY cDNA MICROARRAY ANALYSIS 
Acession no I Abbreviation I Gene Name I Lo22 RatiJ~2 
Transcription Factor 
NM_001621 ~AHR aryl hydrocarbon receptor 2 
NM_001674 ATF3 activating transcription factor 3 4^4 
BG326045 BHLHB2 basic helix-loop-helix domain containing, class B, 2 2.6 
AF288161 BLZFl basic leucine zipper nuclear factor 1 (JEM-1) 5.4 ~ 
NM—001206 BTEBl basic transcription element binding protein 1 ^ 
NM_004405 DLX2 ~ ^ l - l e s s homeo box 2 4 ~ 
NM_002041 GABPB2 GA binding protein transcription factor, beta subunit 2，47kDa 2.6 
W74620 HNRPD heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA 2.8 
BC002646 JUN v-jun sarcoma virus 17 oncogene homolog (avian) 23 
NM_002229 JUNB jun B proto-oncogene 3.1 
AF132818 ~ E 7 f 5 Kruppel-like factor 5 (intestinal) 3.7 “ 
AJ0Q5683 NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive 3 .9 
U76622 ~ s i ^ D 3 SMAD, mothers against DPP homolog 3 (Drosophila) 3.6 
AU121035 Spl transcription factor 2.1 
M l 88786 S ^ serum response factor (c-fos serum response element-binding transcription 2 
NM_005645 " t A F 1 3 TAF13 RNA polymerase II, TATA box binding protein (TBP)-associated 2.1 
NM_005681 TAFIA TATA box binding protein (TBP)-associated factor, RNA polymerase I, A, 2.4 
Transcriptional Regulation 
AI888099 ATXN3 ataxin 3 2.4 
NM—001806 "CEBPG “ CCAAT/enhancer binding protein (C/EBP), gamma 2.5 
BE675435 COPEB core promoter element binding protein ^ 
BC003637 DDIT3 DNA-damage-inducible transcript 3 3.5 
NM_019058 DDIT4 DNA-damage-inducible transcript 4 2.4 
NM_001964 EGRl early growth response 1 4.2 
NM_005230 ELK3 “ ELK3, ETS-domain protein (SRF accessory protein 2) 2.8 
AB002386 ~EZH1 enhancer of zeste homolog 1 (Drosophila) 2.9 
NM一001450 FHL2 four and a half LIM domains 2 2.2 
BC004490 FOS v-fos FBJ murine osteosarcoma viral oncogene homolog ^ 
BG251266 "TOSLI FOS-like antigen 1 3.3 
NM—006582 GMEBl glucocorticoid modulatory element binding protein 1 4.2 
NM—012258 HEYl hairy/enhancer-of-split related with YRPW motif 1 — 5.5 
NM_002131 ~HMGA1 — high mobility group AT-hook 1 
BF514079 KLF4 Kruppel-like factor 4 (gut) 3.7 
NM_012323 MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) ^ 
NM_002359 MAFG v-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian) ^ 
AI827820 ~ N ^ D 2 methyl-CpG binding domain protein 2 2 
NM_021724 NRIDI III nuclear receptor subfamily 1, group D, member 1 III thyroid hormone A2 
N32859 NR1D2 nuclear receptor subfamily 1, group D, member 2 
NM_000280 ~PAX6 paired box gene 6 (aniridia, keratitis) ^ J 
L07592 PPARD peroxisome proliferative activated receptor, delta ^ 
L14611 RORA — RAR-related orphan receptor A 2.7 
AI572079 SNAI2 snail homolog 2 (Drosophila) ^ 
NM_005078 TLE3 transducin-like enhancer of split 3 (E(spl) homolog, Drosophila) ^ 
AL358975 TLE4 transducin-like enhancer of split 4 (E(spl) homolog, Drosophila) ^ 
AW978896 ~TRA2A “ transformer-2 alpha 3.8 
BF592058 — splicing factor YT521-B 2.3 
NM_023929 ZBTBIO zinc finger and BTB domain containing 10 2 
NM_003407 ZFP36 zinc finger protein 36，C3H type, homolog (mouse) ^ 
NM_003411 ZFY zinc finger protein, Y-1 inked ^ 
X52332 " ^ F I O “ zinc finger protein 10 (KOX 1) 3.7 
NM_003447 ~ZNF165 — zinc finger protein 165 2.3 
AI522311 ZNF237 _ zinc finger protein 237 2.2 
NM—005649 ZNF354A zinc finger protein 354A lA 
M58297 ZNF42 zinc finger protein 42 (myeloid-specific retinoic acid-responsive) 2 
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Transferase 
NM_014256 B3GNT3 I UDP-GlcNAc:betaGal beta-l,3-N-acetylglucosaminyltransferase 3 I 2.7 
NM—005504 BCATl branched chain aminotransferase 1, cytosolic 2.2 
AL139812 GALNACT-2 chondroitin sulfate GalNAcT-2 3.8 
NM—020367 PARPll poly (ADP-ribose) polymerase family, member 11 3.1 
BE971383 SAT spermidine/spermine Nl-acetyltransferase 2 
Translational Regulation 
AK001827 I DICERl Dicer l ,Dcr- l homolog(Drosophila) 2.5 
NM_012328 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 3.2 
AI613483 EIF2C2 eukaryotic translation initiation factor 2C, 2 2.9 
NM_019891 EROILB ERO1-like beta (S. cerevisiae) 2.8 
Transport 
BF508244 AKRICI aldo-keto reductase family 1, member CI (dihydrodiol dehydrogenase 1; 2.2 
N74607 AQP3 aquaporin 3 6.8 
U80764 CACNB2 calcium channel, voltage-dependent, beta 2 subunit 4 
BC006332 CLTB clathrin, light polypeptide (Lcb) III clathrin, light polypeptide (Lcb) 2 
AW438464 G 0 L G A 4 golgi autoantigen, golgin subfamily a, 4 2.3 
NM—014407 KCNMB3 potassium large conductance calcium-activated channel, subfamily M beta 2.5 
U93240 KPNA4 karyopherin alpha 4 (importin alpha 3) 2.8 
S70123 LDLR low density lipoprotein receptor (familial hypercholesterolemia) ^ 
NM_014778 NUPLl nucleoporin like 1 3.3 
AUl43984 “ SEC24D SEC24 related gene family, member D (S. cerevisiae) 3.5 
NM_0Q5135 SLC12A6 solute carrier family 12 (potassium/chloride transporters), member 6 2.7 
NM—004694 SLC16A6 solute carrier family 16 (monocarboxylic acid transporters), member 6 ^ 
NM_005415 SLC20A1 solute carrier family 20 (phosphate transporter), member 1 ^ 
NM_002394 SLC3A2 solute carrier family 3 (activators of dibasic and neutral amino acid ^ 
AF053755 SLC4A7 solute carrier family 4, sodium bicarbonate cotransporter, member 7 6 
BC006252 SLC6A6 solute carrier family 6 (neurotransmitter transporter, taurine), member 6 III 4.9 
AW452623 SLC7A1 solute carrier family 7 (cationic amino acid transporter, y+ system), 2.9 
NM_014331 SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ system) 12 
NM_003046 SLC7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), ^ 
NM_015930 TRPV2 transient receptor potential cation channel, subfamily V, member 2 2.2 
Hypothetical Protein 
NM_019044 FLJ10996 hypothetical protein FLJ10996 2.3 
NM—024519 T l J 13725 hypothetical protein FLJ13725 2.2 
NM_019027 ~ F O 2 0 2 7 3 RNA-binding protein 2.4 
NM_025130 ~FLJ22761 hypothetical protein FLJ22761 2.3 
NM_024616 ~FU23186 hypothetical protein FU23186 2.3 
NM_024880 " ? U 2 3 5 5 6 hypothetical protein FLJ23556 5.1 
AI928407 hypothetical protein H41 2 
BC004875 MGC11061 hypothetical protein MGCl 1061 2.1 
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Miscellaneous 
AB003476 AKAP12 A kinase (PRKA) anchor protein (gravin) 12 3.8 
M63310 一 ANXA3 annexin A3 2.7 
NM_001657 AREG amphiregulin (schwannoma-derived growth factor) ^ 
NM_001718 BMP6 bone morphogenetic protein 6 4.2 
BF516433 CYLD cylindromatosis (turban tumor syndrome) ^ 
NM_003566 EEAl early endosome antigen 1, 162kD 2 
NM_001423 EMPl epithelial membrane protein 1 4.7 
NM—012296 GAB2 GRB2-associated binding protein 2 3 
BC0Q1120 GALIG galectin-3 internal gene 2 
NM_019096 GTPBP2 GTP binding protein 2 3.1 
AB056663 ITCH itchy homolog E3 ubiquitin protein ligase (mouse) 
U73936 JAGl jagged 1 (Alagille syndrome) 3.9 
BG054550 LIM LIM protein (similar to rat protein kinase C-binding enigma) 2.8 
AV705559 LPINl lipin 1 2 
BE893893 MAP1LC3B microtubule-associated protein 1 light chain 3 beta 2.5 
BF512200 " l ^ N L l muscleblind-like (Drosophila) 2.5 
AF117233 MKRNl makorin, ring finger protein, 1 2.2 
AFl00763 PRKAAl protein kinase, AMP-activated, alpha 1 catalytic subunit 2A 
NM_020673 RAB22A RAB22A, member RAS oncogene family 2.5 
BC00102S RNA terminal phosphate cyclase-丨ike 1 2 
AF084462 ~RJT1 Ras-like without CAAX 1 2.6 
AB020966 RNMT RNA (guanine-?-) methyltransferase 2 
NM_005620 ~ ^ 0 A 1 1 SI00 calcium binding protein Al l (calgizzarin) 2.6 
NM_005978 ~sT00A2 — SI00 calcium binding protein A2 4.5 
AL574210 SERPINEl serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen 3 
AL541302 SERPINE2 serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen ^ 
AI654869 ~ S ^ R F 1 —— SMAD specific E3 ubiquitin protein ligase 1 4 J 
AL050388 S0D2 superoxide dismutase 2，mitochondrial 3 
NM—006948 STCH stress 70 protein chaperone, microsome-associated, 60kDa ^ 
NM_015641 TES testis derived transcript (3 LIM domains) 2 
NM—005082 TRIM25 tripartite motif-containing 25 
ABO 18265 "ULKI unc-51-like kinase 1 (C. elegans) 2.6 
NM—025090 ~[jSP36 ubiquitin specific protease 36 
NM—023034 WHSC1 LI Wolf-Hirschhom syndrome candidate 1-like 1 III Wolf-Hirschhorn 2 
AI745185 — Yes-associated protein 1, 65kDa 
AI459274 ZFR zinc finger RNA binding protein 2.4 — 
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Function Unknwon 
"nM_007011 ABHD2 abhydrolase domain containing 2 2.4 
AF070610 BEAN brain expressed, associated with Nedd4 3.9 
NM—018017 ClOorf l lS chromosome 10 open reading frame 118 3.9 
NM—015652 C10orfl2 chromosome 10 open reading frame 12 3 
NM_030897 C1 Oorfl 37 chromosome 10 open reading frame 137 III chromosome 10 open reading 2.8 
NM_030952 C l l o r f l ? / / / chromosome 11 open reading frame 17/// likely ortholog of rat 2.2 
AI935123 C14orf78 chromosome 14 open reading frame 78 3.7 
NM_022751 C l S o r f l l chromosome 18 open reading frame 11 4 
NM—016227 C1 orf9 chromosome 1 open reading frame 9 2.1 
NM—023925 C l Q D C l C lq domain containing 1 2.3 
BF969986 C9orf91 chromosome 9 open reading frame 91 2.3 
NM_004748 — CCPGl cell cycle progression 1 2.4 
AL136571 CGI-141 CGI-141 protein 2.3 
NM_012110 CHIC2 cysteine-rich hydrophobic domain 2 2.6 
NM_006697 CRA cisplatin resistance associated 4.2 
AW006750 DREl DREl protein 2.4 
NM—018357 FU11196 acheron 3.6 
BE464161 FLJ23476 ischemia/reperfusion inducible protein 2.3 
BFl25756 GABARAPLl GABA(A) receptor-associated protein like 1 4.9 
AK000478 GARNL4 GTPase activating Rap/RanGAP domain-like 4 2 
U16307 GLIPRl GLI pathogenesis-related 1 (glioma) 3.4 
NM—004907 IER2 immediate early response 2 2 
AK021460 KIAA0690 KIAA0690 2.3 
AA522514 一 KIAA0746 KIAA0746 protein 4.9 
AA044154 KIAA0999 KIAA0999 protein 2.2 
NM_019081 LKAP limkain bl 2.6 
AW084068 PFAAP5 phosphonoformate immuno-associated protein 5 ^ J 
AL050389 PHTF2 putative homeodomain transcription factor 2 2.5 
NM_021127 PMAIPl phorbol-12-myristate-13-acetate-induced protein 1 3A 
NM_014330 PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit ISA 5 
AF142418 QKI quaking homolog, KH domain RNA binding (mouse) ^ 
NM_015577 RAI14 retinoic acid induced 14 2 
NM_003979 RAI3 retinoic acid induced 3 3.6 
NM—014059 RGC32 response gene to complement 32 ^ 
NM_022450 RHBDFl rhomboid family 1 (Drosophila) 3.6 
AI871641 RJPX rap2 interacting protein x 
AW991219 SCC-112 SCC-112 protein 2.9 
NM_002640 SERPINB8 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8 3 
NM_025181 SLC35F5 solute carrier family 35, member F5 2.8 
X83300 SMA4 SMA4 3.9 
NM_003272 TM7SF1 transmembrane 7 superfamily member 1 (upregulated in kidney) ^ 
R61539 TMEM24 transmembrane protein 24 3.5 
BC000464 WDR45 WD repeat domain 45 2.7 
N24643 WSBl WD repeat and SOCS box-containing 1 2.2 
NM_006007 I ZA20D2 zinc finger, A20 domain containing 2 2.3 
The up-regulated genes identified from cDNA microarray analysis were grouped in 
different categories according to their functions. 
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Table 5.2 The down-regulated candidate genes under Sophoraflavanone G 
induction in HepG2 cells. 
Acession no I Abbreviation I Gene Name I Los2 Ratio 
Apoptosis 
AI817801 BIRCl baculoviral lAP repeat-containing 1 -5.1 
U13700 CASPl caspase 1’ apoptosis-related cysteine protease (interleukin 1, beta, -4J 
NM_005256 GAS2 growth arrest-specific 2 -2 
AL567227 TIAl TIA1 cytotoxic granule-associated RNA binding protein -3 
NM—003810 TNFSFIO tumor necrosis factor (ligand) superfamily, member 10 -3.7 — 
Cell Adhesion 
AU150824 DGCR2 DiGeorge syndrome critical region gene 2 -2.1 
AL519710 IGSF4 immunoglobulin superfamily, member 4 -2.1 
BC006329 MCAM melanoma cell adhesion molecule III melanoma cell adhesion molecule -2.6 
AF035307 PLXNCl plexin CI -2.3 
U38276 SEMA3F sema domain, immunoglobulin domain (Ig), short basic domain, secreted, -3.7 
Cell Cycle Regulation 
AA648913 BIRC5 baculoviral lAP repeat-containing 5 (survivin) 
NM_001262 CDKN2C cyclin-dependent kinase inhibitor 2C (pi 8’ inhibits CDK4) -2.5 
AF213033 CDKN3 cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity -2.2 
AA764988 PDCD2 programmed cell death 2 -3.1 
NM_021111 RECK reversion-inducing-cysteine-rich protein with kazal motifs ^ 
Cell Proliferation 
NM—006443 C6orfl08 chromosome 6 open reading frame 108 -2A 
AU 147044 MKI67 antigen identified by monoclonal antibody Ki-67 -2.1 
NM_007083 NUDT6 nudix (nucleoside diphosphate linked moiety X)-type motif 6 -2.2 ~ 
Cytoskeleton Organization 
NM_004434 EMLl echinoderm microtubule associated protein like 1 
N21458 SORBS 1 sorbin and SH3 domain containing 1 -3.5 
NM_006953 UPK3A uroplakin 3A -2.7 
Dehydrogenase 
H71135 ADH6 alcohol dehydrogenase 6 (class V) -2.3 
NM—002301 LDHC lactate dehydrogenase C -2.5 
NM_018245 OGDHL oxoglutarate dehydrogenase-like -3.9 
DNA Repair 
NM_005483 CHAFIA chromatin assembly factor 1, subunit A (pl50) -2.5 
AF104243 MSH4 mutS homolog 4 (E. coli) -4.6 一 
DNA Replication 
NM_021067 KIAA0186 KIAAOl 86 gene product -3.1 
NM_002388 MCM3 MCM3 minichromosome maintenance deficient 3 (S. cerevisiae) -2.1 
AI859865 MCM4 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) 
NM_005915 MCM6 MCM6 minichromosome maintenance deficient 6 (MISS homolog, S. -2.1 
NM—002592 PCNA proliferating cell nuclear antigen -2 
BC003186 ~Pk2 DNA replication complex GINS protein PSF2 -2.7 
NM_002689 POLA2 polymerase (DNA-directed), alpha (70kD) -2.2 
NM_007370 RFC5 replication factor C (activator 1)5,36.5kDa -2.3 "“ 
Electron Transport 
AL353132 | CYB5 | cytochrome b-5 | -2.1 
To be continued in the next page 
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Acession no I Abbreviation I Gene Name I Loe2 Ratio 
Immune Response 
NM—021822 AP0BEC3G apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G -5.2 
NM_004590 CCL16 chemokine (C-C motif) ligand 16 -2.6 
“NM_002987 一 CCL17 chemokine (C-C motif) ligand 17 -3.1 
M28825 CDIA CD 1A antigen, a polypeptide -3.6 
NM_002996 CX3CL1 “ chemokine (C-X3-C motif) ligand 1 -2.5 
NM_000242 MBL2 mannose-binding lectin (protein C) 2, soluble (opsonic defect) -2.4 — 
Kinase 
NM_001823 CKB creatine kinase, brain -2.7 
BC006233 KHK ketohexokinase (fructokinase) III ketohexokinase (fructokinase) -2 
U39657 MAP2K6 mitogen-activated protein kinase kinase 6 -2 
NM_003258 TKl thymidine kinase 1, soluble -2 
Metabolic Regulation 
NM_016236 AGXT alanine-glyoxylate aminotransferase (oxalosis I; hyperoxaluria I; ^ 
NM_005989 AKRIDI aldo-keto reductase family 1, member D1 (delta -2.4 
BC000977 ALAD aminolevulinate, delta-, dehydratase -2.7 
NM_000697 AL0X12 arachidonate 12-lipoxygenase -3.4 
BC004331 C9orf99 chromosome 9 open reading frame 99 -2.1 
BC004331 C9orf99 chromosome 9 open reading frame 99 -2.1 
NM—000072 CD36 CD36 antigen (collagen type I receptor, thrombospondin receptor) -3.9 
BC001362 CNP 2',3'-cyclic nucleotide 3' phosphodiesterase -2 
AW772056 DDC dopa decarboxylase (aromatic L-amino acid decarboxylase) ； 
NM_000791 DHFR dihydrofolate reductase -2.1 
NM_001966 EHHADH enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase 
NM—017770 ELOVL2 elongation of very long chain fatty acids (FENl/Elo2, SUR4/Elo3, -2 
AF233336 EPHX2 epoxide hydrolase 2, cytoplasmic -2 
NM—000799 ^ O erythropoietin -4.2 
NM_001461 F M 0 5 flavin containing monooxygenase 5 ^ 
NM_005258 ~ ^ H F R — GTP cyclohydrolase I feedback regulator -2.9 
NM_002084 GPX3 glutathione peroxidase 3 (plasma) -2.6 
AK024548 H6PD hexose-6-phosphate dehydrogenase (glucose 1 -dehydrogenase) -2.9 
AI986120 LTBPl latent transforming growth factor beta binding protein 1 
AL520774 MDH2 malate dehydrogenase 2, NAD (mitochondrial) -2.9 
BG433489 PAH phenylalanine hydroxylase -3.6 
NM_002614 PDZKl PDZ domain containing 1 -2.5 
NM_006221 PINl protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting 1 
NM_000300 "TLA2G2A phospholipase A2, group IIA (platelets, synovial fluid) -2.2 
N26005 PPP1R3C protein phosphatase 1, regulatory (inhibitor) subunit 3C -2.2 
AI885670 SEPHSl selenophosphate synthetase 1 -2.3 
NM—006215 SERPINA4 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, ； 
NM_005627 SGK serum/glucocorticoid regulated kinase 
AF059203 SOAT2 — sterol O-acyltransferase 2 -2.1 
NM—003385 VSNLl visinin-like 1 -3.9 
Protein Degradation 
N45309 PCYOXl prenylcysteine oxidase 1 -2 
NM_002816 PSMD12 proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 
BE964Q43 ~SKP1A — S-phase kinase-associated protein lA(p l9A) -4.3 
BC001441 SKP2 S-phase kinase-associated protein 2 (p45) - 3 J 
NM_015271 TRIM2 tripartite motif-containing 2 O 
AL031714 UBE2I ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast) -3.5 
To be continued in the next page 
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Acession no I Abbreviation I Gene Name I Los2 Ratio 
Proteolysis 
BC003169 CAPN3 calpain 3’（p94) -3.9 
NM—016413 CPB2 carboxypeptidase B2 (plasma, carboxypeptidase U) -2.4 
NM—002800 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large -2 
NM_024583 SCRN3 secern in 3 -4.4 
Signal Transduction 
NM_003224 I ARFRPl I ADP-ribosylation factor related protein 1 -2.3 
AF070621 DIXDCl DIX domain containing 1 -2.2 
NM_012193 FZD4 frizzled homolog 4 (Drosophila) -3.3 
U58828 GPR30 G protein-coupled receptor 30 -2.8 
AF062006 GPR49 G protein-coupled receptor 49 -2 
NM_005308 GRK5 G protein-coupled receptor kinase 5 -2.5 
D50925 PASK PAS domain containing serine/threonine kinase -2.6 
NM_006207 PDGFRL platelet-derived growth factor receptor-like 
AL360141 P E X l l A “ peroxisomal biogenesis factor 11A -3.9 
AF081583 PLEKHBl pleckstrin homology domain containing, family B (evectins) member 1 -2.1 
NM_007082 RABL2A/ / / RAB, member of RAS oncogene family-like 2A III RAB, member of -2.8 
BC002709 TP53AP1 “ TP53 activated protein 1 -2.5 
NM—006113 VAV3 vav 3 oncogene -3.2 
Structural Protein 
AA534860 H2AFV H2A histone family, member V -2.3 
NM_003536 HIST1H3H histone 1，H3h -3.8 
Transcription Factor 
AF109161 CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal -2.6 
AF327066 F ^ l Friend leukemia virus integration 1 -4.1 
NM_024680 ~ ~ FLJ23311 ~FLJ23311 protein -3.2 
Z49825 HNF4A hepatocyte nuclear factor 4, alpha -2.7 
NM_024501 HOXDl “ homeo b o x D l -2.6 
L22454 NRFl nuclear respiratory factor 1 
NM_004350 RUNX3 一 runt-related transcription factor 3 -3.3 
NM_003195 "TCEA2 一 transcription elongation factor A (SII), 2 -3.4 
NM_007111 TFDPl transcription factor Dp-1 -3.8 
Transcriptional Regulation 
AI872408 CSTF2T cleavage stimulation factor, 3' pre-RNA, subunit 2, 64kDa, tau variant -2.2 _ 
NM_001529 HHEX hematopoietically expressed homeobox -2.2 
W60800 HLF 一 hepatic leukemia factor -2.2 
AW592266 MYBLl v-myb myeloblastosis viral oncogene homolog (avian)-like 1 -2A 
NM_016948 PARD6A par-6 partitioning defective 6 homolog alpha (C.elegans) 
AA456973 PC4 activated RNA polymerase II transcription cofactor 4 -TA 
AF208967 ~PEG3 paternally expressed 3 -2.5 
NM_016932 SIX2 sine oculis homeobox homolog 2 (Drosophila) ^ 
NM_024784 ZBTB3 zinc finger and BTB domain containing 3 -2.5 
Transferase 
NM_006876 B3GNT6 UDP-GlcNAc:betaGal beta-l,3-N-acetylglucosaminyltransferase 6 -4.3 “ 
NM_001713 BHMT betaine-homocysteine methyltransferase 
NM_000098 CPT2 carnitine palmitoyltransferase II ^ 
N m I o 14033 ~DKFZP586A0522~ DKFZP586A0522 protein -2.6 
NM_000156 GAMT guanidinoacetate N-methyltransferase 
U94357 GYG2 — glycogenin 2 -2.1 
L23928 SHMTl serine hydroxymethyltransferase 1 (soluble) -2.7 “ 
To be continued in the next page 
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Acession no \ Ahbreviation I Gene Name I Loq2 Ratio 
Translational Regulation 
AI348935 CALR calreticulin -2.1 
BE542684 EIFIAX eukaryotic translation initiation factor 1 A, X-linked -2.2 
L16895 LOX lysyl oxidase -2.1 
Transport 
AF285167 ABCAl ATP-binding cassette, sub-family A (ABC 1), member 1 -2.1 
AI074459 ABCC6 ATP-binding cassette, sub-family C (CFTR/MRP), member 6 “ -2 一 
Ml2523 ALB “ albumin -3.3 
NM_001153 ANXA4 “ annexinA4 -2 
NM_000040 AP0C3 “ apolipoprotein C-III -2.2 
AF323540 APOLl _ apolipoprotein L, 1 -2.8 
AF161454 APOM “ apolipoprotein M -2 
NM_000052 ATP7A ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome) -2.3 
NM—001443 FABPl “ fatty acid binding protein 1, liver -2.8 
NM_005733 KIF20A “ kinesin family member 20A -2.4 
NM_022449 RAB17 “ RAB17, member RAS oncogene family -2 
NM_020407 RHBG Rhesus blood group, B glycoprotein -4.3 
NM_001756 SERPINA6 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, 
NM_000354 SERPINA7 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, -3 
NM—022829 SLC13A3 solute carrier family 13 (sodium-dependent dicarboxylate transporter), A 
NM_000340 SLC2A2 solute carrier family 2 (facilitated glucose transporter), member 2 
NM—006931 SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3 
NM_005660 SLC35A2 solute carrier family 35 (UDP-galactose transporter), member A2 -4.4 
NM_005629 SLC6A8 solute carrier family 6 (neurotransmitter transporter, creatine), member 8 -2.2 
NM_007256 SLC02B1 solute carrier organic anion transporter family, member 2B1 -2^ 
AI073407 TF transferrin -4.7 
AF 162690 TTR transthyretin (prealbumin, amyloidosis type I) -2.1 
Hypothetical Protein 
AL080169 DKFZP434C171 DKFZP434C171 protein -3.8 
NM_019018 FLJ11127 hypothetical protein FLJl 1127 -3.3 
NM_024908 FLJ12973 “ hypothetical protein FLJ12973 -3.7 
NM_025108 FLJl3909 “ hypothetical protein FLJl3909 -2.5 
NM—024709 FLJ Ml 46 “ hypothetical protein FLJ14146 -2.1 
NM_017854 FLJ20512 hypothetical protein FLJ20512 -2 
AL 134724 LOCI51162 “ hypothetical protein LOCI51162 -2.2 
BE856707 LOC257407 “ hypothetical protein LOC257407 -2.4 
NM—024056 MGC5576 “ hypothetical protein MGC5576 -2.1 
AA993683 PRO 1580 " l^othet ical protein PR01580 -2.5 “ 
NM_017899 TSC hypothetical protein FLJ20607 -2.1 
To be continued in the next page 
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Acession no I Abbreviation I Gene Name I Log2 Ratio 
Miscellaneous 
AA910946 AP1M2 adaptor-related protein complex 1, mu 2 subunit -2 
NM_025080 ASRGLl “ asparaginase like 1 -2.4 
D30751 BMP4 bone morphogenetic protein 4 -2.5 
NM_003633 ENCl ectodemial-neural cortex (with BTB-like domain) -2.1 
NM—000508 FGA “ fibrinogen, A alpha polypeptide -3 
BF793446 FSHPRHl “ FSH primary response (LRPRl homolog, rat) 1 -2.1 
AW874641 GGA2 golgi associated, gamma adaptin ear containing, ARF binding protein 2 -2_5 
NM—000166 GJBl “ gap junction protein, beta 1, 32kDa (connexin 32, Charcot-Marie-Tooth -2.4 
NM—002510 GPNMB “ glycoprotein (transmembrane) nmb -2.3 
AF274949 HMGN3 high mobility group nucleosomal binding domain 3 
NM—020995 HP “ haptoglobin -2.5 
NM_004523 KIFl l “ kinesin family member 11 -2.1 
AA209463 LPPR2 lipid phosphate phosphatase-related protein type 2 -3.2 
AA584297 LRP4 low density lipoprotein receptor-related protein 4 -2 
D80006 MOBKIB “ MOBl , Mps One Binder kinase activator-like IB (yeast) -2 
NM—020190 0LFML3 “ olfactomedin-like 3 -3.5 
D31765 POPl processing of precursor 1, ribonuclease P/MRP subunit (S. cerevisiae) -2 
NM—018663 PXMP2 “ peroxisomal membrane protein 2,22kDa -2.2 
AB018283 RHOBTBl “ Rho-related BTB domain containing 1 -3.2 
AB002438 SEMA6A sema domain, transmembrane domain (TM), and cytoplasmic domain, -2.4 
NM_016261 TUBDl tubulin, delta 1 -2 
Function Unknown 
NM—017855 APIN APin protein -2.1 
NM_018154 ASFIB ASFl anti-silencing function 1 homolog B (S. cerevisiae) -2.2 
AK024064 ASTN2 “ astrotactin 2 -2.2 
AI302100 ClOoiflO chromosome 10 open reading frame 10 -3.5 
NM_024571 C16orf33 chromosome 16 open reading frame 33 -2.1 
NM—004772 C5orf l3 chromosome 5 open reading frame 13 -2.8 
H93077 C5orf4 chromosome 5 open reading frame 4 
NM_020425 C6orfl62 chromosome 6 open reading frame 162 
NM—004056 CAS carbonic anhydrase VIII -2.2 
NM—031299 CDCA3 “ cell division cycle associated 3 III cell division cycle associated 3 -2 
NM_020348 CNNMl cyclinMl -2.1 
NM—001321 CSRP2 cysteine and glycine-rich protein 2 
NM_015492 DKFZP434H132 “ DKFZP434H132 protein -2.1 
AK027138 FAM13A1 family with sequence similarity 13，member A1 
NM—024706 FLJ13479 “ hypothetical protein FLJ13479 -2.6 
NM—017655 ~GIPC2 PDZ domain protein GIPC2 -2.2 
NM—014019 HSPC009 “ HSPC009 protein -2.1 
AB007869 KIAA0409 “ KIAA0409 protein -3.2 
AI978623 KIAA0657 “ KIAA0657 protein -2 
NM_006498 LGALS2 lectin, galactoside-binding, soluble, 2 (galectin 2) -2 
AB042719 MCMIO MCMIO minichromosome maintenance deficient 10 (S. cerevisiae) 
NM_025268 MGC4659 — hole gene -4.4 
ABO 13094 NATS N-acetyltransferase 8 (camello like) — ；4 
W74452 NDRG2 “ NDRG family member 2 -2.5 
NM_016250 NDRG2 一 NDRG family member 2 -3.6 
AY008372 OSBPL3 — oxysterol binding protein-like 3 — -2 
NM_017753 PRG-3 plasticity related gene 3 -3.5 
N38985 RAP 140 retinoblastoma-associated protein 140 
BC000069 RARRES2 retinoic acid receptor responder (tazarotene induced) 2 
NM_003944 SELENBPl selenium binding protein 1 -2.4 
NM_030786 SYNCOILIN intermediate filament protein syncoilin III intermediate filament protein 
NM_014051 TMEM14A transmembrane protein 14A -2.2 
AL021331 UNC93A unc-93 homolog A (C. elegans) -3 
The down-regulated genes identified from cDNA microarray analysis were grouped in 
different categories according to their functions. 
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Among the down-regulated genes identified, one of them was successfully 
validated by traditional reverse transcription polymerase chain reaction (RT-PCR). 
As shown in Fig 5.1, glucose transporter 3 (GLUT 3) was confirmed to be 
down-regulated in HepG2 cells after Sophoraflavanone G treatment. This suggested 
that Sophoraflavanone G may be able to reduce glucose transport in HepG2 cells 
through suppression of GLUT 3 mRNA expression. However, many differentially 
expressed genes with different functions were identified in this assay, detailed 
literature reviews as well as analysis should be done on those identified genes before 
any conclusive action mechanism of Sophoraflavanone is made. 
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Fig. 5.1 RT-PCR result of gene glucose transporter 3 (GLUT 3) in 
Sophoraflavanone G-treated HepG2 cells. The relative band intensities of beta actin 
(B) and GLUT 3 (C) were shown in bar chat. The data showed that GLUT 3 
expression level was decreased by about 20% after 24juM Sophoraflavanone G 
treatment. 
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6.1 Identification of Differentially Expressed Proteins in 
Sophoraflavanone G-treated Human Hepatocellular 
Carcinoma Cells by Two-Dimensional Gel Electrophoresis 
Proteomics is a complementary technology to DNA microarrray for monitoring 
the gene expression. However, instead of mRNA transcriptional levels, proteomics 
helps the researchers analyze the gene expression profile at protein level. In most 
cases, proteins are the functional molecules which reflect the differences in gene 
expression and phenotypes. In contrast, transcribed mRNA may not be translated to 
functional protein and the number of mRNA copies may not be fully represented the 
number of functional protein molecules. Thus, proteomics reveal some intracellular 
events that can not be approached by DNA microaray, for example, the relative 
abundance and subcellular localization of the protein products which in turn, help to 
predict protein-protein interaction as well as functional aspects (Celis et al., 2000). 
2-dimensional gel electrophoresis has been widely chosen for analyzing the 
changes in protein expression profile between two samples, for example normal and 
disease tissue, control and drug-treated samples. This technique was originally 
described by OTarrell (O'Farrell, 1975; O'Farrell et al., 1977) and Klose (Klose, 
1975). For the past 30 years, this technique has been modified by different groups of 
researchers. And now, the protein pattern reaches a high quality and satisfactory 
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reproducibility stage. Thus, 2-D gel electrophoresis analysis was adopted in this 
project to identify the differential display proteins in Sophoraflavanone G-treated 
human hepatocellular carcinoma cells. 
Total cellular proteins were extracted from HepG2 or RHepG2 cells after 24|iM 
of Sophoraflavanone G treatment for 48 hours. Hepatocellular carcinoma cells 
incubated with 0.1% ethanol was served as control. 200|xg of proteins in each 
sample were subjected to isoelectric focusing (lEF) followed by separation in 12.5% 
SDS polyacrylamide gel. The separated proteins were detected by silver staining. A 
pair of gels, one represented control sample and one represented treatment sample 
(Fig. 6.1 and Fig. 6.4), were analyzed by the software ImageMaster 2D version 2.0. 
The spots with differential expression were excised and subjected to in-gel digestion. 
The digested proteins were prepared for identification by matrix assisted laser 
desorption-ionization time-of-flight mass spectrometry (MALDI-TOF-MS) on the 
basis of peptide mass fingerprinting with trypsin digestion. Identities of the proteins 
were predicted through database searching. 
As shown in Fig. 6.2，Fig. 6.3 and Table 6.1, several differentially expressed 
proteins were identified in Sophoraflavanone G-treated HepG2 cells. Aldo-keto 
reductase family member CI and peroxiredoxin 1 were found to be up-regulated 
after Sophoraflavanone G treatment, while the expression of DJ-1 was found to be 
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decreased. Comparing this result with that from cDNA microarray analysis, it was 
found that aldo-keto reductase family member CI was shown to be up-regulated in 
both mRNA and protein level after Sophoraflavanone G treatment. 
In Sophoraflavanone G-treated RHepG2 cells, the differentially expressed 
proteins identified were different from those identified in HepG2 cells. It was found 
that ENOl protein and glyceraldehydes-3 -phosphate dehydrogenase were 
down-regulated after Sophoraflavanone G treatment, while the expression of heat 
shock protein 5 (glucose-regulated protein) was increased. Peroxiredoxin 1 was the 
common up-regulated protein identified in both human hepatocellular carcinoma 
HepG2 cells and multidrug human hepatocellular carcinoma RHepG2 cells (Fig. 6.5， 
Fig. 6.6 and Table 6.2). 
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Fig. 6.1 Protein expression profile of control and Sophoraflavanone G-treated 
HepG2 cells. Total cellular proteins were extracted from A) control and B) 
Sophoraflavanone G-treated (24|LIM for 48 hours) HepG2 cells. 200)ig of proteins 
were subjected to isoelectric focusing and then separated on 12.5% SDS 
polyacrylamide gel. The separated proteins were detected by silver staining. The 
gels were analyzed by the software ImageMaster™. Results shown are the 
representative of two independent experiments. 
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Fig. 6.2 Enlarged regions showing the positions and the identities of the 
differentially expressed proteins in HepG2 cells after Sophoraflavanone G 
treatment. The spots with differential expression were excised and prepared for 
analysis with MALDI-TOF-MS. Aldo-keto reductase family member CI (A) and 
peroxiredoxin 1 (B) were found to be up-regulated after Sophoraflavanone G 
treatment, while the expression of DJ-1 (B) was found to be decreased. 
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Fig. 6.3 Predicted protein identities of the differentially expressed proteins in 
Sophoraflavanone G-treated HepG2 cells. Peptide mass fingerprinting of the 
differentially expressed protein obtained from MALDI-TOF-MS analysis was 
subjected for database searching. The results of database searching were shown with 
matched peptides as well as molecular weight, pi and name of the matched protein. 
The higher the protein score, the higher the confidence of the protein identity. The 
information of the identified differentially expressed protein, aldo-keto reductase 
family member CI (A), DJ-1 protein (B) and peroxiredoxin 1 (C) were shown. 
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Table 6.1 Identity of differentially expressed proteins on HepG2 cells after 
Sphoraflavanone G treatment. 
Pnitem protein Differentia 丨 Protein 
Protein name Molecular 
PI expression Function 
Weight 
Detoxification 
aldo-keto reductase , , „ , ^ � ^ � of polycyclic 
36.7 kDa 8.02 Up-regulated ^ . 
family member CI aromatic 
hydrocarbons 
Tumor 
peroxiredoxin 1 22 kDa 8.27 Up-regulated 
suppressor 
DJ-1 protein 19.8 kDa 6.33 Down-regulated Oncogene 
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Fig. 6.4 Protein expression profile of control and Sophoraflavanone G-treated 
RHepG2 cells. Total cellular proteins were extracted from A) control and B) 
Sophoraflavanone G-treated (24)LIM for 48 hours) RHepG2 cells. 200jxg of proteins 
were separated on immobilized pH 3-10 strip followed by second-dimension 
separation on 12.5% SDS polyacrylamide gel. The separated proteins were stained by 
silver nitrate and the protein pattern was analyzed by the software ImageMaster™. 
Results shown are the representative of two independent experiments 
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Fig. 6.5 Enlarged regions showing the positions and the identities of the 
differentially expressed proteins in RHepG2 cells after Sophoraflavanone G 
treatment. The spots with differential expression were excised and digested for 
analysis with MALDI-TOF-MS. ENOl protein (B) and 
glyceraldehydes-3 -phosphate dehydrogenase (B) were found to be down-regulated 
after Sophoraflavanone G treatment, while the expressions of heat shock protein 5 
(glucose-regulated protein) (A) and peroxiredoxin 1 (C) were found to be increased. 
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Fig. 6.6 Predicted protein identities of the differentially expressed proteins in 
Sophoraflavanone G-treated RHepG2 cells. Peptide mass fingerprinting of the 
excised protein obtained from MALDI-TOF-MS analysis was subjected for 
database searching. The results of database searching were shown with matched 
peptides as well as molecular weight, pi and name of the matched protein. The 
higher the protein score, the higher the confidence of the protein identity. The 
information of the identified differentially expressed protein, heat shock protein 5 
(glucose-regulated protein) (A), ENOl protein (B), glyceraldehydes-3-phosphate 
dehydrogenase (C) and peroxiredoxin 1 (D) were shown. 
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Table 6.2 Identity of differentially expressed proteins on R H e p G 2 cells after 
Sphoraflavanone G treatment. 
Protein 
Protein Differential Protein 
Protein name Molecular _ _ 




Heat shock ,. . 
multimeric 
protein 5 ” ， ， . 
72.2 kDa 5.07 Up-regulated protein 
(glucose-regulat , . . � 
complexes inside 
edprotein 78) , , 
endoplasmic 
reticulum 
Peroxiredoxin 1 22 kDa 8.27 Up-regulated Tumor suppressor 












7.1 Bioassay-guided Isolation of Bioactive Compounds from 
Sophora flavescens 
Root of Sophora flavescens is one of the Traditional Chinese Medicines with 
historical clinical application on human hepatoma treatment. Some researchers have 
isolated several flavanones from root of Sophora flavescens with antitumor activity. 
They include kurarinone, 2 ‘ -methoxykurarinone, leachianone A and 
Sophoraflavanone G (Ryu et al, 1997; Kang et al, 2000; Ko et al, 2000; Naeyer et 
al., 2004). However, no research aims at isolating bioactive compounds from root of 
Sophora flavescens particularly against human heptaocellular carcinoma cells. 
Therefore, this study was developed which aimed at isolating the bioactive 
compounds from root of Sophora flavescens against human hepatocellular carcinoma 
cells. Bioassay-guided isolation was adopted as the first aim of this project. During 
the course of isolation, human hepatocellular carcinoma cells HepG2 and Hep3B were 
used for the screening of the anti-proliferative effect of the isolated fractions. Only the 
fractions with significant anti-proliferative effect were subjected to further 
purification and finally, bioactive compounds against human hepatocellular carcinoma 
cells were isolated. The bioassay-guided fractionation of 95% ethanol extract of roots 
of S. flavescens was conducted and successfully led to the isolation of a new 
lavandulyl flavanone, Sophoraflavanone K, together with five known flavonoids: 
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Maackiain, Leachianone A, Sophoraflavanone G, Kushenol X and Sophoraflavanone 
J. Since ethanol has a much higher extraction power than water, 95% ethanol was 
used for the bioassay-guided isolation. 
The isolated compounds showed significant anti-proliferative effect against 
human hepatocellular carcinoma HepG2 and Hep3B cells, except Maackiain which 
showed the highest IC50. Since Maackiain (70 mg from 2 kg of materials) and 
Leachianone A (160 mg from 2 kg of materials) were isolated from KuS 104 fraction 
and Leachianone A has a higher potency against HepG2 and Hep3B cells, it can be 
concluded that leachianone A mostly contributes to the anti-proliferative effect of KuS 
104 fraction against HepG2 and Hep3B cells. 
Among the six bioactive compounds isolated from root of Sophora flavescens, 
sophoraflavanone G showed the lowest IC50 (19.41 |xM) against HepG2 cells while 
leachianone A showed the lowest IC50 ( 1 2 . 9 2 | L I M ) against Hep3B cells (Table 3 . 5 ) . 
Sophoraflavanone G (380 mg from 2 kg of marterials) has the highest yield 
among the six compounds and it showed the highest anti-proliferative effect against 
HepG2 cells. Since multidrug resistance of tumor cells is the major factor that causes 
the failure of chemotherapy, Sophoraflavanone G was chosen for further mechanistic 
studies on HepG2 cells as well as multidrug resistance hepatocellular carcinoma 
RHepG2 cells. The increased understanding of the working mechanism of 
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Sophoraflavanone G on HepG2 and RHepG2 cells may enhance the understanding of 
drug targeting, especially Sophoraflavanone G, on tumor cells and multidrug 
resistance tumor cells as well as the structure-activity relationship (SAR) of 
compounds with flavonoid backbone. 
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7.2 Induction of Apoptosis in Human Hepatocellular 
Carcinoma Cells and Multidrug Human Hepatocellular 
Carcinoma Cells 
In this study, Sophoraflavanone G was found to inhibit the growth of human 
hepatocellular carcinoma HepG2 and Hep3B cells as well as mutlidrug resistance 
human hepatocellular carcinoma RHepG2 cells in vitro (Fig. 4.1). When compared 
with doxorubicin (with IC50 of 5 | l i M against HepG2 cells) which is a well-known 
anticancer agent, Sophoraflavanone G (with IC50 of 19.41 |xM against HepG2 cells) is 
not as potent as it on HepG2 cells. However, on RHepG2 cells, IC50 of 
Sophoraflavanone G (27 |iM) is much lower than that of doxorubicin (210 |xM). In 
order to explain this observation, this part of the project aimed at identifying and 
comparing the signaling mechanism of Sophoraflavanone G on HepG2 and RHepG2 
cells. 
Most of the common cytotoxic drugs inhibit the growth of tumor cells via cell 
cycle disruption. In order to elucidate the working mechanism of Sohoraflavanone G, 
it is essential to investigate the changes in DNA content of Sophoraflavanone 
G-treated HepG2 and RHepG2 cells. Therefore, the cell cycle profiles of 
Sophoraflavanone G-treated HepG2 and RHepG2 cells were analyzed by PI staining 
and compared with the cell cycle profiles of control cells. It was found that subGi 
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peaks, which represent apoptotic or necrotic cells, were observed in both HepG2 and 
RHepG2 cells after the treatment of Sophoraflavanone G for 24 hours and 48 hours. 
This suggested that Sophoraflavanone G is able to induce cell death in both hepatoma 
cell lines and it may act through the induction of apoptosis. Interestingly, it was 
observed that there was an increased in percentage of G2/M phase after low 
concentration of Sophoraflavanone G treatment on HepG2 cells. This suggested that 
Sophoraflavanone G may be able to induce cell cycle arrest at G2/M phase before 
undergoing apoptosis. However, this observation was not shown on RHepG2 cells. 
The induction of cell cycle arrest by Sophoraflavanone G should be tested in the 
future to elucidate the action mechanism of the compound. 
Since apoptosis is part of programmed cell death with tight regulation, it is 
essential to develop therapeutic agents which are able to induce apoptosis, instead of 
necrosis (uncontrolled cell death), in fast growing tumor cells. In order to test the 
hypothesis that Sophoraflavanone G is able to induce apoptosis, instead of necrosis, in 
HepG2 and RHepG2 cells, PS externalization analysis and DNA fragmentation assay 
were done. 
In PS externalization analysis, Sophoraflavanone G-treated HepG2 and RHepG2 
cells were stained by Annexin V-FITC and PI. The co-staining method helped to 
differentiate the apoptotic and necrotic cells. The data showed that the percentage of 
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HepG2 and RHepG2 cells in early apoptosis stage was increased with increasing 
concentration and time of Sophoraflavanone G treatment (Fig. 4.4 and Fig. 4.5). DNA 
fragmentation, which is the hallmark of apoptosis, was also observed in HepG2 and 
RHepG2 cells treated with Sophoraflavanone G (Fig.4.6 and Fig. 4.7). The results of 
these two assays suggested that Sophoraflavanone G may inhibit the growth of 
HepG2 and RHepG2 cells via the induction of apoptosis. 
To further confirm the ability of Sophoraflavanone G to induce apoptosis in 
HepG2 and RHepG2 cells, the level of pro-caspase-3 in Sophoraflavanone G-treated 
tumor cells was investigated by Western blot analysis. Since caspase-3 is the major 
effector caspase that causes the morphological and biochemical changes in apoptotic 
cells, the decrease of pro-caspase-3, which led to increase of active caspase-3，should 
be observed in apoptotic cells. The data showed that the level of pro-caspase-3 was 
decreased in HepG2 and RHepG2 cells after Sophoraflavanone G treatment for 24 
hours and 48 hours. 
Since PARP is one of the proteins cleaved by activated caspase-3, the level of 
PARP in Sophoraflavanone G-treated HepG2 and RHepG2 was examined to confirm 
the decrease of pro-caspase-3 led to increase in active caspase-3. It was found that the 
level of native PARP was decreased and meanwhile, the level of 85 kDa PARP was 
increased in both cell lines after Sophoraflavanone G treatment. This suggested that 
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Sophoraflavanone G may be able to induce apoptosis via activation of caspase-3 in 
HepG2 and multidrug reistance RHepG2 cells. 
Overall speaking, surprisingly, only higher concentration of Sophoraflavnaone G 
or prolonged incubation was effectively induced apoptotic cell death on both cell lines. 
It may be explained by the fact that IC50 calculated from MTT assay, which is 
sensitive to mitochondrial active cells, may not fully represent the actively 
proliferating cells. At the same time, mitochondrial inactive cells may not totally 
represent the population of cells undergoing apoptosis. Therefore, IC50 calculated 
from MTT assay only represents the drug concentration that leads to 50% of cells in 
the state with inactive mitochondria in which only a portion of this population is 
really undergoing apoptosis. So, presence of subGi peak, PS externalization, DNA 
fragmentation and cleavage of caspase-3, which are the characteristics of apoptotic 
cells, may only be observed in cells treated with higher concentration of 
Sopharaflavanone G or prolonged incubation time. Secondly, it is possible that 
apoptosis may be an indirect effect of the drug. Sophoraflavanone G may be able to 
trigger other major upstream signaling pathways which finally cause apoptotic cell 
death. 
Up till now, the data suggested that Sophoraflavanone Q in the final stage, may 
inhibit the growth of human hepatocellular carcinoma cells as well as multidrug 
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resistance human hepatocellular carcinoma cells through activation of caspase-3 
which in turn, causes apoptosis. At molecular level, there are three pathways leading 
to apoptosis. They are a) death receptor pathway through activation of caspase-8, b) 
mitochondrial pathway which involves cytochrome c and caspase-9 and c) 
caspase-independent pathway through the action of apoptosis-inducing factor (AIF). 
The levels of the hallmark proteins in these three pathways were examined by 
Western blot analysis in HepG2 and RHepG2 cells after Sophoraflavanone G 
treatment. It was found that the level of activated caspase-8, caspase-9 and truncated 
Bid protein were increased in both Sophoraflavanone G-treated cell lines. And the 
cytosolic cytochrome c and AIF were increased after Sophoraflavanone G treatment. 
Moreover, mitochondrial membrane depolarization was induced by Sophoraflavanone 
G in both cell lines. Based on these findings, an apoptotic pathway in HepG2 and 
RHepG2 cells induced by Sophoraflavanone G was proposed (Fig. 7.1). 
Sophoraflavanone G may induce apoptosis through death receptor pathway by 
triggering the activation of caspase-8. Activated caspase-8 can directly activate 
caspase-3 and at the same time, cleaves the Bid protein into its truncated form (tBid). 
tBid in the cytosol is translocated to mitochondrial membrane where it causes the 
disruption of mitochondrial membrane and release of cytochrome c from 
mitochondria into cytosol. Cytosolic cytochrome c catalyzes the oligomerization of 
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apoptotic protease activating factor-1 (Apaf-1) and promotes the activation of 
caspase-9, which is the hallmark caspase in mitochondrial pathway and directly 
activates caspase-3. Thus, mitochondrial pathway may also be involved in 
Sophoraflavanone G- induced apoptosis. In this proposed apoptotic pathway, the 
action of tBid protein provides a cross-talk between mitochondrial and death receptor 
pathway. The disruption of mitochondrial membrane also causes the release of 
apoptosis-inducing factor (AIF) which directly induces DNA fragmentation without 
involvement of caspases. Therefore, caspase-independent pathway may be involved in 
the action mechanism of Sophoraflavanone G. 
Same phenomenon observed as before, higher concentration of 
Sophoraflavanone G or prolonged incubation time was required to induce the changes 
of the hallmark proteins. This suggested that apoptosis may be occurred in both cell 
lines at the late stage of drug treatment indirectly after Sophoraflavanone G treatment. 
To strengthen the conclusion, Western blot analysis should be repeated since the 
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Fig. 7.1 Proposed apoptotic pathway in HepG2 and RHepG2 cells induced by 
Sophoraflavanone G. Sophoraflavanone G may be able to induce apoptosis in 
HepG2 and RHepG2 cells via death receptor pathway, mitochondrial pathway and 
caspase-independent pathway. Upon the induction of Sophoraflavanone G, caspase-8 
is activated which in turn cleaves Bid protein to truncated form (tBid). tBid, which is 
the cross bridge between death receptor pathway and mitochondrial pathway, 
promotes the release of cytochrome c to cytosol. Cytosolic cytochrome c associates 
with Apaf-1 and pro-caspase-9 in the presence of dATP/ATP which leads to activation 
of caspase-9. Activated caspase-9 directly cleaves pro-caspase-3 to active caspase-3 
which executes the morphological and biochemical apoptotic changes. 
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7.3 Differential Gene Expression Induced by 
Sophoraflavanone G in Human Hepatocellular Carcinoma 
Cells 
Due to limited resources, cDNA microarray analysis was performed to screen for 
the differentially expressed gene in Sophoraflavanon G-treated HepG2 cells only. The 
use of microarray technology allows us to investigate the mRNA expression levels of 
thousands of genes simultaneously. Table 5.1 showed the 397 up-regulated genes 
induced by 24|xM Sophoraflavanone G while table 5.2 showed the 240 
down-regulated genes. 
By RT-PCR, glucose transporter 3 (GLUT 3) was confirmed to be 
down-regulated in Sophoraflavanone G-treated HepG2 cells by 20%. As commonly 
known, tumor cells have higher proliferative rate than non-malignant cells. It is not 
surprising to find out that tumor cells have increased metabolic rate as well as 
requirement for ATP production (Macheda et aL, 2005). Actually, it was first observed 
by Warburg (1956) that cancer cells have high rate of aerobic glycolysis which may 
result from the increase in activity of glycolytic enzymes (Hennipman et al.’ 1987; 
Board et al, 1990; Macheda et al., 2005). All these findings suggested that cancer 
cells have a greater need for glycolysis as well as energy generation to support their 
fast-growing properties. Glucose transport is the first rate-limiting step for glycolysis 
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(Hatanaka, 1974) and some cellular transformation studies showed that increased 
glucose transport in cancer cells is associated with increased expression of GLUTs 
(Bimbaum et al., 1987; Murakami et al, 1992; Baron-Delage et al, 1996), therefore 
glucose transporters (GLUTs) are the important regulator of glucose metabolism in 
cancer cells. Hypothesis one: Because of these facts, it is speculated that 
down-regulation of GLUTS, which is one of the facilitative glucose transporters with 
high affinity for glucose and allows transport of glucose at a high rate under normal 
physiological conditions (Macheda et al, 2005; Burant and Bell, 1992), induced by 
Sophoraflavanone G may causes the decrease in glucose transport and intracellular 
glucose. The insufficient glucose supply may result in decreased rate of glycolysis as 
well as ATP generation. We hypothesized that Sophoraflavanone G may indirectly 
reduce the expression of GLUT 3 and trigger the glucose starvation signals which 
may result in stress-induced apoptosis in hepatoma cells. However, this hypothesis 
remains to be resolved. 
This hypothesis was drawn based on the results of cDNA microarray analysis as 
well as RT-PCR. The preliminary data only represents part of the picture of 
Sophoraflavanone G-induced signaling mechanism. More analysis should be done in 
the future to validate the down-regulated pattern of GLUT 3 under the induction of 
Sophoraflavanone G. A thorough analysis on the whole microarray profile should also 
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be done to work out other upstream signaling pathways that cause apoptosis in 
Sophoraflavanone G -treated hepatoma cells. 
As mentioned previously, the action of Sophoraflavanone G is more potent than 
doxorubicin against multidrug resistance RHepG2 cells. Since RHepG2 cells' 
multidrug resistance property was characterized by the over-expression of 
p-glycoprotein, it suggested that Sophoraflavanone G may be able to overcome the 
action of p-glycoprotein and induce apoptosis in MDR tumor cells. This study showed 
the possibility of Sophoraflavanone G to develop as anticancer agents on multidrug 
resistance HCC or apply on long term chemotherapy. However, the exact mechanism 
of Sophoraflavanone G to escape from the action of p-glycoprotein remains to be 
resolved in the future. 
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7.4 Differential Protein Expression Induced by 
Sophoraflavanone G in Human Hepatocellular Carcinoma 
Cells and Multidrug Resistance Human Hepatocellular 
Carcinoma Cells 
Two-dimensional gel electrophoresis was performed to demonstrate the 
differentially expressed proteins induced by Sophorflavanon G in HepG2 and 
RHepG2 cells. Since the translational regulation inside the cells play a critical role in 
protein expression, the changes in mRNA expression profile may not fully represent 
its corresponding protein expression profile. Therefore, analyzing the protein 
expression pattern directly reflects the conditions in the tumor cells after 
Sophoraflavanone G treatment. 
It was found that, in HepG2 cells, Sophoraflavanone G induced the up-regulation 
of aldo-keto reductase family member CI as well as peroxiredoxin 1 (Prdxl) and 
down-regulation of DJ-1 protein. Based on these findings, several hypotheses were 
drawn to give a rough picture of the working mechanism of Sophoraflavanone G. 
It has been reported that aldo-keto reductase family 1 (AKRIC) isozymes were 
highly expressed in human lung carcinoma cell line and in ethacrynic acid-resistant 
colon carcinoma cell line (Ciaccio et al, 1993). Research founding demonstrated that 
cellular proximate carcinogens, for example, polycyclic aromatic hydrocarbons 
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(PAHs) can activate AKRIC isozymes. In the case of lung carcinoma, it has been 
proposed that PAHs, which are tobacco carcinogens, can induce the expression of 
AKRIC isozymes and increase the influx of rra«5-dihydrodiols to redox-active 
o-quinones and enhance the production of reactive oxygen species (ROS) which may 
cause DNA damage, for example change-in-function mutation in p53. Since AKRIC 
isozymes can also provide a defense mechanism against the harmful effect of ROS, 
the production of ROS would lead to further overexpression of AKRIC. In short, the 
expression of AKRIC isozymes can be increased by PAHs and causes the generation 
of ROS which in turn further enhances the expression of AKRIC and finally lead to 
carcinogenesis (Nisha T. et al, 2002). In our case, HepG2 cells treated with 
Sophoraflavanone G, which is polycyclic hydrocarbon with flavonoid backbone, 
showed the up-regulation of AKRIC 1. Hypothesis two: It is speculated that AKRICI 
overexpression may be a cellular response which may aim either to detoxify 
Sophoraflavanone G or protect the ceils from free radicals generated by the action of 
Sophoraflavanone G. This hypothesis should be tested in the future to confirm the 
expression pattern of AKRlCl. 
Peroxiredoxin 1 (Prdxl) belongs to a family of small antioxidant proteins that 
contain essential catalytic cysteine residues and use thioredoxin as an electron donor. 
It is thought to be involved in cellular response to reactive oxygen species (ROS). 
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Transfection studies also showed that Prxdl can eliminate peroxide in vivo. Neumann 
et al (2003) used the Prdxl kockout mice model to characterize the biological role of 
Prdx 1. They found that the malignancies, which include lymphomas, sarcomas, HCC 
etc, are frequently associated with loss of Prdxl expression. They suggested that 
Prdxl functions as a tumor suppressor by eliminating ROS and preventing oxidative 
DNA damage (Neumann et al., 2003). Besides antioxidant activity, Prdx family 
members have been shown to mediate signaling cascade leading to cell proliferation, 
differentiation and apoptosis (Butterfield et aL, 1999; Wood et al” 2003). Our result 
showed that Sophoraflavanone G induced the up-regulation of Prdxl on HepG2 cells. 
Hypothesis three: It is speculated that Sophoraflavanone G may indirectly enhance the 
expression of tumor suppressor gene, Prdxl, which may regulate the signal 
transduction pathway utilizing e.g. caspases to affect cell apoptosis. Similarly, this 
hypothesis remains to be elucidated in the future. 
Sophoraflavanone G was also found to be able to down-regulate DJ-1 protein in 
HepG2 cells. DJ-1 was reported to play a role in human tumorigenesis acting as 
oncogene. Le Naour et al (2001) found that breast cancer patients have increased 
levels of circulating DJ-1; MacKeigan et al (2003) also found that DJ-1 protein was 
up-regulated in primary non-small cell lung carcinoma samples but when the 
carcinoma cells treated with taxol, DJ-1 protein expression was decreased. Kim et al 
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(2005) demonstrated that DJ-1 is a negative regulator ofPTEN tumor suppressor gene. 
They found that overexpression of DJ-1 causes the hyperphosphorylation of protein 
kinase B which results in up-regulation of downstream effectors and therefore 
promote cells survive, while knockdown of DJ-1 decreases the phosphorylation of 
protein kinase B. Hypothesis four: Based on the findings of pervious research, it is 
speculated that Sophoraflavanone G-induced down-regulation of DJ-1 may remove 
the suppression signal on PTEN tumor suppressor which may consequently inhibit 
protein kinase B-mediated cell survival. However, this hypothesis should further be 
tested in order to drawn a conclusive comment. 
In RHepG2 cells, it was found that ENOl protein and 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) were down-regulated after 
Sophoraflavanone G treatment, while the expression of heat shock protein 5 
(glucose-regulated protein) (GRP78) and peroxiredoxin 1 (Prdxl) were increased. 
As explained in previous section, fast-growing cancer cells require more energy 
for proliferation. Thus, the activities of glycolytic enzymes in cancer cells are usually 
increased to enhance glucose metabolism and energy production. In RHepG2 cells, 
ENOl and GAPDH, which are the glycolytic enzymes, was down-regulated by the 
action of Sophoraflavanone G. Hypothesis five: It is speculated that Sophoraflavanone 
G may induce apoptosis in RHepG2 cells by causing the decrease in glucose 
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metabolism and energy production which may finally trigger the glucose starvation 
signals and result in stress-induced apoptosis in multidrug resistance hepatoma cells. 
The glucose starvation signal triggered in the cells is able to increase the expression of 
GRP78 (Lee, 1992). Hypothesis six: So it is speculated that the increased expression 
of GRP78 found in 2-dimensional gel electrophoretic analysis may be the cellular 
response to glucose starvation signal but may not directly response to 
Sophoraflavanone G action. Since Prdxl was also up-regulated in Sophoraflavanone 
G-treated RHepG2 cells, Hypothesis seven: it is speculated that Sophoraflavanone G 
may induce apoptosis in RHepG2 cells by regulating the signal transduction pathway 
through the tumor suppressor gene, Prdxl. The three hypotheses drawn on the action 
mechanism of Sophoraflavanone G against RHepG2 cells are remains to be elucidated 
in the future and so no conclusive comment could me made at this stage about the 
action mechanism of Sophoraflavanone G. 
To conclude, our results suggested the probably that the action mechanisms of 
Sophoraflavanone G on HepG2 and RHepG2 cells have some differences. Based on 
the hypothesis drawn in cDNA microarray analysis, Sophoraflavanone G may 
decrease the expression of GLUT 3 in HepG2 cells and may therefore decrease the 
supply of glucose for metabolism as well as energy production. The glucose starvation 
signal, induced by shortage of glucose, may trigger stress-induced apoptosis in 
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HepG2 cells. While in RHepG2 cells, Sophoraflavanone G may decrease the 
expression levels of glycolytic enzymes and may therefore decrease glucose 
metabolism and energy production. The glucose starvation signal induced by 
decreased rate of glucose metabolism, instead of glucose supply, may trigger 
stress-induced apoptosis in RHepG2 cells. However, this preliminary data only give 
us some hints on the Sophoraflavanone G-induced signaling mechanism. Before 
drawing any conclusive comment, further analysis should be done to test the 
hypothesis as well as to identify other differentially expressed proteins which can 
shed some light on the underlying mechanism of Sophoraflavanone G. 
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7.5 Toxicity of Sophoraflavanone G against Normal Liver 
Cells 
Data presented above showed that the ability of Sophoraflavanone G to inhibit 
the growth of tumor cells as well as multidrug resistance tumor cells. However, it also 
showed the anti-proliferative effect on normal liver WRL-68 cells in vitro with the 
IC50 of 8 . 6 1 fiM (Fig 7.2). This suggested that the action of Sophoraflavanone G is not 
specific to cancer cells. Since the mechanism of Sophoraflavanone G on normal liver 
cells was not investigated in this study, no conclusion could be drawn on the 
specificity of the apoptotic effect of Sophoraflavanone G on cancer cells. 
The toxicity towards normal cells is one of the barriers for the development of 
anticancer drugs from TCMs. Therefore, several advancements should be done on the 
drug. In general, two ways could be adopted. Firstly, Sophoraflavanone G may be 
bound to certain carriers which are targeted to cancer cells. This may help to reduce 
the chance of normal cell to have contact with the toxic compounds. For example, 
Wilson et al (2004) showed that, in four patients, doxorubicin bound to magnetic 
targeted carrier was selectively delivered to hepatic artery by using intraprocedural 
magnetic resonance imaging and interimcatheter manipulation was performed with 
fluoroscopic guidance to maximize the delivery of doxorubicin to the tumor and at the 
same time minimize delivery to normal tissue. The four patients showed reduction in 
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tumor size as well as reduction in tumor-associated abdominal pain. Secondly, 
structure-activity relationship (SAR) on Sophoraflavanone G could be done to work 
out the effects of each functional group on tumor cells as well as normal cells. By 
doing modification on the backbone of Sophoraflavanone G, the toxicity towards 
normal cells may be reduced and at the same time the potency towards the tumor cells 
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Fig. 7.2 Anti-proliferative effect of Sophoraflavanone G on WRL-68 cells. 
WRL-68 cells were seeded on 96-well plates (1 x 10^ cells per well). After 24 hours, 
the cells were incubated with different concentrations of bioactive compounds for 48 
hours at 37°C, 5% CO2. The percentage of cell survival, which calculated with 
respective to the control, was determined by MTT assay. Data shown were the mean 土 
standard deviation of six replicates. 
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8.1 Conclusion 
Bioassay-guided isolation of root of Sophora flavescens successfully purified six 
bioactive compounds which were Maackiain, Leachianone A, Sophoraflavanone Q 
Kushenol X, Sophoraflavanone J and Sophoraflavanone K. Except Maackiain, they 
all showed significant anti-proliferative effect on human hepatocellular carcinoma 
HepG2 and Hep3B cells with IC50 values around 20 to 30 |xM in vitro. 
Since Sophoraflavanone G has the highest yield among the six compounds and it 
showed the highest anti-proliferative effect against HepG2 cells, it was chosen for 
further mechanistic study against human hepatocellular carcinoma HepG2 and 
multidrug resistance human hepatocellular carcinoma RHepG2 cells. The results 
suggested that Sophoraflavanone G may induce apoptosis via death receptor pathway, 
mitochondrial pathway and caspase-independent pathway in both hepatoma cell lines. 
Based on the findings from Western blot analysis, an apoptotic pathway induced by 
Sophoraflavanone G in HepG2 and RHepG2 cells was proposed (Fig 7.1). 
In order to elucidate the upstream signaling pathway of Sophoraflavanone G on 
HepG2 cells, cDNA microrray analysis was performed. It was found that 397 genes 
were up-regulated and 240 genes were down-regulated (the threshold log ratio was set 
as above 2 or below -2) by Sophoraflavanone G. Among the differentially expressed 
gene, glucose transporter 3 (GLUT 3) was validated, by RT-PCR, to be 
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down-regulated in Sophoraflavanone G-treated HepG2 cells. It was hypothesized that 
Sophoraflavanone G may indirectly reduce the expression of GLUT 3 and therefore 
may trigger the glucose starvation signals and result in stress-induced apoptosis in 
HepG2 cells. 
Two-dimensional gel electrophoretic analysis showed that Sophoraflavanone G 
induced the up-regulation of aldo-keto reductase family member CI as well as 
peroxiredoxin 1 (Prdxl) and down-regulation of DJ-1 protein in HepG2 cells. In 
RHepG2 cells, Sophoraflavanone G induced the up-regulation of heat shock protein 5 
(glucose-regulated protein) (GRP78) and peroxiredoxin 1 (Prdxl) and 
down-regulation of ENOl protein and glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH). Based on these findings, it is hypothesized that Sophoraflavanone G may 
induce apoptosis in HepG2 cells by decreasing the supply of glucose which finally 
triggers glucose starvation signal and stress-induced apoptosis, while in RHepG2 cells, 
it is hypothesized that Sophoraflavanone G may decrease the rate of glucose 
metabolism by decreasing the expression of glycolytic enzymes which may finally 
trigger glucose starvation signal and stress-induced apoptosis. 
However, in the future, more analysis and experiments should be done to test the 
hypotheses before any conclusive comment is made. 
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8.2 Future Prospects 
Since cDNA microarray technology was adopted in this project to screen for 
differentially expressed genes under induction of Sophoraflavanone Q validation of 
some of the candidate genes would be one of the important aspects in the future. 
Before choosing the candidate genes for validation, a detailed literature review should 
be done to reveal possible relationship between the candidate genes and upstream 
signaling pathways which lead to apoptosis. Quantitaive real-time-PCR, which is a 
more sensitive method than traditional RT-PCR, can be used to validate the 
differential expression pattern of the candidate genes. The hypothesis established 
regarding the down-regulation of GLUT 3 can be tested by glucose uptake assay. 
However, many questions still remain unsolved. Therefore, a more detailed 
understanding of the molecular changes induced by Sophoraflavanone G is required 
before any conclusive mechanism can be suggested. 
Besides validation of candidate genes identified from cDNA microarray, western 
blot analysis should be used to confirm the differential expression pattern of the 
candidate proteins identified from 2-D PAGE. Other protein spots which showed 
differential expression will also be subjected for protein identification by 
MALDI-TOF-MS. The relationships between the candidate proteins, established by 
literature review and their functions, reveal some possible upstream signaling 
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mechanism of Sophoraflavanone G on human hepatocellular carcinoma HepG2 and 
multidrug resistant human hepatocellular carcinoma RHepG2 cells. 
The results from cDNA microarray analysis and 2-dimensional gel 
electrophoretic analysis provide us with a better understanding on the upstream 
signaling mechanism induced by Sophoraflavanone G on human hepatocellular 
carcinoma HepG2 and multidrug resistant human hepatocellular carcinoma RHepG2 
cells. Understanding the working mechanism of Sophoraflavanone G gives us more 
information on drug targeting research as well as the structure-activity relationship of 
compounds with flavonoid backbone. 
Structure-activity relationship on the structure of Sophoraflavanone G should be 
done to minimize the toxicity of Sophoraflavanone G towards the normal cells as 
well as to maximize its potency towards to cancer cells. 
To conduct researches on drug development, apart from in vitro anti-proliferative 
effect, it is also essential to evaluate the in vivo toxicity and potency of 
Sophoraflavanon G. Nude mice models subcantaneously injected with HepG2 and 
RHepG2 cells can be used to study the in vivo effect of Sophoraflavanone G. Toxicity 
assessment of Sophoraflavanone G can be done by testing the serum level of 
tissue-specific enzymes, like alamine transminase (ALT), aspartate transaminase 
(AST), creatine kinase (CK) and lactate dehydrogenase (LDH) which can demonstrate 
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the presence of heart and liver damage upon Sophoraflavanone G treatment. 
In conclusion, our results showed that Sophoraflavanone G is effective in 
inhibiting the growth of human hepatocellular carcinomca cells and multidrug 
resistance human hepatocellular carcinomca cells. This exciting finding suggests that 
Sophoraflavanone G is a potential anticancer agent against tumor cells and multidurg 
resistant tumor cells. However, there is still a long way to go for Sophorafavanone G 
to become a common anticancer drug against human hepatocellular carcinoma. At 
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